18186519	Disease	Gene	D001943	3845	False	1	What is [EMU_BC] between @DiseaseSrc$ colon and breast cancer @/DiseaseSrc$ and @GeneTgt$ KRAS @/GeneTgt$ ? [SEP] Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection ( MRD ) . Mismatch repair detection ( MRD ) was used to screen 93 matched tumor-normal sample pairs and 22 cell lines for somatic mutations in 30 cancer relevant genes . Using a starting amount of only 150 ng of genomic DNA , we screened 102 kb of sequence for somatic mutations in @DiseaseSrc$ colon and breast cancer @/DiseaseSrc$ . A total of 152 somatic mutations were discovered , encompassing previously reported mutations , such as BRAF V600E and @GeneTgt$ KRAS @/GeneTgt$ G12S , G12V , and G13D , as well as novel mutations , including some in genes in which somatic mutations have not previously been reported , such as MAP2K1 and MAP2K2 . The distribution of mutations ranged widely within and across tumor types . The functional significance of many of these mutations is not understood , with patterns of selection only evident in @GeneTgt$ KRAS @/GeneTgt$ and BRAF in colon cancer . These results present a novel approach to high-throughput mutation screening using small amounts of starting material and reveal a mutation spectrum across 30 genes in a large cohort of breast and colorectal cancers .	2 2 5 5 2 7 5 7 7 11 7 2 15 15 12 17 15 17 2 22 22 27 24 22 24 27 27 29 27 34 34 34 34 29 34 38 38 34 41 41 38 44 44 46 46 29 27 48 51 51 48 55 54 55 51 58 58 55 61 61 48 63 61 65 63 68 68 65 70 68|69|70 68|69|70 68|69|70 68|69|70 68|70 68|69|70 61 78 84 82 82 82 78 84 84 84 84 88 89 86 89 94 91 94 89 94 95|98 98 95|98 94 98 98 98 94 94 89 89 105 105 109 89 109 112 109 114 112 116 123 118 123 123 123 123 123 114 114 127 125 114 127 127 84 133 136 135 133 136 136 142 138 138 142 136 136 146 146 154 148 146 151 151 148 154 154 154 154 157 161 159 157 161 154 163 161|162 161 161|162 163 163 169 169 163 154 173 174 174 177 177 174 181 181 181 177 177 184 182 186 184 186 174 174 192 192 189 195 195 192 199 199 199 192 201 199 201 201 201 174	Association
18186519	Disease	Gene	D001943	673	False	1	What is [EMU_BC] between @DiseaseSrc$ colon and breast cancer @/DiseaseSrc$ and @GeneTgt$ BRAF @/GeneTgt$ ? [SEP] Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection ( MRD ) . Mismatch repair detection ( MRD ) was used to screen 93 matched tumor-normal sample pairs and 22 cell lines for somatic mutations in 30 cancer relevant genes . Using a starting amount of only 150 ng of genomic DNA , we screened 102 kb of sequence for somatic mutations in @DiseaseSrc$ colon and breast cancer @/DiseaseSrc$ . A total of 152 somatic mutations were discovered , encompassing previously reported mutations , such as @GeneTgt$ BRAF @/GeneTgt$ V600E and KRAS G12S , G12V , and G13D , as well as novel mutations , including some in genes in which somatic mutations have not previously been reported , such as MAP2K1 and MAP2K2 . The distribution of mutations ranged widely within and across tumor types . The functional significance of many of these mutations is not understood , with patterns of selection only evident in KRAS and @GeneTgt$ BRAF @/GeneTgt$ in colon cancer . These results present a novel approach to high-throughput mutation screening using small amounts of starting material and reveal a mutation spectrum across 30 genes in a large cohort of breast and colorectal cancers .	2 2 5 5 2 7 5 7 7 11 7 2 15 15 12 17 15 17 2 22 22 27 24 22 24 27 27 29 27 34 34 34 34 29 34 38 38 34 41 41 38 44 44 46 46 29 27 48 51 51 48 55 54 55 51 58 58 55 61 61 48 63 61 65 63 68 68 65 70 68|69|70 68|69|70 68|69|70 68|69|70 68|70 68|69|70 61 78 84 82 82 82 78 84 84 84 84 88 89 86 89 95 91 92|95 95 92|95 89 95 98 95 98 98 98 95 95 89 89 105 105 109 89 109 112 109 114 112 116 123 118 123 123 123 123 123 114 114 127 125 114 127 127 84 133 136 135 133 136 136 142 138 138 142 136 136 146 146 154 148 146 151 151 148 154 154 154 154 157 161 159 157 161 154 163 161 163 163|164 163 163|164 169 169 163 154 173 174 174 177 177 174 181 181 181 177 177 184 182 186 184 186 174 174 192 192 189 195 195 192 199 199 199 192 201 199 201 201 201 174	Association
18332865	Disease	Gene	D001943	5728	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ PTEN @/GeneTgt$ ? [SEP] Suppression of @GeneTgt$ PTEN @/GeneTgt$ function @DiseaseSrc$ increases breast cancer @/DiseaseSrc$ chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors . Ectopic expression of mutant forms of phosphatase and tensin homologue deleted on chromosome 10 ( @GeneTgt$ PTEN @/GeneTgt$ ) lacking lipid ( G129E ) or lipid and protein ( C124S ) phosphatase activity decreased sensitivity of @DiseaseSrc$ MCF-7 breast cancer @/DiseaseSrc$ cells , which have wild-type @GeneTgt$ PTEN @/GeneTgt$ , to doxorubicin and increased sensitivity to the mammalian target of rapamycin ( mTOR ) inhibitor rapamycin . Cells transfected with a mutant @GeneTgt$ PTEN @/GeneTgt$ gene lacking both lipid and protein phosphatase activities were more resistant to doxorubicin than cells transfected with the @GeneTgt$ PTEN @/GeneTgt$ mutant lacking lipid phosphatase activity indicating that the protein phosphatase activity of @GeneTgt$ PTEN @/GeneTgt$ was also important in controlling the sensitivity to doxorubicin , while no difference was observed between the lipid ( G129E ) and lipid and protein ( C124S ) phosphatase @GeneTgt$ PTEN @/GeneTgt$ mutants in terms of sensitivity to rapamycin . A synergistic inhibitory interaction was observed when doxorubicin was combined with rapamycin in the phosphatase-deficient @GeneTgt$ PTEN-transfected @/GeneTgt$ cells . Interference with the lipid phosphatase activity of @GeneTgt$ PTEN @/GeneTgt$ was sufficient to activate Akt/mTOR/p70S6 K signaling . These studies indicate that disruption of the normal activity of the @GeneTgt$ PTEN @/GeneTgt$ phosphatase can have dramatic effects on the therapeutic sensitivity of @DiseaseSrc$ breast cancer @/DiseaseSrc$ cells . Mutations in the key residues which control @GeneTgt$ PTEN @/GeneTgt$ lipid and protein phosphatase may act as dominant-negative mutants to suppress endogenous @GeneTgt$ PTEN @/GeneTgt$ and alter the sensitivity of @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients to chemo- and targeted therapies .	6 5 2|5 5 2|5 1 4|12|6 4|12|6 4|12|6 12|6 4|12|6 12 12 6 14 6 14 18 18 15 6 23 54 26 26 23 28 26 28 31 28 23 34 32 34 37 34|36 34 34|36 37 34 53 43 41 43 41 41 46 46 50 48 50 53 40 54 54 61 61|55 61|55 61|55 61 61|55 55 61 64 61 66 61|64 64 61|64 66 70 66 54 54 72 77 77 77 73 83 83 83 83 83 84 77 54 106 89 96 96 96 96|93 96 96|93 90 96 99 97 99 102 99 99 106 106 106 108 106 110 106 110 116 116 112|116 116 112|116 111 116 120 120 117 106 132 126 126 126 132 128 125|126 126 125|126 132 132 121 134 132 136 134 138 136 132 144 142 144 144 132 149 149 149 149 144 149 149 161 152 152 156 161 161 161 161|155 161 161|155 149 163 144 165 163 167 165 106 176 176 176 178 178 178 182 182 182 178 184 182 190 190 190 190|187 190 190|187 184 178 203 198 198 198 198 193 200 198|199 198 198|199 203 203 205 203 208 208 205 203 212 213 213 226 226 219 219 219 215 224 224 221|224 224 221|224 219 226 213 228 226 232 232 232 226 237 237|232 237|232 237 237|232 232 213 255 245 245 245 241 247 245 250|247 250 250|247 247 250 253 250 255 255 258 258 255 260 255 262 260 260 260 260 260 267 265 272 272|266 272|266 272 272|266 267 274 277 274 274 267 255	Association
12917204	Disease	Gene	D001943	472	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ ATM @/GeneTgt$ ? [SEP] The relationship between twenty missense @GeneTgt$ ATM @/GeneTgt$ variants and @DiseaseSrc$ breast cancer @/DiseaseSrc$ risk : the Multiethnic Cohort . Deficiencies in tasks of detecting and repairing DNA damage lead to mutations and chromosomal abnormalities , a hallmark of cancer . The gene mutated in ataxia-telangiectasia ( A-T ) , @GeneTgt$ ATM @/GeneTgt$ , is a proximal component in performing such tasks . Studies of A-T families have suggested an increased risk of @DiseaseSrc$ breast cancer @/DiseaseSrc$ among obligate female heterozygous carriers of @GeneTgt$ ATM @/GeneTgt$ mutations . Paradoxically , studies of sporadic and @DiseaseSrc$ familial breast cancer @/DiseaseSrc$ have failed to demonstrate an elevated prevalence of mutations among @DiseaseSrc$ breast cancer @/DiseaseSrc$ cases . We characterized the prevalence and distribution of 20 @GeneTgt$ ATM @/GeneTgt$ missense mutations/polymorphisms in a population-based case-control study of 854 African-American , Latina , Japanese , and Caucasian women aged > /== " BORDER="0">45 years participating in the Multiethnic Cohort Study . The study population included 428 incident @DiseaseSrc$ breast cancer @/DiseaseSrc$ cases and 426 controls . The prevalence of variants ranged from 0 % to 13.6 % among controls and varied by ethnicity ( 0 - 32.5 % ) . Overall , these data provide little support for an association of @GeneTgt$ ATM @/GeneTgt$ missense mutations with @DiseaseSrc$ breast cancer @/DiseaseSrc$ among older women . We observed only one sequence variation ( L546V ) , common among African-American women , to be overrepresented among all high-stage @DiseaseSrc$ breast cancer @/DiseaseSrc$ cases ( odds ratio , 3.35 ; 95 % confidence interval , 1.27 - 8.84 ) . After correction for multiple comparisons , this observed risk modification did not attain statistical significance . The distribution of @GeneTgt$ ATM @/GeneTgt$ missense mutations and polymorphisms varied widely across the four ethnic groups studied . Although a single missense variant ( L546V ) appeared to act as a modest predictor of risk , the remaining variants were no more common in @DiseaseSrc$ breast cancer @/DiseaseSrc$ cases as compared with controls .	2 2 8 8 8 8|5 8 8|5 2 8 8|10|13 8|10|13 10|13 8|10|13 8 8 17 17 8 2 30 23 21 25 23 25 25 29 25 30 32 30 32 35 32 35 38 35 40 38 30 43 57 43 46 44 48 46 48 46 50|46 46 50|46 43 57 57 57 57 59 57 61 59 57 69 67 67 64 69 69 72 72 69 74 72|73|74 72|73|74 72|74 72|73|74 81 81 81 81 72 85 80|85 85 80|85 81 69 100 100 100 93 95 93 91|93|94|95 91|93|94|95 91|93|94|95 91|93|95 91|93|94|95 100 100 102 100 105 105 102 107 105 112 112|105 112|105 112 112|105 107 100 117 117 119 117 119 119 127 127 123|127 127 123|127 127 119 132 132 132 132 119 143 143 143 135 135 137 137 139 139 139 132 143 146 149 148 149 144 149 155 155 155 155 150 117 160 160 161 161 167 167 167|163 167|163 167 167|163 161 167 170 167 161 174 177 176 174 177 180 180 177 183 183 177 185 177 177 177 189 187 194 193 193 194 189 194 177 201 201 200 201 201 203 201 206 206 203 211 207|211 211 207|211 211 206 213 213|206|211 213|206|211 213|206 213|206|211 218 218 206 201 223 223 225 227 227 223 229 227 229 227 227 235 235 232 227 239 239 227 246 246 246 246|242 246|242 246 246|242 239 249 249 246 249 249 249 256 256 256 249 256 260 260 256 249 223 265 271 268 268 265 271 271 271 273 276 276 276 271 278 276 271 281 289 286 282|286 286 282|286 286 281 286 286 289 289 295 295 295 295 289 295 289 307 303 303 303 307 305 303 305 323 309 307 313 313 313 309 315 313 323 319 319 323 323 323 323 323 328 324|328 324|328 328 324|328 323 330 323 332 330 323	Association
15059511	Disease	Gene	D001943	675	True	0	What is [EMU_BC] between @DiseaseSrc$ familial breast cancer @/DiseaseSrc$ and @GeneTgt$ BRCA2 @/GeneTgt$ ? [SEP] [ Germline mutations in the BRCA1 and @GeneTgt$ BRCA2 @/GeneTgt$ genes from @DiseaseSrc$ breast cancer @/DiseaseSrc$ families in China Han people ] . OBJECTIVE : To detect BRCA1 and @GeneTgt$ BRCA2 @/GeneTgt$ gene germline mutation in the Chinese @DiseaseSrc$ breast cancer @/DiseaseSrc$ families . METHODS : Samples of peripheral blood were collected to prepare genomic DNA by conventional techniques from 15 inherited @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients from @DiseaseSrc$ 14 breast cancer @/DiseaseSrc$ families , 76 sporadic @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients , and 100 healthy controls based on informed consent . Exons 4 , 8 , 11 and 18 - 20 of BRCA1 , and exons 1 - 14 , 17 - 24 and 27 of @GeneTgt$ BRCA2 @/GeneTgt$ , were analyzed using DNA direct sequencing . RESULTS : Six single nucleotide polymorphisms ( SNPs ) were found on the exon 11 of BRCA1 , 2 being silent changes without change of amino acid coding , and 4 with change of amino acid coding among which 2 were polymorphic amino acid alterations and 2 were pathogenic SNPs , i.e. mutational sites . One novel BRCA1 mutation , C1196 T ( Pro 359 Leu ) , was identified in a family @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients , who was diagnosed at the age of 37 . Another BRCA1 mutation , Trp 372 stop was found in a @DiseaseSrc$ breast cancer @/DiseaseSrc$ patient who was diagnosed at the age 29 . Eight SNPs were found on the exon3 , 10 and 11 of @GeneTgt$ BRCA2 @/GeneTgt$ , among which 5 were silent changes and 3 were polymorphic amino acid alterations . A1093C ( Asn289His ) in exon 10 and A 3199 G ( Asn991Asp ) in exon 11 being found simultaneously in the patients of 2 families but not appearing in pool DNA sample , and Asn 371 His appearing as A/C heterozygote in pool DNA sample . CONCLUSION : Two pathogenic SNPs have been found in BRCA1 and may be related to early-onset @DiseaseSrc$ breast cancer @/DiseaseSrc$ . One of them may be a novel mutation characterized of @DiseaseSrc$ familial breast cancer @/DiseaseSrc$ in China .	3 3 3 10 10 5 6 6|7 6 6|7 3 15 10|15 10|15 15 10|15 10 19 18 19 15 3 3 24 24 27 24 27 28 28|29 28 28|29 34 34 28 41 41 41 41|36 41|36 41 41|36 27 24 52 52 52 50 50 47 52 52 54 52 56 54 59 59 54 66 66 66 62|66 62|66 66 62|66 59 72 72|65 72|65 72|65 72 72|65 66 66 79 79 70|79 70|79 79 70|79 66 79 66 84 84 66 88 88 88 54 52 122 93 93 93 93 93 98 98 102 93 104 93 104 104 104 107 114 114 114 114 114 104 114 114 118 117|93 93 117|93 93 122 122 122 126 126 123 122 150 129 134 134 134 139 136 134 136 139 129 142 142 139 142 145 143 139 139 150 150 178 152 150 156 155 156 152 152 150 150 161 150 164 164 161 164 167 173 167 173 173 173 173 164 161 161 178 178 178 178 182 182 178 178 187 187 187 198 187 190 187 194 194 194 190 194 187 198 198 205 205 205 201|205 201|205 205 201|205 198 205 209 209 205 212 212 209 214 212 198 219 219 225 225 223 223 225 225 225 231 231 227|231 227|231 231 227|231 225 234 234 231 237 237 234 237 225 242 244 244 244 247 247 244 247 247 249 249 253 249|252 249 249|252 253 257 258 253 261 261 244 261 261 268 268 268 268 261 244 271 273 271 273 276 271 276 276 283 281 283 283 276 283 286 276 286 289 271 289 293 293 289 296 296 293 293 299 293 303 303 303 299 293 293 309 306 306 289 312 312 309 316 316 316 309 271 318 325 322 322 325 325 325 318 327 325 325 331 331 325 334 334 333|334|331 333|334|331 334|331 333|334|331 325 346 341 339 346 346 346 346 346 346 349 347|348|349 347|348|349 347|348|349 347|349 347|348|349 354 349 346	Association
15059511	Disease	Gene	D001943	672	True	0	What is [EMU_BC] between @DiseaseSrc$ familial breast cancer @/DiseaseSrc$ and @GeneTgt$ BRCA1 @/GeneTgt$ ? [SEP] [ Germline mutations in the @GeneTgt$ BRCA1 @/GeneTgt$ and BRCA2 genes from @DiseaseSrc$ breast cancer @/DiseaseSrc$ families in China Han people ] . OBJECTIVE : To detect @GeneTgt$ BRCA1 @/GeneTgt$ and BRCA2 gene germline mutation in the Chinese @DiseaseSrc$ breast cancer @/DiseaseSrc$ families . METHODS : Samples of peripheral blood were collected to prepare genomic DNA by conventional techniques from 15 inherited @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients from @DiseaseSrc$ 14 breast cancer @/DiseaseSrc$ families , 76 sporadic @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients , and 100 healthy controls based on informed consent . Exons 4 , 8 , 11 and 18 - 20 of @GeneTgt$ BRCA1 @/GeneTgt$ , and exons 1 - 14 , 17 - 24 and 27 of BRCA2 , were analyzed using DNA direct sequencing . RESULTS : Six single nucleotide polymorphisms ( SNPs ) were found on the exon 11 of @GeneTgt$ BRCA1 @/GeneTgt$ , 2 being silent changes without change of amino acid coding , and 4 with change of amino acid coding among which 2 were polymorphic amino acid alterations and 2 were pathogenic SNPs , i.e. mutational sites . One novel @GeneTgt$ BRCA1 @/GeneTgt$ mutation , C1196 T ( Pro 359 Leu ) , was identified in a family @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients , who was diagnosed at the age of 37 . Another @GeneTgt$ BRCA1 @/GeneTgt$ mutation , Trp 372 stop was found in a @DiseaseSrc$ breast cancer @/DiseaseSrc$ patient who was diagnosed at the age 29 . Eight SNPs were found on the exon3 , 10 and 11 of BRCA2 , among which 5 were silent changes and 3 were polymorphic amino acid alterations . A1093C ( Asn289His ) in exon 10 and A 3199 G ( Asn991Asp ) in exon 11 being found simultaneously in the patients of 2 families but not appearing in pool DNA sample , and Asn 371 His appearing as A/C heterozygote in pool DNA sample . CONCLUSION : Two pathogenic SNPs have been found in @GeneTgt$ BRCA1 @/GeneTgt$ and may be related to early-onset @DiseaseSrc$ breast cancer @/DiseaseSrc$ . One of them may be a novel mutation characterized of @DiseaseSrc$ familial breast cancer @/DiseaseSrc$ in China .	3 3 3 10 10 5 5 5 6 6 3 15 10|15 10|15 15 10|15 10 19 18 19 15 3 3 24 24 27 24 27 27 27 28 28 34 34 28 41 41 41 41|36 41|36 41 41|36 27 24 52 52 52 50 50 47 52 52 54 52 56 54 59 59 54 66 66 66 62|66 62|66 66 62|66 59 72 72|65 72|65 72|65 72 72|65 66 66 79 79 70|79 70|79 79 70|79 66 79 66 84 84 66 88 88 88 54 52 122 93 93 93 93 93 98 98 102 93 104 93|103 93 93|103 104 104 104 108 115 115 115 115 115 104 115 115 119 93 93 122 122 122 126 126 123 122 151 129 134 134 134 139 136 134 136 139 129 142 142 139 142 145 144|143 143 144|143 139 139 151 151 179 153 151 157 156 157 153 153 151 151 162 151 165 165 162 165 168 174 168 174 174 174 174 165 162 162 179 179 179 179 183 183 179 179 190 190 187|190 190 187|190 201 190 193 190 197 197 197 193 197 190 201 201 208 208 208 203|208 203|208 208 203|208 201 208 212 212 208 215 215 212 217 215 201 224 221|224 224 221|224 230 230 228 228 230 230 230 236 236 236|231 236|231 236 236|231 230 239 239 236 242 242 239 242 230 248 250 250 250 253 253 250 253 253 255 255 259 255 259 262 263 259 266 266 250 266 266 273 273 273 273 266 250 275 277 275 277 280 275 280 280 287 285 287 287 280 287 290 280 290 293 275 293 297 297 293 300 300 297 297 303 297 307 307 307 303 297 297 313 310 310 293 316 316 313 320 320 320 313 275 322 329 326 326 329 329 329 322 331 329|330 329 329|330 329 336 336 329 339 339 337|339|336 337|339|336 339|336 337|339|336 329 352 347 345 352 352 352 352 352 352 355 353|354|355 353|354|355 353|354|355 353|355 353|354|355 360 355 352	Association
16168123	Disease	Gene	D001943	675	True	0	What is [EMU_BC] between @DiseaseSrc$ bilateral breast cancer @/DiseaseSrc$ and @GeneTgt$ BRCA2 @/GeneTgt$ ? [SEP] Strong evidence that the common variant S384F in @GeneTgt$ BRCA2 @/GeneTgt$ has no pathogenic relevance in @DiseaseSrc$ hereditary breast cancer @/DiseaseSrc$ . INTRODUCTION : Unclassified variants ( UVs ) of unknown clinical significance are frequently detected in the @GeneTgt$ BRCA2 @/GeneTgt$ gene . In this study , we have investigated the potential pathogenic relevance of the recurrent UV S384F ( @GeneTgt$ BRCA2 @/GeneTgt$ , exon 10 ) . METHODS : For co-segregation , four women from a large kindred ( BN326 ) suffering from @DiseaseSrc$ breast cancer @/DiseaseSrc$ were analysed . Moreover , paraffin-embedded tumours from two patients were analysed for loss of heterozygosity . Co-occurrence of the variant with a deleterious mutation was further determined in a large data set of 43,029 index cases . Nature and position of the UV and conservation among species were evaluated . RESULTS : We identified the unclassified variant S384F in three of the four @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients ( the three were diagnosed at 41 , 43 and 57 years of age ) . One woman with @DiseaseSrc$ bilateral breast cancer @/DiseaseSrc$ ( diagnosed at ages 32 and 50 ) did not carry the variant . Both tumours were heterozygous for the S384F variant , so loss of the wild-type allele could be excluded . Ser384 is not located in a region of functional importance and cross-species sequence comparison revealed incomplete conservation in the human , dog , rodent and chicken @GeneTgt$ BRCA2 @/GeneTgt$ homologues . Overall , the variant was detected in 116 patients , five of which co-occurred with different deleterious mutations . The combined likelihood ratio of co-occurrence , co-segregation and loss of heterozygosity revealed a value of 1.4 x 10 - 8 in favour of neutrality of the variant . CONCLUSION : Our data provide conclusive evidence that the S384F variant is not a disease causing mutation .	2 2 11 7 7 7 11 9 8|7 7 8|7 2 14 14 11 16 16|14 16|14 16|14 16|14 16|14 2 23 23 26 36 28 26 28 33 33 33 26 36 36 23 41 41 38|41 41 38|41 36 36 46 46 50 50 50 50 50 54 54 54 50 59 59 59 59 54 61 59|60 59 59|60 61 61 64 61 50 89 89 72 89 89 75 89 79 79 79 83 81 79 81 75 85 84|85|83 84|85|83 85|83 84|85|83 89 89 89 100 100 95 100 98 98 95 100 100 102 100 104 102 100 116 109 109 106 113 113 113 109 116 116 116 120 120 120 116 120 125 125 125 121 116 138 127 127 132 132 129 132 132 136 132 138 138 138 140 140 143 140 147 147 147 143 149 143 156 156 156 156|152 156|152 156 156|152 149 161 159 161 161 143 163 168 163 163 165 165 161 170 168 161 140 175 191 177 175|176|177 175|176|177 175|176|177 175|177 175|176|177 182 175 184 182 184 185 185 182 191 191 191 193 191 191 197 199 199 199 203 203 203 199 199 199 213 210 210 210 206 213 213 199 213 218 218 218 218 221 221 218 224 224 221 224 224 228 224 218 231 229 236 236 236 234 231 236 236 236 241 240|243 243 240|243 236 218 251 251 249 251 251 251 254 254 251 254 259 258 256 254 263 263 263 259 251 268 268 268 277 270 268 270 270 272 268 276 274 277 279 277 285 285 281 281 285 279 287 279 289 287 292 292 289 277 298 298 297 298 298 300 298 309 304 304 309 308 308 308 309 300 309 298	Association
17427234	Disease	Gene	D009447	7157	True	0	What is [EMU_BC] between @DiseaseSrc$ neuroblastoma @/DiseaseSrc$ and @GeneTgt$ TP53 @/GeneTgt$ ? [SEP] Composite @DiseaseSrc$ adrenal anaplastic neuroblastoma @/DiseaseSrc$ and virilizing adrenocortical tumor with germline @GeneTgt$ TP53 @/GeneTgt$ R248W mutation . Composite tumors are extremely rare . Such tumors in adrenal glands are usually of neuroendocrine-neural type and occur mostly in adults . Their pathogenesis remains elusive . We report a patient with composite @DiseaseSrc$ neuroblastoma @/DiseaseSrc$ ( NB ) , adrenocortical tumor ( ACT ) , and Li-Fraumeni syndrome ( LFS ) with germline @GeneTgt$ TP53 @/GeneTgt$ R248W mutation . LFS predisposes to the development of leukemia , sarcomas , adrenocortical and breast carcinomas , brain tumors and , questionably , NB . A unique correlation between a single @GeneTgt$ TP53 @/GeneTgt$ mutation ( R337H ) and ACT has been reported in southern Brazilian children . It remains unclear at this time whether a similar association of NB and R248W in patients with LFS exists .	2 1|2 1|2 1|2 2 1|2 2 9 9 2 15 15 8|15 15 8|15 15 2 2 20 23 23 23 23 23 26 31 29 29 26 31 31 34 34 31 31 31 36 39 36 31 42 43 43 43 43 47 47 49 47 52 52 49|51 49 49|51 55 52 55 52 59 52 61 59 61 52 52 66 52 68 66 68 75 75 70|75 75 70|75 75 49 47 80 80 83 83 80 85 83 85 85 87 85 89 89 85 85 95 85 83 83 100 100 80 80 104 104 118 110 110 110 110|107 110 110|107 104 112 110 112 110 110 118 118 118 122 122 122 118 118 126 126 126 130 130 127 143 134 134 143 136 134 136 136 140 134 142 140 126 126	Association
17427234	Disease	Gene	D016864	7157	True	0	What is [EMU_BC] between @DiseaseSrc$ Li-Fraumeni syndrome @/DiseaseSrc$ and @GeneTgt$ TP53 @/GeneTgt$ ? [SEP] Composite adrenal anaplastic neuroblastoma and virilizing adrenocortical tumor with germline @GeneTgt$ TP53 @/GeneTgt$ R248W mutation . Composite tumors are extremely rare . Such tumors in adrenal glands are usually of neuroendocrine-neural type and occur mostly in adults . Their pathogenesis remains elusive . We report a patient with composite neuroblastoma ( NB ) , adrenocortical tumor ( ACT ) , and @DiseaseSrc$ Li-Fraumeni syndrome @/DiseaseSrc$ ( LFS ) with germline @GeneTgt$ TP53 @/GeneTgt$ R248W mutation . LFS predisposes to the development of leukemia , sarcomas , adrenocortical and breast carcinomas , brain tumors and , questionably , NB . A unique correlation between a single @GeneTgt$ TP53 @/GeneTgt$ mutation ( R337H ) and ACT has been reported in southern Brazilian children . It remains unclear at this time whether a similar association of NB and R248W in patients with LFS exists .	4 4 4 4 4 8 8 4 14 14 10|14 14 10|14 14 4 4 18 21 21 21 21 21 24 29 27 27 24 29 29 32 32 29 29 29 34 37 34 29 40 41 41 41 41 45 45 47 45 50 50 47 52 50 52 50 56 50 58 56 58 50 50 61|62|50 61|62|50 62|50 61|62|50 66 62 66 73 73 67|73 73 67|73 73 47 45 78 78 81 81 78 83 81 83 83 85 83 87 87 83 83 93 83 81 81 98 98 78 78 102 102 116 108 108 108 108|105 108 108|105 102 110 108 110 108 108 116 116 116 120 120 120 116 116 124 124 124 128 128 125 141 132 132 141 134 132 134 134 138 132 140 138 124 124	Association
12872252	Disease	Gene	D010051	59348	True	0	What is [EMU_BC] between @DiseaseSrc$ breast and ovarian cancer @/DiseaseSrc$ and @GeneTgt$ ZBRK1 @/GeneTgt$ ? [SEP] Mutational analysis of the BRCA1-interacting genes @GeneTgt$ ZNF350/ZBRK1 @/GeneTgt$ and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from @DiseaseSrc$ breast-ovarian cancer @/DiseaseSrc$ families and among early-onset breast cancer cases and reference individuals . Two potential breast cancer susceptibility genes , encoding the BRCA1-interacting proteins @GeneTgt$ ZNF350 @/GeneTgt$ ( or @GeneTgt$ ZBRK1 @/GeneTgt$ ) and BRIP1 ( or BACH1 ) , have been identified in yeast two-hybrid screens . We sequenced these genes in probands from 21 families with potentially inherited breast/ovarian cancer , all of which were negative for BRCA1/BRCA2 mutations . Families had at least one case of male breast cancer , two cases of @DiseaseSrc$ ovarian cancer @/DiseaseSrc$ , or three or more cases of @DiseaseSrc$ breast and ovarian cancer @/DiseaseSrc$ . In addition , 58 early-onset ( before age 35 ) breast cancer cases and 30 reference individuals were analyzed . Of 17 variants detected in @GeneTgt$ ZBRK1 @/GeneTgt$ , a missense mutation Val524Ile was identified in the proband of one high-risk family , but no other family members were available for testing . Of 25 variants identified in BRIP1 , in addition to four common silent or missense mutations , we identified Gln540Leu , a non-conservative amino acid change , in a single familial proband with inflammatory breast cancer , but this mutation was not present in her three relatives with breast cancer . Haplotype analysis suggests that all @GeneTgt$ ZBRK1 @/GeneTgt$ SNPs fall within a single block with two SNPs capturing 92 % of the haplotype diversity , while the BRIP1 SNPs fall in two blocks , with five SNPs capturing 89 % of the haplotype diversity . Based on sequencing of @GeneTgt$ ZBRK1 @/GeneTgt$ and BRIP1 in 21 BRCA1/2-negative probands from inherited breast/ovarian cancer families , it appears unlikely that mutations in these genes account for a significant fraction of inherited breast cancer . Further analysis in unselected cases will be required to know whether the identified variants play a role in genetic predisposition to breast cancer in the general population . Hum Mutat 22:121 - 128 , 2003 . Published 2003 Wiley-Liss , Inc.	2 2 6 6 6 2 6 6 6 7 7 12 7 12 15 12 20 20|15 20|15 20 20|15 2 20 26 26 26 26 20 26 29 26 2 38 38 38 38 38 60 38 38 43 43 44 40|43 40 40|43 48 46 44|46 44 44|46 48 44 44 52 52 52 52 44 60 60 60 64 64 64 60 60 69 69 71 69 73 71 76 76 73 81 79 81 81 76 87 87 85 83 87 69 90 90 87 87 93 93 95 96 97 93 101 101 101 97 97 104 97 106 104|105|106 104|105|106 104|106 104|105|106 106 106 114 111 111 106 116 116|113|114 116|113|114 116|113|114 116|113|114 116|114 116|113|114 93 125 142 142 128 142 136 131 129 136 136 136 136 128 128 140 140 142 142 142 142 145 146 157 146 149 147|148 147 147|148 149 155 155 155 149 157 157 160 160 157 164 164 164 160 157 157 170 170 170 172 172 157 174 172 172 178 179 195 179 182 180 179 185 189 189 189 189 179 189 189 189 195 195 195 195 196 202 202 202 202 196 196 208 208 208 208 196 212 212 212 208 195 195 216 219 219 219 195 223 223 223 219 226 226 223 195 229 230 230 236 235 235|232 235 235|232 236 230 240 240 240 236 243 243 240 243 246 244 250 250 250 246 236 256 255 255 256 236 259 259 256 236 263 263 236 263 266 264 270 270 270 266 230 292 275 273 277 275|276 275 275|276 277 277 284 284 284 275 289 289 289 289 284 292 292 292 292 299 299 298 298 295 293 303 303 303 299 307 307 307 303 292 311 317 314 314 311 317 317 317 319 317 324 323 323 324 319 326 324 329 329 324 332 332 329 336 336 336 329 317 339 340 340 340 340 342 340 340 350 350 350 350 350	Association
12872252	Disease	Gene	D001943	59348	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ ZBRK1 @/GeneTgt$ ? [SEP] Mutational analysis of the BRCA1-interacting genes @GeneTgt$ ZNF350/ZBRK1 @/GeneTgt$ and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset @DiseaseSrc$ breast cancer @/DiseaseSrc$ cases and reference individuals . Two potential @DiseaseSrc$ breast cancer @/DiseaseSrc$ susceptibility genes , encoding the BRCA1-interacting proteins @GeneTgt$ ZNF350 @/GeneTgt$ ( or @GeneTgt$ ZBRK1 @/GeneTgt$ ) and BRIP1 ( or BACH1 ) , have been identified in yeast two-hybrid screens . We sequenced these genes in probands from 21 families with potentially inherited breast/ovarian cancer , all of which were negative for BRCA1/BRCA2 mutations . Families had at least one case of male breast cancer , two cases of ovarian cancer , or three or more cases of breast and ovarian cancer . In addition , 58 early-onset ( before age 35 ) @DiseaseSrc$ breast cancer @/DiseaseSrc$ cases and 30 reference individuals were analyzed . Of 17 variants detected in @GeneTgt$ ZBRK1 @/GeneTgt$ , a missense mutation Val524Ile was identified in the proband of one high-risk family , but no other family members were available for testing . Of 25 variants identified in BRIP1 , in addition to four common silent or missense mutations , we identified Gln540Leu , a non-conservative amino acid change , in a single familial proband with inflammatory breast cancer , but this mutation was not present in her three relatives with @DiseaseSrc$ breast cancer @/DiseaseSrc$ . Haplotype analysis suggests that all @GeneTgt$ ZBRK1 @/GeneTgt$ SNPs fall within a single block with two SNPs capturing 92 % of the haplotype diversity , while the BRIP1 SNPs fall in two blocks , with five SNPs capturing 89 % of the haplotype diversity . Based on sequencing of @GeneTgt$ ZBRK1 @/GeneTgt$ and BRIP1 in 21 BRCA1/2-negative probands from inherited breast/ovarian cancer families , it appears unlikely that mutations in these genes account for a significant fraction of inherited breast cancer . Further analysis in unselected cases will be required to know whether the identified variants play a role in genetic predisposition to @DiseaseSrc$ breast cancer @/DiseaseSrc$ in the general population . Hum Mutat 22:121 - 128 , 2003 . Published 2003 Wiley-Liss , Inc.	2 2 6 6 6 2 6 6 6 7 7 12 7 12 15 12 19 19 19 2 19 26 26 26|21 26|21 26 26|21 19 26 29 26 2 39 39 34|39 34|39 39 34|39 39 61 39 39 44 44 45 41|42 41 41|42 49 47 45 45 45 49 45 45 53 53 53 53 45 61 61 61 65 65 65 61 61 71 71 73 71 75 73 78 78 75 83 81 83 83 78 89 89 87 85 89 71 92 92 89 89 95 95 97 98 99 95 103 103 103 99 99 106 99 109 109 106 109 109 115 112 112 109 117 115 117 120 117 95 123 141 141 126 141 135 129 127 135 135 131|135 131|135 135 131|135 126 126 139 139 141 141 141 141 145 146 157 146 149 147|148 147 147|148 149 155 155 155 149 157 157 160 160 157 164 164 164 160 157 157 170 170 170 172 172 157 174 172 172 178 179 195 179 182 180 179 185 189 189 189 189 179 189 189 189 195 195 195 195 196 202 202 202 202 196 196 208 208 208 208 196 212 212 212 208 195 195 216 219 219 219 195 223 223 223 219 225 224|225|223 224|225|223 225|223 224|225|223 195 231 232 232 238 237 237|234 237 237|234 238 232 242 242 242 238 245 245 242 245 248 246 252 252 252 248 238 258 257 257 258 238 261 261 258 238 265 265 238 265 268 266 272 272 272 268 232 294 277 275 279 277|278 277 277|278 279 279 286 286 286 277 291 291 291 291 286 294 294 294 294 301 301 300 300 297 295 305 305 305 301 309 309 309 305 294 313 319 316 316 313 319 319 319 321 319 326 325 325 326 321 328 326 331 331 326 333 331|332|333 331|332|333 331|333 331|332|333 339 339 339 331 319 343 344 344 344 344 346 344 344 354 354 354 354 354	Association
12872252	Disease	Gene	D001943	83990	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ BRIP1 @/GeneTgt$ ? [SEP] Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and @GeneTgt$ BRIP1/BACH1 @/GeneTgt$ among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset @DiseaseSrc$ breast cancer @/DiseaseSrc$ cases and reference individuals . Two potential @DiseaseSrc$ breast cancer @/DiseaseSrc$ susceptibility genes , encoding the BRCA1-interacting proteins ZNF350 ( or ZBRK1 ) and @GeneTgt$ BRIP1 @/GeneTgt$ ( or BACH1 ) , have been identified in yeast two-hybrid screens . We sequenced these genes in probands from 21 families with potentially inherited breast/ovarian cancer , all of which were negative for BRCA1/BRCA2 mutations . Families had at least one case of male breast cancer , two cases of ovarian cancer , or three or more cases of breast and ovarian cancer . In addition , 58 early-onset ( before age 35 ) @DiseaseSrc$ breast cancer @/DiseaseSrc$ cases and 30 reference individuals were analyzed . Of 17 variants detected in ZBRK1 , a missense mutation Val524Ile was identified in the proband of one high-risk family , but no other family members were available for testing . Of 25 variants identified in @GeneTgt$ BRIP1 @/GeneTgt$ , in addition to four common silent or missense mutations , we identified Gln540Leu , a non-conservative amino acid change , in a single familial proband with inflammatory breast cancer , but this mutation was not present in her three relatives with @DiseaseSrc$ breast cancer @/DiseaseSrc$ . Haplotype analysis suggests that all ZBRK1 SNPs fall within a single block with two SNPs capturing 92 % of the haplotype diversity , while the @GeneTgt$ BRIP1 @/GeneTgt$ SNPs fall in two blocks , with five SNPs capturing 89 % of the haplotype diversity . Based on sequencing of ZBRK1 and @GeneTgt$ BRIP1 @/GeneTgt$ in 21 BRCA1/2-negative probands from inherited breast/ovarian cancer families , it appears unlikely that mutations in these genes account for a significant fraction of inherited breast cancer . Further analysis in unselected cases will be required to know whether the identified variants play a role in genetic predisposition to @DiseaseSrc$ breast cancer @/DiseaseSrc$ in the general population . Hum Mutat 22:121 - 128 , 2003 . Published 2003 Wiley-Liss , Inc.	2 2 6 6 6 2 6 7 8|7 7 8|7 12 7 12 15 12 19 19 19 2 19 26 26 26|21 26|21 26 26|21 19 26 29 26 2 39 39 34|39 34|39 39 34|39 39 60 39 39 44 44 45 41 48 46 45 48 45 48|45 45 48|45 51 51 51 51 45 60 60 60 64 64 64 60 60 69 69 71 69 73 71 76 76 73 81 79 81 81 76 87 87 85 83 87 69 90 90 87 87 93 93 95 96 97 93 101 101 101 97 97 104 97 107 107 104 107 107 113 110 110 107 115 113 115 118 115 93 121 139 139 124 139 133 127 125 133 133 129|133 129|133 133 129|133 124 124 137 137 139 139 139 139 143 144 154 144 147 145 147 152 152 152 147 154 154 157 157 154 161 161 161 157 154 154 167 167 167 169 169 154 171 169 169 174 175 192 175 178 176|177 176 176|177 175 182 186 186 186 186 175 186 186 186 192 192 192 192 193 199 199 199 199 193 193 205 205 205 205 193 209 209 209 205 192 192 213 216 216 216 192 220 220 220 216 222 220|222 220|222 220|222 220|222 192 229 230 230 235 234 234 235 230 239 239 239 235 242 242 239 242 245 243 249 249 249 245 235 256 255 252|255 255 252|255 256 235 259 259 256 235 263 263 235 263 266 264 270 270 270 266 230 292 275 273 277 275 277 277|278 277 277|278 284 284 284 275 289 289 289 289 284 292 292 292 292 299 299 298 298 295 293 303 303 303 299 307 307 307 303 292 311 317 314 314 311 317 317 317 319 317 324 323 323 324 319 326 324 329 329 324 331 329|330|331 329|330|331 329|331 329|330|331 337 337 337 329 317 341 342 342 342 342 344 342 342 352 352 352 352 352	Association
12872252	Disease	Gene	D010051	83990	True	0	What is [EMU_BC] between @DiseaseSrc$ breast and ovarian cancer @/DiseaseSrc$ and @GeneTgt$ BRIP1 @/GeneTgt$ ? [SEP] Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and @GeneTgt$ BRIP1/BACH1 @/GeneTgt$ among BRCA1 and BRCA2-negative probands from @DiseaseSrc$ breast-ovarian cancer @/DiseaseSrc$ families and among early-onset breast cancer cases and reference individuals . Two potential breast cancer susceptibility genes , encoding the BRCA1-interacting proteins ZNF350 ( or ZBRK1 ) and @GeneTgt$ BRIP1 @/GeneTgt$ ( or BACH1 ) , have been identified in yeast two-hybrid screens . We sequenced these genes in probands from 21 families with potentially inherited breast/ovarian cancer , all of which were negative for BRCA1/BRCA2 mutations . Families had at least one case of male breast cancer , two cases of @DiseaseSrc$ ovarian cancer @/DiseaseSrc$ , or three or more cases of @DiseaseSrc$ breast and ovarian cancer @/DiseaseSrc$ . In addition , 58 early-onset ( before age 35 ) breast cancer cases and 30 reference individuals were analyzed . Of 17 variants detected in ZBRK1 , a missense mutation Val524Ile was identified in the proband of one high-risk family , but no other family members were available for testing . Of 25 variants identified in @GeneTgt$ BRIP1 @/GeneTgt$ , in addition to four common silent or missense mutations , we identified Gln540Leu , a non-conservative amino acid change , in a single familial proband with inflammatory breast cancer , but this mutation was not present in her three relatives with breast cancer . Haplotype analysis suggests that all ZBRK1 SNPs fall within a single block with two SNPs capturing 92 % of the haplotype diversity , while the @GeneTgt$ BRIP1 @/GeneTgt$ SNPs fall in two blocks , with five SNPs capturing 89 % of the haplotype diversity . Based on sequencing of ZBRK1 and @GeneTgt$ BRIP1 @/GeneTgt$ in 21 BRCA1/2-negative probands from inherited breast/ovarian cancer families , it appears unlikely that mutations in these genes account for a significant fraction of inherited breast cancer . Further analysis in unselected cases will be required to know whether the identified variants play a role in genetic predisposition to breast cancer in the general population . Hum Mutat 22:121 - 128 , 2003 . Published 2003 Wiley-Liss , Inc.	2 2 6 6 6 2 6 7 8|7 7 8|7 12 7 12 15 12 20 20|15 20|15 20 20|15 2 20 26 26 26 26 20 26 29 26 2 38 38 38 38 38 59 38 38 43 43 44 40 47 45 44 47 44 49|44 44 49|44 50 50 50 50 44 59 59 59 63 63 63 59 59 67 67 69 67 71 69 74 74 71 79 77 79 79 74 85 85 83 81 85 67 88 88 85 85 91 91 93 94 95 91 99 99 99 95 95 102 95 104 102|103|104 102|103|104 102|104 102|103|104 104 104 112 109 109 104 114 114|111|112 114|111|112 114|111|112 114|111|112 114|112 114|111|112 91 123 140 140 126 140 134 129 127 134 134 134 134 126 126 138 138 140 140 140 140 143 144 154 144 147 145 147 152 152 152 147 154 154 157 157 154 161 161 161 157 154 154 167 167 167 169 169 154 171 169 169 174 175 192 175 178 176|177 176 176|177 175 182 186 186 186 186 175 186 186 186 192 192 192 192 193 199 199 199 199 193 193 205 205 205 205 193 209 209 209 205 192 192 213 216 216 216 192 220 220 220 216 223 223 220 192 227 228 228 233 232 232 233 228 237 237 237 233 240 240 237 240 243 241 247 247 247 243 233 254 253 250|253 253 250|253 254 233 257 257 254 233 261 261 233 261 264 262 268 268 268 264 228 290 273 271 275 273 275 275|276 275 275|276 282 282 282 273 287 287 287 287 282 290 290 290 290 297 297 296 296 293 291 301 301 301 297 305 305 305 301 290 309 315 312 312 309 315 315 315 317 315 322 321 321 322 317 324 322 327 327 322 330 330 327 334 334 334 327 315 337 338 338 338 338 340 338 338 348 348 348 348 348	Association
12628588	Disease	Gene	D001943	1052	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ C/EBPD @/GeneTgt$ ? [SEP] Detection of base sequence changes in the @GeneTgt$ CEBPD @/GeneTgt$ gene in human @DiseaseSrc$ breast cancer @/DiseaseSrc$ cell lines and primary @DiseaseSrc$ breast cancer @/DiseaseSrc$ isolates . Single strand conformation polymorphism ( SSCP ) analysis was performed on genomic DNA from 97 human @DiseaseSrc$ breast cancer @/DiseaseSrc$ samples and 10 breast cell lines to screen for mutations in the single exon @GeneTgt$ C/EBPD @/GeneTgt$ gene . Three @GeneTgt$ C @/GeneTgt$ -- > T transitions resulting in silent mutations were detected in three individual @DiseaseSrc$ breast cancer @/DiseaseSrc$ samples . One @DiseaseSrc$ breast cancer @/DiseaseSrc$ sample also contained a G -- > T transversion ( Q253H ) . The SUM-52PE cell line contained an A -- > T transversion ( AAG -- > TAG ) resulting in a nonsense mutation ( K180Stop ) . All mutations identified in genomic DNA isolates were in highly conserved regions of the @GeneTgt$ C/EBPD @/GeneTgt$ gene . This study indicates that mutational alterations in the coding region of the @GeneTgt$ C/EBPD @/GeneTgt$ gene are relatively uncommon in human @DiseaseSrc$ breast cancer @/DiseaseSrc$ .	1 5 5 5 1 10 10 10|7 10 10|7 5 17 17 17|11 17|11 17 17|11 17 10 17 23 16|20|23 16|20|23 20|23 16|20|23 17 1 31 31 31 35 33 35 35 37 37 37 40 40 37 47 47 47 43|47 43|47 47 43|47 37 47 52 52 52 47 54 37 56 54 63 63 63 63 63|58 63 63|58 56 37 68 67|73 73 67|73 73 73 73 79 73 77 77 74 79 79 86 86 86 86|81 86|81 86 86|81 79 79 94 90|94 90|94 94 90|94 96 96 96 98 96 102 102 102 98 104 102 104 96 111 111 111 112 112 114 112 118 118 118 114 120 118 123 123 120 123 118 129 129 129 125 131 129 131 112 135 145 135 140 140 140 136 145 145 144 145 145 150 150 150|147 150 150|147 145 145 154 155 155 170 158 170 162 162 162 158 167 167 164|167 167 164|167 162 170 170 155 173 173 170|171|173 170|171|173 170|173 170|171|173 155	Association
12649339	Disease	Gene	D001943	7157	False	2	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ TP53 @/GeneTgt$ ? [SEP] Characterization of a novel @DiseaseSrc$ breast carcinoma xenograft @/DiseaseSrc$ and cell line derived from a BRCA1 germ-line mutation carrier . A human tumor xenograft ( L56Br-X1 ) was established from a breast cancer axillary lymph node metastasis of a 53-year-old woman with a BRCA1 germ-line nonsense mutation ( 1806C > T ; Q563X ) , and a cell line ( L56Br-C1 ) was subsequently derived from the xenograft . The xenograft carries only the mutant BRCA1 allele and expresses mutant BRCA1 mRNA but no BRCA1 protein as determined by immunoprecipitation or Western blotting . The primary tumor , lymph node metastasis , and xenograft were hypodiploid by DNA flow cytometry , whereas the cell line displayed an aneuploidy apparently developed via polyploidization . Cytogenetic analysis , spectral karyotyping , and comparative genomic hybridization of the cell line revealed a highly complex karyotype with numerous unbalanced translocations . The xenograft and cell line had retained a somatic @GeneTgt$ TP53 @/GeneTgt$ missense mutation ( S215I ) originating from the primary tumors , as well as a lack of immunohistochemically detectable expression of steroid hormone receptors , epidermal growth factor receptor , human epidermal growth factor receptor 2 ( HER-2 ) , and keratin 8 . Global gene expression analysis by cDNA microarrays supported a correlation between the expression profiles of the primary tumor , lymph node metastasis , xenograft , and cell line . We conclude that L56Br-X1 and L56Br-C1 are useful model systems for studies of the pathogenesis and new therapeutic modalities of BRCA1-induced human @DiseaseSrc$ breast cancer @/DiseaseSrc$ .	1 5 5 5 1|4|5 1|4|5 1|4|5 1|5 1|4|5 5 11 5 5 18 18 18 18 18 12 1 24 24 24 29 26 24 26 29 29 37 37 33 37 37 37 37 29 41 41 41 37 47 47 47 47 47 41 53 53 53 53 53 47 53 29 29 59 59 65 61 59 61 65 65 29 68 68 65 29 71 72 72 77 77 77 77 72 72 72 82 82 79 72 86 86 72 88 72 90 88 90 93 90 72 97 97 106 97 101 101 97 97 97 97 106 106 110 110 110 106 106 106 115 115 116 106 118 116 120 116 122 120 116 125 138 125 128 125 128 125 133 133 125 137 137 137 133 138 142 141 142 138 146 146 146 142 138 149 154 149 152 149 154 154 162 162 156|162 162 156|162 162 162 162 154 162 162 168 168 168 164 162 162 170 170 174 162 178 177 178 174 182 182 182 178 182 187 187 187 182 182 193 193 193 193 182 193 196 193 196 182 182 182 200 154 207 207 207 211 210 210 207 211 213 211 217 217 217 213 221 221 221 217 221 225 225 221 221 221 221 221 231 221 211 234 234 242 242 236 236 242 242 242 234 244 242 247 247 244 247 251 251 247 255 255 255 247|254|255 247|254|255 247|255 247|254|255 234	Association
12649339	Disease	Gene	D001943	672	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ BRCA1 @/GeneTgt$ ? [SEP] Characterization of a novel @DiseaseSrc$ breast carcinoma xenograft @/DiseaseSrc$ and cell line derived from a @GeneTgt$ BRCA1 @/GeneTgt$ germ-line mutation carrier . A human tumor xenograft ( L56Br-X1 ) was established from a breast cancer axillary lymph node metastasis of a 53-year-old woman with a @GeneTgt$ BRCA1 @/GeneTgt$ germ-line nonsense mutation ( 1806C > T ; Q563X ) , and a cell line ( L56Br-C1 ) was subsequently derived from the xenograft . The xenograft carries only the mutant @GeneTgt$ BRCA1 @/GeneTgt$ allele and expresses mutant @GeneTgt$ BRCA1 @/GeneTgt$ mRNA but no @GeneTgt$ BRCA1 @/GeneTgt$ protein as determined by immunoprecipitation or Western blotting . The primary tumor , lymph node metastasis , and xenograft were hypodiploid by DNA flow cytometry , whereas the cell line displayed an aneuploidy apparently developed via polyploidization . Cytogenetic analysis , spectral karyotyping , and comparative genomic hybridization of the cell line revealed a highly complex karyotype with numerous unbalanced translocations . The xenograft and cell line had retained a somatic TP53 missense mutation ( S215I ) originating from the primary tumors , as well as a lack of immunohistochemically detectable expression of steroid hormone receptors , epidermal growth factor receptor , human epidermal growth factor receptor 2 ( HER-2 ) , and keratin 8 . Global gene expression analysis by cDNA microarrays supported a correlation between the expression profiles of the primary tumor , lymph node metastasis , xenograft , and cell line . We conclude that L56Br-X1 and L56Br-C1 are useful model systems for studies of the pathogenesis and new therapeutic modalities of @GeneTgt$ BRCA1-induced @/GeneTgt$ human @DiseaseSrc$ breast cancer @/DiseaseSrc$ .	1 5 5 5 1|4|5 1|4|5 1|4|5 1|5 1|4|5 5 11 5 5 19 19 19|11 19 19|11 19 19 12 1 26 26 26 31 28 26 28 31 31 39 39 35 39 39 39 39 31 43 43 43 39 50 50 50|45 50 50|45 50 50 43 56 56 56 56 56 50 56 31 31 62 62 68 64 62 64 68 68 31 71 71 68 31 75 76 76 82 82 82 82|79 82 82|79 76 76 76 88 84|88 88 84|88 84 76 93 93|88 93 93|88 76 95 76 97 95 97 100 97 76 107 107 116 107 111 111 107 107 107 107 116 116 120 120 120 116 116 116 125 125 126 116 128 126 130 126 132 130 126 135 148 135 138 135 138 135 143 143 135 147 147 147 143 148 152 151 152 148 156 156 156 152 148 159 164 159 162 159 164 164 171 171 171 171 171 171 164 171 171 177 177 177 173 171 171 179 179 183 171 187 186 187 183 191 191 191 187 191 196 196 196 191 191 202 202 202 202 191 202 205 202 205 191 191 191 209 164 215 215 215 219 218 218 215 219 221 219 225 225 225 221 229 229 229 225 229 233 233 229 229 229 229 229 239 229 219 242 242 250 250 244 244 250 250 250 242 252 250 255 255 252 255 259 259 255 264 264|260 264 264|260 264 264|262|255 264|262|255 264|255 264|262|255 242	Association
16503999	Disease	Gene	D001943	3077	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ HFE @/GeneTgt$ ? [SEP] @GeneTgt$ HFE @/GeneTgt$ H63D mutation frequency shows an increase in Turkish women with @DiseaseSrc$ breast cancer @/DiseaseSrc$ . BACKGROUND : The hereditary hemochromatosis gene @GeneTgt$ HFE @/GeneTgt$ plays a pivotal role in iron homeostasis . The association between cancer and @GeneTgt$ HFE @/GeneTgt$ hetero- or homozygosity has previously been shown including hepatocellular and nonhepatocellular malignancies . This study was performed to compare frequencies of @GeneTgt$ HFE @/GeneTgt$ C282Y and H63D variants in Turkish women with @DiseaseSrc$ breast cancer @/DiseaseSrc$ and healthy controls . METHODS : Archived DNA samples of Hacettepe University Oncology Institute were used in this study . The @GeneTgt$ HFE @/GeneTgt$ gene was investigated by PCR-RFLP . RESULTS : All subjects studied were free from C282Y mutation . Thirty-nine patients had H63D mutation and were all heterozygous . H63D allele frequency was 22.2 % ( 39/176 ) in the @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients , and 14 % ( 28/200 ) in the healthy volunteers . Statistical analysis of cases with @GeneTgt$ HFE @/GeneTgt$ H63D phenotype showed significant difference between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and healthy volunteers ( P = 0.02 ) . CONCLUSION : Our results suggest that @GeneTgt$ HFE @/GeneTgt$ H63D mutation frequencies were increased in the @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients in comparison to those in the general population . Also , odds ratios ( odds ratio = 2.05 ) computed in this study suggest that H63D has a positive association with @DiseaseSrc$ breast cancer @/DiseaseSrc$ .	0|5 5 0|5 5 5 6 6 8 6 11 11 8 13 8|11|13 8|11|13 8|13 8|11|13 6 27 19 25 25 25 25 27|24 27 27|24 27 30 30 27 33 33 27 27 37 49 39 37 39 43|40 43 43|40 39 43 43 49 49 49 49 51 49 51 51 51 49 58 60 60 60 62 60 62 67 64|67 67 64|67 63 67 67 67 73 73 70 75 73|75 73|75 73|75 73|75 75 80 75 60 95 95 88 88 95 93 91 93 93 88 95 95 98 98 95 95 103 100|103 103 100|103 105 105 105 107 105 105 116 110 113 116 113 116 116 119 119 116 116 122 123 123 125 123 123 129 129 123 123 133 133 136 136 136 136 138 136 138 145 145 141|145 141|145 145 141|145 136 145 145 149 145 151 149 151 156 156 156 145 136 160 168 162 160 167 167|163 167 167|163 167 162 168 170 168 172 170|172 170|172 170|172 170|172 172 177 172 179 180 177 180 168 168 190 190 189 190 190 198 196|191 196 196|191 196 196 198 198 190 204 204 204|199 204|199 204 204|199 198 206 198 208 206 212 212 212 208 190 230 230 219 230 222 222 219 222 223 222 219 229 229 226 230 233 233 230 236 236 233 238 236|237|238 236|237|238 236|238 236|237|238 230	Association
12702523	Disease	Gene	D001943	7157	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ p53 @/GeneTgt$ ? [SEP] Prognostic value of @GeneTgt$ p53 @/GeneTgt$ molecular status in high-risk primary @DiseaseSrc$ breast cancer @/DiseaseSrc$ . BACKGROUND : Mutations in the @GeneTgt$ p53 @/GeneTgt$ gene are the most common genetic alterations in human primary @DiseaseSrc$ breast carcinoma @/DiseaseSrc$ and these mutations are often associated with worse prognosis and chemo/radioresistance . PATIENTS AND METHODS : The analysis of the @GeneTgt$ p53 @/GeneTgt$ gene was performed by fluorescence-assisted mismatch analysis in 13 consecutive high-risk primary @DiseaseSrc$ breast cancer @/DiseaseSrc$ ( HR-BC ) patients with 10 or more involved axillary nodes to evaluate its prognostic value . RESULTS : Three @GeneTgt$ p53 @/GeneTgt$ mutations ( 23 % ) and four allelic variants were detected . After a median follow-up of 52 months the HR-BC disease-free survival ( DFS ) was 51 % and overall survival 79 % . All patients harboring a @GeneTgt$ p53 @/GeneTgt$ mutation ( @GeneTgt$ p53(mut @/GeneTgt$ ) ) relapsed within 10 months of the median DFS while 67 % of those showing a wild-type @GeneTgt$ p53 @/GeneTgt$ status ( @GeneTgt$ p53(wt @/GeneTgt$ ) ) survive disease-free at a median follow-up of 43 months . One @GeneTgt$ p53(mut @/GeneTgt$ ) patient is still alive while all the @GeneTgt$ p53(wt @/GeneTgt$ ) patients survive at 56 months median follow-up . Two out of the four @GeneTgt$ p53(wt @/GeneTgt$ ) relapsing @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients showed the Arg72Pro allelic variant ; one of these died at 75 months . CONCLUSIONS : @GeneTgt$ p53 @/GeneTgt$ mutations may help identify a subset of very high risk @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients ( vHR-BC ) with worse prognosis .	2 2 7 3|7 7 3|7 7 2 11 11 11 9|11|7 9|11|7 11|7 9|11|7 2 17 17 30 24 24 24|21 24 24|21 19 30 30 28 30 30 17 34 34 34 32|34|30 32|34|30 34|30 32|34|30 30 39 42 42 42 30 45 45 42 45 45 17 51 51 51 51 56 63 61 61 58|61 61 58|61 56 63 51 67 67 67 63 79 79 79 79 79 79|71|73 79|71|73 79|73 79|71|73 77 79 79 67 86 86 81 84 81 86 79 88 63 91 91 88 63 95 95 100 97|100 100 97|100 110 103 103 100 103 100 108 108 100 110 95 95 116 116 116 129 119 119 116 123 123 123 129 125 123 125 129 129 129 129 132 129 134 129 129 137 148 137 142 139|142 142 139|142 138 144 137|142 137 137|142 144 144 148 151 151 148 155 155 155 151 172 158 172 160 158 160 166 166 161|166 166 161|166 161 168 164|166 166 164|166 168 168 148 172 177 177 177 172 180 180 177 148 187 186|190 190 186|190 190 193 193 193 193 201 200 200 195|200 200 195|200 200 201 193 204 204 201 206 201 193 223 210 222 222 215 218|214 218 218|214 218 222 217|222 217|222 222 217|222 211 223 227 227 227 223 223 232 231 229 223 235 235 232 223 239 239 240|243 243 240|243 246 246 246 239 248 246 256 251 252 256 256|251 256|251 256 256|251 248 258 256 258 262 262 246 239	Association
12668615	Disease	Gene	D001943	7517	False	2	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ XRCC3 @/GeneTgt$ ? [SEP] A naturally occurring mutation in an ATP-binding domain of the recombination repair gene @GeneTgt$ XRCC3 @/GeneTgt$ ablates its function without causing cancer susceptibility . Inherited mutations of the BRCA1 and BRCA2 genes , whose protein products are necessary for the homology-directed DNA repair pathway , confer a dominant susceptibility to cancer . We have investigated whether mutations of genes encoding other components of the same DNA repair pathway can also affect cancer susceptibility . We have identified three novel non-synonymous substitutions in one such gene , encoding the RAD51-related protein @GeneTgt$ XRCC3 @/GeneTgt$ . One of these variants , D213N , occurs in a highly conserved ATP-binding domain and completely abrogates the ability of the transfected gene to correct the phenotype of @GeneTgt$ XRCC3 @/GeneTgt$ deficient cells . The D213N variant was found in the heterozygous state in DNA from 3/1577 healthy individuals . However , we did not detect this variant at all amongst 187 @DiseaseSrc$ breast cancer @/DiseaseSrc$ families and 1300 unrelated patients with common cancers . Thus we have no evidence that D213N increases the risk of cancer . We propose that not all components of the homologous recombination repair complex can act as cancer susceptibility genes .	4 3 4 16 8 8 8 4 14 14 14 14 14 8|13 8 8|13 16 18 16 20 16 22 20 16 26 38 32 32 28 29 29 26 32 36 36 38 38 38 44 44 44 44 44 38 38 38 49 49 46 51 49 38 55 55 55 71 71 59 57 59 62 60 68 68 68 68 68 62 71 71 55 73 71 55 77 77 77 81 81 81 77 85 85 85 81 77 77 91 91 91 90|87 87 90|87 77 102 98 98 95 95 95 95 102 108 108 106 108 108 102 102 111 102 113 111 117 117 117 113 119 113 121 119 126 122|125 125 122|125 126 121 102 131 131 133 133 133 137 137 137 133 139 137 143 143 143 137 133 150 150 150 150 150 150 152 150 160 156 156 160 160|156 160|156 160 160|156 152 160 164 164 160 167 167 164 150 172 172 172 174 172 177 177 174 179 177 181 179 172 184 184 196 187 188 196 194 194 194 194 194 188 196 184 200 200 200 196 184	Association
15870154	Disease	Gene	D001943	1543	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ CYP1A1 @/GeneTgt$ ? [SEP] @GeneTgt$ Cytochrome P-450 1A1 @/GeneTgt$ gene polymorphisms and risk of @DiseaseSrc$ breast cancer @/DiseaseSrc$ : a HuGE review . @GeneTgt$ Cytochrome P-450 ( CYP ) 1A1 @/GeneTgt$ plays a key role in phase I metabolism of polycyclic aromatic hydrocarbons and in estrogen metabolism . It is expressed predominantly in extrahepatic tissues , including the breast . Four @GeneTgt$ CYP1A1 @/GeneTgt$ gene polymorphisms ( 3801 T -- > C , Ile462Val , 3205 T -- > C , and Thr461Asp ) have been studied in relation to @DiseaseSrc$ breast cancer @/DiseaseSrc$ . The 3801C variant is more common than the Val variant . Both variants occur more frequently in Asians than in White populations . The 3205 T -- > C polymorphism has been observed in African Americans only . Little data are available on the geographic/ethnic distribution of the Thr461Asp polymorphism . The functional significance of the polymorphisms is unclear . In 17 studies , no consistent association between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ CYP1A1 @/GeneTgt$ genotype was found . Meta-analysis found no significant risk for the genotypes 1 ) 3801C/C ( relative risk ( RR ) = 0.97 , 95 % confidence interval ( CI ): 0.52 , 1.80 ) or 3801T/C ( RR = 0.91 , 95 % CI : 0.70 , 1.19 ) versus 3801T/T , 2 ) Val/Val ( RR = 1.04 , 95 % CI : 0.63 , 1.74 ) or Ile/Val ( RR = 0.92 , 95 % CI : 0.76 , 1.10 ) versus Ile/Ile , or 3 ) Asp/Asp ( RR = 0.95 , 95 % CI : 0.20 , 4.49 ) or Thr/Asp ( RR = 1.12 , 95 % CI : 0.87 , 1.43 ) versus Thr/Thr . Future studies should explore possible interactions between @GeneTgt$ CYP1A1 @/GeneTgt$ and sources of polycyclic aromatic hydrocarbons , markers of estrogen exposure , other lifestyle factors influencing hormonal levels , and other genes involved in polycyclic aromatic hydrocarbon metabolism or hormonal biosynthesis .	0|6 0|6 0|6 6 0|6 6 6 6 6 10 8|10|6 8|10|6 8|10 8|10|6 6 16 16 6 6 19|20|27 19|20|27 19|20|27 19|20|27 19|20|27 19|20|27 27|20 19|20|27 27 30 30 27 34 34 34 27 38 38 38 34 34 42 42 34 27 47 47 47 47 51 51 47 51 55 55 51 47 61 57|61 61 57|61 61 82 64 64 61 64 67 64 67 67 72 72 67 75 75 72 75 75 75 72 82 82 82 84 82 86 84|86 84|86 84|86 84|86 82 94 94 97 97 97 97 101 101 101 97 97 104 105 105 107 105 109 107 113 113 113 105 105 117 117 124 117 121 121 124 124 124 124 127 127 124 124 124 131 133 133 133 137 137 137 133 141 141 141 137 133 145 145 150 148 148 145 150 150 150 154 154 168 168 158 158 168 160 159|160|158 159|160|158 160|158 159|160|158 160 161|166 166 161|166 160 168 168 168 173 173 176 176 173 179 179 176 179 180 179 185 185 182 187 185 187 185 189 190 195 195 195 190 197 195 197 197 199 197 197 195 195 207 207 195 207 207 211 212 173 212 212 214 214 214 212 223 219 219 221 212 225 223 225 226 226 230 231 223 231 235 233 231 235 223 223 240 223 240 241 241 245 246 223 250 250 248 246 250 246 246 253 253 258 258 223 261 261 258 261 261 265 266 261 266 270 268 266 270 261 261 276 276 261 276 276 280 281 223 281 285 283 281 285 223 223 173 291 293 293 293 295 293 297 295|296 295 295|296 297 297 304 304 304 300 297 297 309 309 306 297 313 313 297 313 316 314 316 316 320 316 320 326 326 326 326 321 326 329 326 293	Association
17001622	Disease	Gene	D001943	472	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ ATM @/GeneTgt$ ? [SEP] Characterization of the @DiseaseSrc$ breast cancer @/DiseaseSrc$ associated @GeneTgt$ ATM @/GeneTgt$ 7271T > G ( V2424 G ) mutation by gene expression profiling . Mutations in @GeneTgt$ ATM @/GeneTgt$ are responsible for the autosomal recessive disorder ataxia telangiectasia . Heterozygous mutations in @GeneTgt$ ATM @/GeneTgt$ have been associated with an elevated risk of @DiseaseSrc$ breast cancer @/DiseaseSrc$ . We previously reported one @DiseaseSrc$ breast cancer @/DiseaseSrc$ family in which @GeneTgt$ ATM @/GeneTgt$ 7271T > G ( V2424 G ) segregated with disease , and apparently acted in a dominant negative manner . We now report the screening of 782 multiple-case @DiseaseSrc$ breast cancer @/DiseaseSrc$ families that identified two additional index cases with @GeneTgt$ ATM @/GeneTgt$ 7271T > G. Phylogenetic sequence analysis showed that V2424 is a highly conserved residue , and that the 2424 G variant is likely to interfere with function . To elucidate the consequences of this mutation , we expression profiled wild-type , heterozygous , and homozygous lymphoblastoid cell lines ( LCLs ) from Scottish and Australian families using an oligonucleotide microarray . Cluster analysis revealed 77 genes that were differentially expressed in homozygous and heterozygous V2424 G cells ( compared to wild-type ) and 11 genes differentially expressed in the homozygous cells . We also evaluated the profiles of LCLs after exposure to ionizing radiation ( IR ) and identified 77 genes that were differentially expressed in wild-type cells , but not in homozygous or heterozygous V2424 G cells . We validated the expression differences by RT-PCR in additional heterozygous V2424 G LCLs from another @DiseaseSrc$ breast cancer @/DiseaseSrc$ family . We found no consistent cytotoxicity or abrogation of @GeneTgt$ ATM @/GeneTgt$ kinase activity after IR in seven heterozygous V2424 G LCLs , compared to wild-type LCLs , but did find an increase in the number of chromosomal aberrations . These data suggest that the V2424 G missense mutation acts largely as a dominant negative in terms of the associated expression profiles .	7 4 4 1|3|4 1|3|4 1|4 1|3|4 7 10|5 10 10|5 12 12 17 15 15 17 17 7 21 21 21 17 7 30 27 25|26 25 25|26 30 30 35 35 35 35 30 37 35 30 41 47 43 41|42 41 41|42 47 47 47 51 51 51 47 53 51|53 51|53 51|53 51|53 47 61 61 61 66 66|62 66|62 66 66|62 61 68 78 66|71 71 66|71 78 73 78 76 76 73 76 66 80 78 66 61 84 61 89 89 89 89 84 61 95 95 95 97 95 104 104 104 100|104 100|104 104 100|104 97 106 104 110 110 110 106 114 109|114 114 109|114 106 119 119 119 119 120 95 127 127 127 127 126 127 120 127 127 136 134 134 134 136 136 127 138 136 140 138 95 145 154 147 145 150 150 147 154 153 154 154 171 155 155 155 155 155 163 163 155 165 163 165 168 171 168 168 154 171 175 175 172 154 178 179 179 181 179 185 185 185 181 187 185 187 187 192 192 187 194 185 196 194 196 196 200 196 202 200 206 206 206 202 179 210 210 210 212 210 214 212 216 210 219 219 216 221 219 221 210 210 226 224 230 230 230 226 233 233 230 233 233 238 238 233 238 238 243 243 238 210 246 246 249 249 246 251 249 257 257 257 257 257 251 263 263 263|259 263|259 263 263|259 257 246 267 267 270 270 267 270 270 277 273|277 277 273|277 277 272 279 272 285 285 285 285 285 272 267 267 290 290 287 267 267 294 267 296 294 299 299 296 302 302 299 267 306 307 307 314 313 313 313 313 314 307 314 319 319 319 314 321 319 326 326 326 326 321 307	Association
12023985	Disease	Gene	D001943	7516	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ XRCC2 @/GeneTgt$ ? [SEP] A potential role for the @GeneTgt$ XRCC2 @/GeneTgt$ R188H polymorphic site in DNA-damage repair and @DiseaseSrc$ breast cancer @/DiseaseSrc$ . An acquired genetic instability , resulting from the loss of some types of DNA repair , is an early event in the development of a subset of human cancers . The involvement of BRCA1 and BRCA2 in the homologous recombination repair ( HRR ) of double-strand breaks in DNA implicates this pathway in the suppression of @DiseaseSrc$ breast cancer @/DiseaseSrc$ . A family of proteins related to human RAD51 , including @GeneTgt$ XRCC2 @/GeneTgt$ , are essential components of this repair pathway . Using site-directed mutagenesis of @GeneTgt$ XRCC2 @/GeneTgt$ , we show that non-conservative substitution or deletion of amino acid 188 of @GeneTgt$ XRCC2 @/GeneTgt$ can significantly affect cellular sensitivity to DNA damage , and that a polymorphic variant at this site ( R188H ) , present on 6 % of chromosomes in the population , has a weak effect on damage sensitivity . We tested the hypothesis that the R188H polymorphism could be a low-penetrance susceptibility factor for @DiseaseSrc$ breast cancer @/DiseaseSrc$ , by genotyping 521 women with @DiseaseSrc$ breast cancer @/DiseaseSrc$ and a total of 895 control women . Carriage of the rare allele of @GeneTgt$ XRCC2 @/GeneTgt$ R188H was associated with @DiseaseSrc$ breast cancer @/DiseaseSrc$ overall [ odds ratio 1.3 ; 95 % confidence interval (CI)=(1.0 , 1.8 ) ] and when younger-onset cases with a positive family history were compared with older controls with no family history [ odds ratio 1.9 ; 95 % CI=(1.0 , 3.8 ) ] . These results support the hypothesis that subtle variation in DNA repair capacity may influence cancer susceptibility in the population .	3 3 3 10 10 10|5 10 10|5 10 10 3 13 13 10 13 13|15 13|15 13|15 13|15 3 24 24 24 40 24 24 29 29 26 32 32 29 35 35 32 24 40 40 40 40 43 43 40 46 46 43 49 49 46 40 52 70 54 52 54 54 61 61 61 61 52 63 61 63 67 67 61 69 67 70 72 70 75 75 72 77 75|76|77 75|76|77 75|77 75|76|77 70 83 97 85 83 85 89 89 86 89 92 89|91 89 89|91 83 97 97 97 101 101 101 97 97 112 106 104 108 106|107 106 106|107 112 112 112 127 115 127 115 115 120 120 115 120 123 121|115 115 121|115 127 127 112 129 127 132 132 129 127 127 156 138 138 156 141 141 138 143 141 143 138 138 149 149 146 151 149 154 154 149 156 127 159 159 156 162 162 156 112 167 167 169 167 179 173 173 179 179 179 179 179 179 169 181 181|179|180 181|179|180 181|179 181|179|180 179 186 179 188 186 190 190|187|188 190|187|188 190|188 190|187|188 188 195 186 199 199 199 195 167 213 207 207 207 203 211 211|208 211 211|208 207 213 213 215 213|215 213|215 213|215 213|215 213 221 221 218 221 221 225 227 227 228 221 228 228 230 228 221 243 236 243 241 241 241 241 236 243 213 246 246 243 250 250 250 246 253 253 246 253 253 257 258 253 260 243 260 213 213 267 268 268 270 268 279 273 279 277 277 277 273 279 270 281 279 284 284 281 268	Association
16822847	Disease	Gene	D001943	2264	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ FGFR4 @/GeneTgt$ ? [SEP] @GeneTgt$ FGFR4 @/GeneTgt$ Arg388 allele is associated with resistance to adjuvant therapy in primary @DiseaseSrc$ breast cancer @/DiseaseSrc$ . PURPOSE : A recent study presented first evidence that a single nucleotide polymorphism ( SNP ) at codon 388 of @GeneTgt$ fibroblast growth factor receptor 4 @/GeneTgt$ ( @GeneTgt$ FGFR4 @/GeneTgt$ ) gene , causing a transmembrane domain missense mutation ( Gly388Arg ) , is associated with disease outcome in node-positive @DiseaseSrc$ breast cancer @/DiseaseSrc$ . This article addresses the clinical relevance of this SNP , @GeneTgt$ FGFR4 @/GeneTgt$ genotype , phenotype , and HER2 regarding patient outcome and influence of adjuvant systemic therapy in a substantial primary @DiseaseSrc$ breast cancer @/DiseaseSrc$ collective ( n = 372 ; median follow-up , 94.5 months ) . METHODS : Polymerase chain reaction restriction fragment length polymorphism analysis of germ-line polymorphism was performed in uninvolved lymph nodes ; @GeneTgt$ FGFR4 @/GeneTgt$ and HER2 expression were assessed immunohistochemically in tissue microarrays . RESULTS : In 51 % of patients , homo- or heterozygous Arg388 allele was present . No correlation existed between @GeneTgt$ FGFR4 @/GeneTgt$ genotype and expression or HER2 status . In node-negative patients , @GeneTgt$ FGFR4 @/GeneTgt$ genotype was not correlated with disease outcome . In node-positive patients , however , @GeneTgt$ FGFR4 @/GeneTgt$ Arg388 was significantly associated with poor disease-free survival ( DFS ; P = .02 ) and overall survival ( OS ; P = .04 ) . Notably , this association seems to be attributable to relatively poor therapy response in Arg388 carriers , reflected in their significantly shorter DFS ( P = .02 ) and OS ( P = .045 ) among patients receiving adjuvant systemic therapy . It is also seen as a significant interaction term in a multivariate proportional hazards model with Arg388 carriers having only about half as much benefit from adjuvant systemic therapy as wild-type carriers . CONCLUSION : According to this study , @GeneTgt$ FGFR4 @/GeneTgt$ Arg388 genotype is a marker for @DiseaseSrc$ breast cancer @/DiseaseSrc$ progression in patients with adjuvant systemic therapy , particularly chemotherapy , and thus may indicate therapy resistance .	0|4 4 0|4 4 6 6 6 8 6 11 11 8 14 14 11|12|14 11|12|14 11|14 11|12|14 6 20 20 24 24 25 20 27 25 63 32 32 32 63 34 32 34 37 32 37 50 39|40|50 39|40|50 39|40|50 39|40|50 39|40|50 40|50 39|40|50 50 41|50 50 41|50 50 37 32 32 57 57 57 57 52 59 57 59 32 63 27 66 66 63 69 69 69|62|66 69|62|66 69|66 69|62|66 20 77 78 78 81 81 78 84 84 81 84 85|88 88 85|88 84 84 84 90 84 84 96 96 81 96 96 102 102 102 98 107 107 107 107 107|105|98 107|105|98 107|98 107|105|98 107 113 113 110 113 113 117 113 117 120 113 113 78 139 139 134 134 134 134 134 134 134 139 137 137 134 139 139 143 143 143 139 139 149|144 149 149|144 145 145 151 151 139 151 155 155 151 151 172 158 162 162 166 164 162 164 158 166 166 170 166 172 172 172 175 176 176 180 177|180 180 177|180 176 180 180 182 182 180 176 190 190 197 197 191|194 194 191|194 197 197 197 197 200 200 197 197 205 205 214 214 214 214 211|208 211 211|208 214 214 214 214 218 218 218 214 220 218 223 223 220 223 223 220 228 220 230 228 233 233 230 233 233 214 242 242 241 242 242 245 245 242 250 248 250 250 245 253 253 250 250 250 260 260 259 260 255 263 263 260 263 263 260 260 269 267 269 270 269 274 260 274 278 278 275 242 283 283 283 283 288 288 288 288 283 294 294 294 294 294 288 297 297 294 283 303 303 303 303 304 298 308 308 308 304 311 311 308 283 313 313 318 315 318 326 326 323|319 323 323|319 323 326 326 326 313 331 331|326 331|326 331 331|326 326 333 331 337 337 337 333 337 340 337 326 326 345 345 326 347 345 326	Association
18375489	Disease	Gene	D015179	5290	True	0	What is [EMU_BC] between @DiseaseSrc$ colorectal cancer @/DiseaseSrc$ and @GeneTgt$ PIK3CA @/GeneTgt$ ? [SEP] Multiplexed assays for detection of mutations in @GeneTgt$ PIK3CA @/GeneTgt$ . BACKGROUND : Mutations in the @GeneTgt$ PIK3CA @/GeneTgt$ gene ( @GeneTgt$ phosphoinositide-3-kinase , catalytic , alpha polypeptide @/GeneTgt$ ) have recently been described in a number of cancers , and their detection is currently limited because of the low sensitivity of conventional sequencing techniques . METHODS : We combined Amplification Refractory Mutation System ( ARMS ; AstraZeneca ) allele-specific PCR and Scorpions ( DxS ) to develop assays for tumor-borne @GeneTgt$ PIK3CA @/GeneTgt$ mutations and used real-time PCR to develop high-throughput multiplexed assays for the most commonly reported @GeneTgt$ PIK3CA @/GeneTgt$ mutants ( H1047L , H1047R , E542 K , E545 K ) . RESULTS : These assays were more sensitive than sequencing and could detect 5 copies of mutant DNA in proportions as low as 0.1 % of the total DNA . We assayed DNA extracted from human tumors and detected @GeneTgt$ PIK3CA @/GeneTgt$ mutation frequencies of 10.2 % in @DiseaseSrc$ colorectal cancer @/DiseaseSrc$ , 38.7 % in breast cancer , 1.9 % in lung cancer , and 2.9 % in melanoma . In contrast , sequencing detected only 53 % of the mutations detected by our assay . CONCLUSIONS : Multiplexed assays , which can easily be applied to clinical samples , have been developed for the detection of @GeneTgt$ PIK3CA @/GeneTgt$ mutations .	2 2 4 2 6 4 8 6|7 6 6|7 2 12 12 32 19 19 19|16 19 19|16 14 21 19|21 19|21 19|21 19|21 19|21 19|21 19|21 19|21 21 32 32 32 12 35 35 32 37 35 32 32 41 44 44 44 32 49 45 49 49 44 53 53 53 49 32 60 60 60 60 64 64 64 60 66 64 66 66 68 71 66 71 71 75 71 75 78 60 78 84 84 81|84 84 81|84 79 78 78 88 86 90 86 93 93 90 101 101 97 98 101 97|101 101 97|101 93 103 101 103 103 103 108 103 103 111 103 103 60 116 116 119 122 122 122 116 124 122 122 127 122 129 127 132 132 129 134 127 136 134 138 139 134 143 143 143 139 122 146 146 146 147 151 151 148 146 146 153|157 157 153|157 157 153 160 160 157 162 160|162|157 160|162|157 162|157 160|162|157 162 167 157 170 170 167 167 173 167 176 176 173 157 146 180 146 182 180 146 187 190 190 190 190 192 193 190 196 196 193 196 200 200 197 190 202 202 205 218 205 211 211 211 211 205 214 214 211 205 218 218 202 221 221 218 225 225|222 225 225|222 221 218	Association
18375489	Disease	Gene	D008175	5290	True	0	What is [EMU_BC] between @DiseaseSrc$ lung cancer @/DiseaseSrc$ and @GeneTgt$ PIK3CA @/GeneTgt$ ? [SEP] Multiplexed assays for detection of mutations in @GeneTgt$ PIK3CA @/GeneTgt$ . BACKGROUND : Mutations in the @GeneTgt$ PIK3CA @/GeneTgt$ gene ( @GeneTgt$ phosphoinositide-3-kinase , catalytic , alpha polypeptide @/GeneTgt$ ) have recently been described in a number of cancers , and their detection is currently limited because of the low sensitivity of conventional sequencing techniques . METHODS : We combined Amplification Refractory Mutation System ( ARMS ; AstraZeneca ) allele-specific PCR and Scorpions ( DxS ) to develop assays for tumor-borne @GeneTgt$ PIK3CA @/GeneTgt$ mutations and used real-time PCR to develop high-throughput multiplexed assays for the most commonly reported @GeneTgt$ PIK3CA @/GeneTgt$ mutants ( H1047L , H1047R , E542 K , E545 K ) . RESULTS : These assays were more sensitive than sequencing and could detect 5 copies of mutant DNA in proportions as low as 0.1 % of the total DNA . We assayed DNA extracted from human tumors and detected @GeneTgt$ PIK3CA @/GeneTgt$ mutation frequencies of 10.2 % in colorectal cancer , 38.7 % in breast cancer , 1.9 % in @DiseaseSrc$ lung cancer @/DiseaseSrc$ , and 2.9 % in melanoma . In contrast , sequencing detected only 53 % of the mutations detected by our assay . CONCLUSIONS : Multiplexed assays , which can easily be applied to clinical samples , have been developed for the detection of @GeneTgt$ PIK3CA @/GeneTgt$ mutations .	2 2 4 2 6 4 8 6|7 6 6|7 2 12 12 32 19 19 19|16 19 19|16 14 21 19|21 19|21 19|21 19|21 19|21 19|21 19|21 19|21 21 32 32 32 12 35 35 32 37 35 32 32 41 44 44 44 32 49 45 49 49 44 53 53 53 49 32 60 60 60 60 64 64 64 60 66 64 66 66 68 71 66 71 71 75 71 75 78 60 78 84 84 81|84 84 81|84 79 78 78 88 86 90 86 93 93 90 101 101 97 98 101 97|101 101 97|101 93 103 101 103 103 103 108 103 103 111 103 103 60 116 116 119 122 122 122 116 124 122 122 127 122 129 127 132 132 129 134 127 136 134 138 139 134 143 143 143 139 122 146 146 146 147 151 151 148 146 146 153|157 157 153|157 157 153 160 160 157 163 163 157 163 166 157 169 169 166 166 172 166 174 172|174 172|174 172|174 172|174 157 146 180 146 182 180 146 187 190 190 190 190 192 193 190 196 196 193 196 200 200 197 190 202 202 205 218 205 211 211 211 211 205 214 214 211 205 218 218 202 221 221 218 225 225|222 225 225|222 221 218	Association
18375489	Disease	Gene	D001943	5290	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ PIK3CA @/GeneTgt$ ? [SEP] Multiplexed assays for detection of mutations in @GeneTgt$ PIK3CA @/GeneTgt$ . BACKGROUND : Mutations in the @GeneTgt$ PIK3CA @/GeneTgt$ gene ( @GeneTgt$ phosphoinositide-3-kinase , catalytic , alpha polypeptide @/GeneTgt$ ) have recently been described in a number of cancers , and their detection is currently limited because of the low sensitivity of conventional sequencing techniques . METHODS : We combined Amplification Refractory Mutation System ( ARMS ; AstraZeneca ) allele-specific PCR and Scorpions ( DxS ) to develop assays for tumor-borne @GeneTgt$ PIK3CA @/GeneTgt$ mutations and used real-time PCR to develop high-throughput multiplexed assays for the most commonly reported @GeneTgt$ PIK3CA @/GeneTgt$ mutants ( H1047L , H1047R , E542 K , E545 K ) . RESULTS : These assays were more sensitive than sequencing and could detect 5 copies of mutant DNA in proportions as low as 0.1 % of the total DNA . We assayed DNA extracted from human tumors and detected @GeneTgt$ PIK3CA @/GeneTgt$ mutation frequencies of 10.2 % in colorectal cancer , 38.7 % in @DiseaseSrc$ breast cancer @/DiseaseSrc$ , 1.9 % in lung cancer , and 2.9 % in melanoma . In contrast , sequencing detected only 53 % of the mutations detected by our assay . CONCLUSIONS : Multiplexed assays , which can easily be applied to clinical samples , have been developed for the detection of @GeneTgt$ PIK3CA @/GeneTgt$ mutations .	2 2 4 2 6 4 8 6|7 6 6|7 2 12 12 32 19 19 19|16 19 19|16 14 21 19|21 19|21 19|21 19|21 19|21 19|21 19|21 19|21 21 32 32 32 12 35 35 32 37 35 32 32 41 44 44 44 32 49 45 49 49 44 53 53 53 49 32 60 60 60 60 64 64 64 60 66 64 66 66 68 71 66 71 71 75 71 75 78 60 78 84 84 81|84 84 81|84 79 78 78 88 86 90 86 93 93 90 101 101 97 98 101 97|101 101 97|101 93 103 101 103 103 103 108 103 103 111 103 103 60 116 116 119 122 122 122 116 124 122 122 127 122 129 127 132 132 129 134 127 136 134 138 139 134 143 143 143 139 122 146 146 146 147 151 151 148 146 146 153|157 157 153|157 157 153 160 160 157 163 163 157 163 166 157 168 168|166 168|166 168|166 168|166 166 173 166 176 176 173 157 146 180 146 182 180 146 187 190 190 190 190 192 193 190 196 196 193 196 200 200 197 190 202 202 205 218 205 211 211 211 211 205 214 214 211 205 218 218 202 221 221 218 225 225|222 225 225|222 221 218	Association
10534763	Disease	Gene	D001943	472	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ ATM @/GeneTgt$ ? [SEP] Identification of germline missense mutations and rare allelic variants in the @GeneTgt$ ATM @/GeneTgt$ gene in early-onset @DiseaseSrc$ breast cancer @/DiseaseSrc$ . Epidemiological studies have shown an increased risk of @DiseaseSrc$ breast cancer @/DiseaseSrc$ in obligate ataxia telangiectasia ( A-T ) heterozygotes . We analyzed 100 samples from young @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients for mutations in ataxia-telangiectasia mutated ( @GeneTgt$ ATM @/GeneTgt$ ) , the gene responsible for the autosomal recessive condition , A-T , to determine whether A-T heterozygosity predisposes such individuals to develop @DiseaseSrc$ breast cancer @/DiseaseSrc$ . These patients were selected from families with a moderate or absent family history of @DiseaseSrc$ breast cancer @/DiseaseSrc$ and included a subset of 16 radiosensitive patients . Forty-four germline sequence variants were detected by fluorescent chemical cleavage of mismatch of RT-PCR products . These included seven rare variants found in nine patients ( three described for the first time ) , but no truncating mutations . Although three variants were detected in the radiosensitive subset , this was not statistically significant compared to the nonradiosensitive group . One variant , G2765S , is likely to be a missense mutation , but the other six variants probably represent rare polymorphisms . However , five of the seven rare germline variants detected showed loss of heterozygosity of the wild-type @GeneTgt$ ATM @/GeneTgt$ allele for one or more markers close to the @GeneTgt$ ATM @/GeneTgt$ locus in matched tumor DNA . This high rate of somatic inactivation of @GeneTgt$ ATM @/GeneTgt$ may indicate either that these rare variants play a role in @DiseaseSrc$ breast cancer @/DiseaseSrc$ development or alternatively that a neighboring tumor suppressor gene is important for tumorigenesis . We found germline truncating @GeneTgt$ ATM @/GeneTgt$ mutations to be rare in these young @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients and therefore they are unlikely to play a role in the etiology of their disease . Genes Chromosomes Cancer 26:286 - 294 , 1999 .	1 5 5 5 1 5 9 9 5 14 14 11|14 14 11|14 5 17 17 17|14|15 17|14|15 17|14 17|14|15 1 24 26 26 26 29 29 26 31 30|31|29 30|31|29 31|29 30|31|29 41 41 41 41 39 41 41 29 26 45 45 47 45 53 53 53|49 53|49 53 53|49 47 55 53 58 58 55 60 57|58 58 57|58 60 58 65 55 65 71 71 71 71 66 71 71 71 76 45 80 79 80 76 82 80 84 80 84|85|81 84|85|81 84|85 84|85|81 45 93 95 95 95 97 95 104 104 104 100 100 104 97 106 104|105|106 104|105|106 104|106 104|105|106 95 95 112 110 116 116 116 112 95 122 122 122 124 124 124 128 128 128 124 130 128 133 133 130 124 136 136 139 139 136 139 143 143 140 145 143 145 150 150 150 146 145 136 136 156 156 136 136 162 160 162 162 172 166 166 166 162 172 172 172 172 172 172 172 177 177 177 173 172 180 185 180 180 180 185 185 190 190 190 190 185 185 185 196 196 196 198 198 185 200 198 198 212 212 212 210 210 210 210 210 204 210 212 212 215 213 221 221 221 218|221 221 218|221 215 226 226 223 223 213 226 232 232 228|232 232 228|232 227 236 236 236 213 212 242 242 250 245 245 242 247 245|246 245 245|246 250 250 250 256 255 255 256 250 258 256 263 263|258|260 263|258|260 263|260 263|258|260 256 256 273 273 271 271 271 271 273 273 256 275 273 250 280 280 282 280 282|285 285 282|285 282 288 288 282 295 295 295 295|290 295|290 295 295|290 288 288 300 300 300 288 302 300 304 302 307 307 302 310 310 307 280 316 316 316 316 317 316 316 316 316	Association
16760288	Disease	Gene	D010051	672	True	0	What is [EMU_BC] between @DiseaseSrc$ breast and/or ovarian cancer @/DiseaseSrc$ and @GeneTgt$ BRCA1 @/GeneTgt$ ? [SEP] Y179C , F486L and N550H are @GeneTgt$ BRCA1 @/GeneTgt$ variants that may be associated with breast cancer in a Sicilian family : results of a 5-year GOIM ( Gruppo Oncologico dell'Italia Meridionale ) prospective study . BACKGROUND : Over 600 different pathogenic mutations have been identified in the @GeneTgt$ BRCA1 @/GeneTgt$ gene . Nevertheless , numerous missense mutations of unknown biological function still exist . Understanding of biological significance of these mutations should help in genetic counselling to carriers and their families . PATIENTS AND METHODS : A total of 104 patients with @DiseaseSrc$ breast and/or ovarian cancer @/DiseaseSrc$ whose genetic counselling answered the criteria of the American Society of Clinical Oncology ( ASCO 2003 ) , were prospectively screened for mutations in all coding exons of the @GeneTgt$ BRCA1 @/GeneTgt$ gene by automatic direct sequencing . RESULTS : During these mutational screening procedures one case presented three mutations classified in the Breast Cancer Information Core Database as unknown variants . These were 655A/G found in exon 8 of @GeneTgt$ BRCA1 @/GeneTgt$ , 1575T/C and 1767A/C found in exon 11 of the same gene . The identification of the three unknown variants in the proband ( 16SIRIO ) and in her mother and sister indicates that such alterations exist in cis . CONCLUSIONS : Our results suggest that the charge and stechiometry variations determined by the changes in the amino acids Y179C , F486L and N550H might produce an effect on the conformation of the protein and , consequently , on its function .	9 1 1 1 1 9 9|6 9 9|6 9 13 13 13 9 16 16 13 20 20 20 16 9 9 26 26 26 34 31 31 31 31 34 34 34 22 9 37 37 40 43 43 41 46 46 46 37 51 51 48|51 51 48|51 46 46 64 64 58 58 64 62 62 62 58 64 64 64 74 69 69 66 72 72 69 74 74 77 77 74 79 77 79 82 79 74 84 84 84 84 89 102 92 92 89 94 92|93|94 92|93|94 92|93|94 92|93|94 92|94 92|93|94 101 101 102 84 104 102 108 108 108 104 111 111 108 113 111 113 108 102 119 119 102 121 119 125 125 125 121 130 130 123|130 130 123|130 125 134 134 134 119 102 138 138 144 144 144 144 147 146 147 138 149 147 149 157 157 154 156 156 157 150 160 160 150 138 165 164 165 165 167 165 167 170 169|167 167 169|167 170 170 167 167 167 178 176 178 183 183 183 178 165 187 205 192 192 192 192 187 195 195 192 197 195 197 192 202 202 192 202 202 205 209 208 209 205 211 209 205 213 213 216 217 213 238 220 238 220 220 220 220 227 227 224 231 231 231 227 231 232 232 232 232 238 217 240 238 243 243 240 246 246 243 238 238 238 249 253 253 249 213	Association
16760288	Disease	Gene	D001943	672	True	0	What is [EMU_BC] between @DiseaseSrc$ Breast Cancer @/DiseaseSrc$ and @GeneTgt$ BRCA1 @/GeneTgt$ ? [SEP] Y179C , F486L and N550H are @GeneTgt$ BRCA1 @/GeneTgt$ variants that may be associated with @DiseaseSrc$ breast cancer @/DiseaseSrc$ in a Sicilian family : results of a 5-year GOIM ( Gruppo Oncologico dell'Italia Meridionale ) prospective study . BACKGROUND : Over 600 different pathogenic mutations have been identified in the @GeneTgt$ BRCA1 @/GeneTgt$ gene . Nevertheless , numerous missense mutations of unknown biological function still exist . Understanding of biological significance of these mutations should help in genetic counselling to carriers and their families . PATIENTS AND METHODS : A total of 104 patients with breast and/or ovarian cancer whose genetic counselling answered the criteria of the American Society of Clinical Oncology ( ASCO 2003 ) , were prospectively screened for mutations in all coding exons of the @GeneTgt$ BRCA1 @/GeneTgt$ gene by automatic direct sequencing . RESULTS : During these mutational screening procedures one case presented three mutations classified in the @DiseaseSrc$ Breast Cancer @/DiseaseSrc$ Information Core Database as unknown variants . These were 655A/G found in exon 8 of @GeneTgt$ BRCA1 @/GeneTgt$ , 1575T/C and 1767A/C found in exon 11 of the same gene . The identification of the three unknown variants in the proband ( 16SIRIO ) and in her mother and sister indicates that such alterations exist in cis . CONCLUSIONS : Our results suggest that the charge and stechiometry variations determined by the changes in the amino acids Y179C , F486L and N550H might produce an effect on the conformation of the protein and , consequently , on its function .	9 1 1 1 1 9 9|6 9 9|6 9 13 13 13 9 15 13|15 13|15 13|15 13|15 21 21 21 15 9 9 27 27 27 35 32 32 32 32 35 35 35 23 9 39 39 42 45 45 43 48 48 48 39 53 53 50|53 53 50|53 48 48 66 66 60 60 66 64 64 64 60 66 66 66 76 71 71 68 74 74 71 76 76 79 79 76 81 79 81 84 81 76 86 86 86 86 91 103 94 94 91 96 94 96 99 96 102 102 103 86 105 103 109 109 109 105 112 112 109 114 112 114 109 103 120 120 103 122 120 126 126 126 122 131 131 128|131 131 128|131 126 135 135 135 120 103 138 138 144 144 144 144 147 146 147 138 149 147 149 158 158 153|157|152 153|157|152 153|157 153|157|152 157 158 150 161 161 150 138 167 166 167 167 169 167 169 172 171|169 169 171|169 172 172 169 169 169 180 178 180 185 185 185 180 167 189 207 194 194 194 194 189 197 197 194 199 197 199 194 204 204 194 204 204 207 211 210 211 207 213 211 207 215 215 218 219 215 240 222 240 222 222 222 222 229 229 226 233 233 233 229 233 234 234 234 234 240 219 242 240 245 245 242 248 248 245 240 240 240 251 255 255 251 215	Association
16969499	Disease	Gene	D010051	672	True	0	What is [EMU_BC] between @DiseaseSrc$ breast and ovarian cancer @/DiseaseSrc$ and @GeneTgt$ BRCA1 @/GeneTgt$ ? [SEP] Missense mutations of @GeneTgt$ BRCA1 @/GeneTgt$ gene affect the binding with p53 both in vitro and in vivo . Women with @GeneTgt$ BRCA1 @/GeneTgt$ gene mutations have an increased risk for @DiseaseSrc$ breast and ovarian cancer @/DiseaseSrc$ ( BOC ) . Classification of missense variants as neutral or disease causing is still a challenge and has major implications for genetic counseling . @GeneTgt$ BRCA1 @/GeneTgt$ is organized in an N-terminal ring-finger domain and two BRCT ( breast cancer C-terminus ) domains , involved in protein-protein interaction . The integrity of the C-terminal , BRCT repeat region is also critical for BRCA1 tumor suppressor function . Several molecular partners of @GeneTgt$ BRCA1 @/GeneTgt$ have so far been identified ; among them , the tumor suppressor protein p53 seems to play a major role . This study was aimed at evaluating the impact of two missense mutations , namely the W1837R and the S1841N , previously identified in BOC patients and located in the BRCT domain of the @GeneTgt$ BRCA1 @/GeneTgt$ gene , on the binding capacity of this protein to p53 . Co-immunoprecipitation assays of E. coli-expressed wild-type and mutated BRCTs challenged with a HeLa cell extract revealed , for the S1841N variant a significant reduction in the binding activity to p53 , while the W1837R mutant showed an inverse effect . Furthermore , a clonogenic soft agar growth assay performed on HeLa cells stably transfected with either wild-type or mutant @GeneTgt$ BRCA1 @/GeneTgt$ showed a marked decrease of the growth in wild-type @GeneTgt$ BRCA1-overexpressing @/GeneTgt$ cells and in BRCA1S1841N-transfected cells , while no significant changes were detected in the @GeneTgt$ BRCA1W1837R-transfected @/GeneTgt$ cells . These results demonstrate that : i ) distinct single nucleotide changes in the BRCT domain of @GeneTgt$ BRCA1 @/GeneTgt$ affect binding of this protein to the tumor suppressor p53 , and ii ) the two missense mutations here described are likely to play a role in breast tumorigenesis . We suggest that in vitro/in vivo experiments testing the effects of unclassified @GeneTgt$ BRCA1 @/GeneTgt$ gene variants should therefore be taken in to consideration and that increased surveillance should be adopted in individuals bearing these two @GeneTgt$ BRCA1 @/GeneTgt$ missense alterations .	2 7 6 3|6 6 3|6 2 7 9 7 11 9 15 14 15 7 17 15 7 26 25 21|25 25 21|25 25 20 26 29 29 26 31 29|31 29|31 29|31 29|31 29|31 29|31 37 31 37 26 54 45 45 42 47 42 47 47 42 54 54 54 54 54 54 58 56 61 61 58 54 62|66 66 62|66 66 66 71 71 71 71 66 71 74 80 78 78 78 74 78 71 80 80 85 85 82 66 89 99 96 96 96 96 96 96 89 99 99 99 104 104 104 104 99 99 108 108 116 110 108|109 108 108|109 116 114 116 116 116 116 119 126 126 125 125 125 125 126 116 128 126 131 131 128 126 135 137 137 137 139 137 141 139 145 145 145 141 145 149 149 145 149 152 149 137 155 137 158 158 155 155 155 164 164 164 160 169 169 166|169 169 166|169 164 160 174 174 174 160 177 177 174 179 174 137 183 191 187 186 187 183 187 187 187 191 196 196 196 196 191 191 197 202 202 202 197 205 205 197 209 209 209 205 211 209 197 217 216 216 217 197 220 220 217 191 243 243 229 229 229 229 229 243 229 233 233 230 235 233 238 238 235 238 238 240|243 243 240|243 243 246 246 243 249 249 246 254 254 254|250 254 254|250 249 254 258 258 254 243 265 263 263 265 265 243 270 270 270|265 270 270|265 265 243 276 277 277 293 280 285 280 285 285 285 293 289 289 289 285 291 290|289 289 290|289 277 293 297 297 294 302 302 302 302 294 293 293 293 305 310 310 310 305 310 293 314 293 316 314 318 316 321 321 318 277 325 325 343 330 330 328 343 330 333 331 339 339 339|335 339 339|335 339 333 343 343 343 325 343 346 343 343 353 350 353 353 353 343 355 353 355 362 362 357|362 362 357|362 362 356 325	Association
16969499	Disease	Gene	D001943	672	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer C-terminus @/DiseaseSrc$ and @GeneTgt$ BRCA1 @/GeneTgt$ ? [SEP] Missense mutations of @GeneTgt$ BRCA1 @/GeneTgt$ gene affect the binding with p53 both in vitro and in vivo . Women with @GeneTgt$ BRCA1 @/GeneTgt$ gene mutations have an increased risk for breast and ovarian cancer ( BOC ) . Classification of missense variants as neutral or disease causing is still a challenge and has major implications for genetic counseling . @GeneTgt$ BRCA1 @/GeneTgt$ is organized in an N-terminal ring-finger domain and two BRCT ( @DiseaseSrc$ breast cancer C-terminus @/DiseaseSrc$ ) domains , involved in protein-protein interaction . The integrity of the C-terminal , BRCT repeat region is also critical for BRCA1 tumor suppressor function . Several molecular partners of @GeneTgt$ BRCA1 @/GeneTgt$ have so far been identified ; among them , the tumor suppressor protein p53 seems to play a major role . This study was aimed at evaluating the impact of two missense mutations , namely the W1837R and the S1841N , previously identified in BOC patients and located in the BRCT domain of the @GeneTgt$ BRCA1 @/GeneTgt$ gene , on the binding capacity of this protein to p53 . Co-immunoprecipitation assays of E. coli-expressed wild-type and mutated BRCTs challenged with a HeLa cell extract revealed , for the S1841N variant a significant reduction in the binding activity to p53 , while the W1837R mutant showed an inverse effect . Furthermore , a clonogenic soft agar growth assay performed on HeLa cells stably transfected with either wild-type or mutant @GeneTgt$ BRCA1 @/GeneTgt$ showed a marked decrease of the growth in wild-type @GeneTgt$ BRCA1-overexpressing @/GeneTgt$ cells and in BRCA1S1841N-transfected cells , while no significant changes were detected in the @GeneTgt$ BRCA1W1837R-transfected @/GeneTgt$ cells . These results demonstrate that : i ) distinct single nucleotide changes in the BRCT domain of @GeneTgt$ BRCA1 @/GeneTgt$ affect binding of this protein to the tumor suppressor p53 , and ii ) the two missense mutations here described are likely to play a role in breast tumorigenesis . We suggest that in vitro/in vivo experiments testing the effects of unclassified @GeneTgt$ BRCA1 @/GeneTgt$ gene variants should therefore be taken in to consideration and that increased surveillance should be adopted in individuals bearing these two @GeneTgt$ BRCA1 @/GeneTgt$ missense alterations .	2 7 6 3|6 6 3|6 2 7 9 7 11 9 15 14 15 7 17 15 7 26 25 21|25 25 21|25 25 20 26 29 29 26 31 29 31 34 31 36 34 36 26 52 43 43 40 45 40 45 45 40 52 52 52 52 52 52 56 54 59 59 56 52 60|64 64 60|64 64 64 69 69 69 69 64 69 72 79 74 72|74 72|74 72|74 72|74 72|74 74 69 79 79 84 84 81 64 89 99 96 96 96 96 96 96 89 99 99 99 104 104 104 104 99 99 108 108 116 110 108|109 108 108|109 116 114 116 116 116 116 119 126 126 125 125 125 125 126 116 128 126 131 131 128 126 135 137 137 137 139 137 141 139 145 145 145 141 145 149 149 145 149 152 149 137 155 137 158 158 155 155 155 164 164 164 160 169 169 166|169 169 166|169 164 160 174 174 174 160 177 177 174 179 174 137 183 191 187 186 187 183 187 187 187 191 196 196 196 196 191 191 197 202 202 202 197 205 205 197 209 209 209 205 211 209 197 217 216 216 217 197 220 220 217 191 243 243 229 229 229 229 229 243 229 233 233 230 235 233 238 238 235 238 238 240|243 243 240|243 243 246 246 243 249 249 246 254 254 254|250 254 254|250 249 254 258 258 254 243 265 263 263 265 265 243 270 270 270|265 270 270|265 265 243 276 277 277 293 280 285 280 285 285 285 293 289 289 289 285 291 290|289 289 290|289 277 293 297 297 294 302 302 302 302 294 293 293 293 305 310 310 310 305 310 293 314 293 316 314 318 316 321 321 318 277 325 325 343 330 330 328 343 330 333 331 339 339 339|335 339 339|335 339 333 343 343 343 325 343 346 343 343 353 350 353 353 353 343 355 353 355 362 362 357|362 362 357|362 362 356 325	Association
17317153	Disease	Gene	D001943	672	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancers @/DiseaseSrc$ and @GeneTgt$ BRCA1 @/GeneTgt$ ? [SEP] @GeneTgt$ BRCA1 @/GeneTgt$ promoter deletions in young women with @DiseaseSrc$ breast cancer @/DiseaseSrc$ and a strong family history : a population-based study . Women diagnosed with @DiseaseSrc$ breast cancer @/DiseaseSrc$ before the age of 40 years who have a strong family history of breast and/or ovarian cancer were selected from an Australian population-based case-control-family study for large deletion screening within the @GeneTgt$ BRCA1 @/GeneTgt$ promoter . Deletions within the @GeneTgt$ BRCA1 @/GeneTgt$ promoter region are usually not detected by the methods applied in routine clinical mutation detection strategies . Fifty-one of the 66 women ( 77 % ) who met our inclusion criteria were tested for promoter deletions using linkage disequilibrium analysis of two @GeneTgt$ BRCA1 @/GeneTgt$ polymorphic sites ( C/G1802 and Pro871Leu ) and multiplex ligation-dependent probe amplification . Two cases of @GeneTgt$ BRCA1 @/GeneTgt$ promoter deletion involving exons 1A-2 and exons 1A-23 were detected . The morphology of the @DiseaseSrc$ breast cancers @/DiseaseSrc$ arising in these women with @GeneTgt$ BRCA1 @/GeneTgt$ promoter deletions was consistent with the morphology associated with other germline @GeneTgt$ BRCA1 @/GeneTgt$ mutations . Large genomic deletions that involve the promoter regions of @GeneTgt$ BRCA1 @/GeneTgt$ make up 20 % ( 2/10 ) of all known @GeneTgt$ BRCA1 @/GeneTgt$ mutations in this group of young women with a strong family history of breast and ovarian cancer . Our data support the inclusion of testing for large genomic alterations in the @GeneTgt$ BRCA1 @/GeneTgt$ promoter region in routine clinical mutation detection within @GeneTgt$ BRCA1 @/GeneTgt$ .	0|4 4 0|4 4 4 7 7 4 9 9|7 9|7 9|7 9|7 4 16 16 16 4 4 20 20 4 4 25 25 27 25|26|27 25|26|27 25|27 25|26|27 32 32 25 35 35 32 37 35 41 41 41 37 43 41 43 46 43 48 25 54 54 54 54 54 48 58 58 58 54 63 63 63|58 63 63|58 58 25 77 73 73 69|73 73 69|73 73 67 77 77 77 77 80 80 77 80 87 87 87 87 87 81 77 105 94 94 94 90 97 97 94 97 100 94 103 103 100 105 105 108 108 105 108 112 112 109 118 118 114|118 118 114|118 118 112 120 118 120 120 120 118 126 128 128 118 105 132 145 137 133|137 137 133|137 137 132 137 138 139 140 140 142 145 145 145 149 165 152 152 149|151|152 149|151|152 149|152 149|151|152 152 158 158 155 163 163|157 163 163|157 163 158 165 165 168 168 165 168 175 175 175 175|169 175 175|169 169 165 182 182 191 184 182 187 187 184 189 187|188 187 187|188 191 191 194 191 196 194 196 203 203 203 203|199 203 203|199 194 206 206 191 209 209 206 214 214 214 214 206 216 214 216 216 216 191 224 225 225 227 225 229 227 233 233 233 229 239 239 239|235 239 239|235 239 233 244 244 244 244 227 246 244 244 244 225	Association
16333312	Disease	Gene	D010051	580	True	0	What is [EMU_BC] between @DiseaseSrc$ breast and ovarian cancer @/DiseaseSrc$ and @GeneTgt$ BARD1 @/GeneTgt$ ? [SEP] @GeneTgt$ BARD1 @/GeneTgt$ variants Cys557Ser and Val507Met in breast cancer predisposition . @GeneTgt$ BARD1 @/GeneTgt$ ( @GeneTgt$ BRCA1-associated RING-domain 1 @/GeneTgt$ ) is a tumor suppressor whose protein product interacts with BRCA1 , and in which rare somatic and germline mutations have been reported in breast , uterine , and endometrial cancers . We aimed to evaluate whether there are @GeneTgt$ BARD1 @/GeneTgt$ genetic variants that contribute to breast cancer risk by screening the gene for germline alterations in 45 Finnish familial breast cancer patients and in seven patients with both @DiseaseSrc$ breast and ovarian cancer @/DiseaseSrc$ . Two of the missense alterations identified ( Cys557Ser and Val507Met ) were recently suggested to associate with an increased breast cancer risk . We also analyzed these variants in large and independent series of familial and unselected breast cancer patients and healthy controls . No clearly deleterious mutations were detected in the initial mutation screening . No association of the Cys557Ser and breast cancer risk was observed as the variant was found altogether in 1.4 % ( 16/1181 ) of familial and 2.2 % ( 34/1565 ) of unselected breast cancer patients , and in 2.5 % ( 27/1083 ) of healthy controls . The frequency of the Val-allele of the Val507Met variant was modestly higher among breast cancer patients than among healthy controls , although the difference did not reach statistical significance . No statistically significant association of the Cys557Ser or Val507Met variants with any clinicopathologic parameters was observed . These results suggest that the contribution of the @GeneTgt$ BARD1 @/GeneTgt$ germline variants to breast cancer predisposition is very limited , and that neither Cys557Ser nor Val507Met have an effect on familial breast cancer susceptibility .	0|3 3 0|3 3 3 4 4 10 10 10 3 3 12|24 24 12|24 16 13|14|16 13|14|16 13|14|16 13|16 13|14|16 16 24 24 24 24 27 27 28 24 30 28 30 30 34 42 36 42 36 36 36 42 42 24 44 42 44 44 46 44 50 44 24 55 55 57 55 60 60 57 63|60 63 63|60 64 60 66 64 70 69 70 66 72 66 74 72 77 77 74 84 84 84 84 84 84 77 84 88 88 84 91 91 88|89|91 88|89|91 88|89|91 88|89|91 88|91 88|89|91 55 104 103 103 103 99 104 106 112 106 106 106 112 112 104 114 112 120 120 120 119 120 114 104 124 124 124 126 124 131 131 128 128 126 133 131 133 133 138 138 133 138 141 138 124 146 145 146 148 148 148 153 153 153 153 148 148 156 165 163 163 163 159 159 163 156 165 165 170 168 170 170 165 170 174 174 170 176 174 176 179 174 179 182 179 184 182 184 190 190 190 190 179 174 170 195 195 170 197 195 197 201 201 195 165 204 214 207 207 204 211 211 211 207 214 214 214 218 218 218 214 222 222 222 214 214 229 226 229 229 229 214 231 229 214 236 235 236 248 242 242 238 239 239 236 246 246 246 236 248 248 248 251 252 252 268 255 268 261 261 257|261 261 257|261 261 255 265 265 265 255 268 268 252 268 268 276 273 276 273 273 268 278 276 283 283 283 283 278 252	Association
16333312	Disease	Gene	D001943	580	True	0	What is [EMU_BC] between @DiseaseSrc$ familial breast cancer @/DiseaseSrc$ and @GeneTgt$ BARD1 @/GeneTgt$ ? [SEP] @GeneTgt$ BARD1 @/GeneTgt$ variants Cys557Ser and Val507Met in @DiseaseSrc$ breast cancer @/DiseaseSrc$ predisposition . @GeneTgt$ BARD1 @/GeneTgt$ ( @GeneTgt$ BRCA1-associated RING-domain 1 @/GeneTgt$ ) is a tumor suppressor whose protein product interacts with BRCA1 , and in which rare somatic and germline mutations have been reported in breast , uterine , and endometrial cancers . We aimed to evaluate whether there are @GeneTgt$ BARD1 @/GeneTgt$ genetic variants that contribute to @DiseaseSrc$ breast cancer @/DiseaseSrc$ risk by screening the gene for germline alterations in 45 Finnish @DiseaseSrc$ familial breast cancer @/DiseaseSrc$ patients and in seven patients with both breast and ovarian cancer . Two of the missense alterations identified ( Cys557Ser and Val507Met ) were recently suggested to associate with an increased @DiseaseSrc$ breast cancer @/DiseaseSrc$ risk . We also analyzed these variants in large and independent series of familial and unselected @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients and healthy controls . No clearly deleterious mutations were detected in the initial mutation screening . No association of the Cys557Ser and @DiseaseSrc$ breast cancer @/DiseaseSrc$ risk was observed as the variant was found altogether in 1.4 % ( 16/1181 ) of familial and 2.2 % ( 34/1565 ) of unselected @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients , and in 2.5 % ( 27/1083 ) of healthy controls . The frequency of the Val-allele of the Val507Met variant was modestly higher among @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients than among healthy controls , although the difference did not reach statistical significance . No statistically significant association of the Cys557Ser or Val507Met variants with any clinicopathologic parameters was observed . These results suggest that the contribution of the @GeneTgt$ BARD1 @/GeneTgt$ germline variants to @DiseaseSrc$ breast cancer @/DiseaseSrc$ predisposition is very limited , and that neither Cys557Ser nor Val507Met have an effect on @DiseaseSrc$ familial breast cancer @/DiseaseSrc$ susceptibility .	0|3 3 0|3 3 3 4 4 11 11|6 11|6 11 11|6 3 3 14|26 26 14|26 18 15|16|18 15|16|18 15|16|18 15|18 15|16|18 18 26 26 26 26 29 29 30 26 32 30 32 32 36 44 38 44 38 38 38 44 44 26 46 44 46 46 48 46 52 46 26 57 57 59 57 62 62 59 65|62 65 65|62 66 62 68 66 73 73|68|70 73|68|70 73|70 73|68|70 68 75 68 77 75 80 80 77 88 88 88 80|88 80|88 80|88 88 80|88 80 88 92 92 88 95 95 92 95 98 95 57 108 107 107 107 103 108 110 116 110 110 110 116 116 108 118 116 125 125 125 121|122|125 121|122|125 122|125 121|122|125 118 108 130 130 130 132 130 137 137 134 134 132 139 137 139 139 145|141 145|141 145 145|141 139 145 148 145 130 154 153 154 156 156 156 161 161 161 161 156 156 164 174 172 172 172 167 172|167|168 172|167|168 172|167 172|167|168 164 174 174 179 177 179 179 174 179 183 183 179 185 183 185 188 183 188 191 188 193 191 193 200 200 194|200 194|200 200 194|200 188 183 179 205 205 179 207 205 207 211 211 205 174 216 226 219 219 216 223 223 223 219 226 226 226 231 231|227 231|227 231 231|227 226 235 235 235 226 226 242 239 242 242 242 226 244 242 226 250 249 250 262 256 256 252 253 253 250 260 260 260 250 262 262 262 265 266 266 283 269 283 275 275 271|275 275 271|275 275 269 280 280|275 280|275 280 280|275 269 283 283 266 283 283 291 288 291 288 288 283 293 291 299 291|299 291|299 291|299 299 291|299 293 266	Association
17553133	Disease	Gene	D001943	2099	True	0	What is [EMU_BC] between @DiseaseSrc$ breast tumors @/DiseaseSrc$ and @GeneTgt$ ESR1 @/GeneTgt$ ? [SEP] Risk factors for @DiseaseSrc$ breast cancer @/DiseaseSrc$ characterized by the @GeneTgt$ estrogen receptor alpha @/GeneTgt$ A908 G ( K303R ) mutation . INTRODUCTION : Estrogen is important in the development of @DiseaseSrc$ breast cancer @/DiseaseSrc$ , and its biological effects are mediated primarily through the two estrogen receptors alpha and beta . A point mutation in the @GeneTgt$ estrogen receptor alpha @/GeneTgt$ gene , @GeneTgt$ ESR1 @/GeneTgt$ , referred to as A908 G or K303R , was originally identified in breast hyperplasias and was reported to be hypersensitive to estrogen . We recently detected this mutation at a low frequency of 6 % in @DiseaseSrc$ invasive breast tumors of the Carolina Breast Cancer @/DiseaseSrc$ Study ( CBCS ) . METHODS : In this report , we evaluated risk factors for invasive @DiseaseSrc$ breast cancer @/DiseaseSrc$ classified according to the presence or absence of the @GeneTgt$ ESR1 @/GeneTgt$ A908 G mutation in the CBCS , a population-based case-control study of @DiseaseSrc$ breast cancer @/DiseaseSrc$ among younger and older white and African-American women in North Carolina . Of the 653 @DiseaseSrc$ breast tumors @/DiseaseSrc$ evaluated , 37 were @GeneTgt$ ESR1 @/GeneTgt$ A908 G mutation-positive and 616 were mutation-negative . RESULTS : @GeneTgt$ ESR1 @/GeneTgt$ A908 G mutation-positive @DiseaseSrc$ breast cancer @/DiseaseSrc$ was significantly associated with a first-degree family history of @DiseaseSrc$ breast cancer @/DiseaseSrc$ ( odds ratio [ OR ] = 2.69 , 95 % confidence interval [ CI ] = 1.15 to 6.28 ) , whereas mutation-negative @DiseaseSrc$ breast cancer @/DiseaseSrc$ was not . Comparison of the two case subgroups supported this finding ( OR = 2.65 , 95 % CI = 1.15 to 6.09 ) . There was also the suggestion that longer duration of oral contraceptive ( OC ) use ( OR = 3.73 , 95 % CI = 1.16 to 12.03 ; Ptrend = 0.02 for use of more than 10 years ) and recent use of OCs ( OR = 3.63 , 95 % CI = 0.80 to 16.45 ; Ptrend = 0.10 for use within 10 years ) were associated with @GeneTgt$ ESR1 @/GeneTgt$ A908 G mutation-positive @DiseaseSrc$ breast cancer @/DiseaseSrc$ ; however , ORs for comparison of the two case subgroups were not statistically significant . Hormone replacement therapy use was inversely correlated with mutation-negative @DiseaseSrc$ breast cancer @/DiseaseSrc$ , but the effect on mutation-positive cancer was unclear due to the small number of postmenopausal cases whose tumors carried the mutation . Mutation-negative @DiseaseSrc$ breast cancer @/DiseaseSrc$ was associated with several reproductive factors , including younger age at menarche ( OR = 1.46 , 95 % CI = 1.09 to 1.94 ) and greater total estimated years of ovarian function ( OR = 1.82 , 95 % CI = 1.21 to 2.74 ) . CONCLUSION : These preliminary results suggest that OCs may interact with the @GeneTgt$ ESR1 @/GeneTgt$ A908 G mutant receptor to drive the development of some @DiseaseSrc$ breast tumors @/DiseaseSrc$ .	2 2 4 2|3|4 2|3|4 2|4 2|3|4 4 19 19 19|7 19|7 19|7 19 19|7 19 19 17 19 19 7 2 27 27 27 27 27 30 30 27 32 30|31|32 30|31|32 30|32 30|31|32 27 27 39 39 41 41 27 41 47 47 47 47 41 47 48 48 27 55 55 77 62 62 62|57 62|57 62|57 62 62|57 55 62 60|62 62 60|62 62 55 67 71 71 67 71 71 55 77 77 77 80 80 77 77 83 77 86 86 83 88 86 77 94 94 94 96 94 100 100 100 94 103 103 100 105 100|104|105|114 100|104|105|114 100|104|105|114 100|104|105|114 100|104|105|114 100|104|105|114 100|104|105|114 100|104|105|114 100|105|114 100|104|105|114 105 116 114 116 94 127 127 124 124 127 127 127 127 129 127 132 132 129|131|132 129|131|132 129|132 129|131|132 129 139 136 139 135 139 139 148 148 148|141 148 148|141 148 148 139 151 151 148 151 156 156 156 151 158 154|156|158 154|156|158 156|158 154|156|158 162 168 162 162 168 165 165 156 171 171 168 127 179 179 179 178|179|189 178|179|189 179|189 178|179|189 179 189 189 189 183|189 189 183|189 189 189 189 190 190 194 189 194 198 198 205|199 205 205|199 205 205 205 205|210|203 205|210|203 205|210 205|210|203 210 210 198 215 215 215 215 210 217 213|215|217 213|215|217 215|217 213|215|217 222 222 217 222 222 224 222 226 226 230 232 232 222 234 232 234 232 239 239 236 222 210 210 244 238|247|244 238|247|244 247|244 238|247|244 210 247 198 260 259 259 259 259 254 260 262 260 265 265 262 265 265 269 270 265 270 274 274 271 265 260 278 278 278 281 278 344 284 344 287 287 291 289 287 289 284 293 291 293 294 294 298 299 291 299 300 303 300 306 306 284 306 309 306 314 313 313 314 309 306 284 318 344 320 318 323 323 318 323 323 327 328 323 328 329 330 330 323 335 323 335 338 335 341 341 338 323 344 281 351 351|345 351 351|345 351 351 351 349|351|344 349|351|344 351|344 349|351|344 281 368 368 368 359 357 364 364 364 364 359 368 368 368 278 368 375 375 375 378 378 378 378 381 381 380|381|378 380|381|378 381|378 380|381|378 378 378 387 392 390 390 387 392 378 397 393 397 397 392 400 400 397 402 403 400 405 403 392 409 408|409|413 408|409|413 409|413 408|409|413 413 413 417 417 417 413 417 421 421 417 423 421 426 426 421 426 426 430 431 426 431 435 435 432 435 426 439 426 441 426 444 444 441 447 447 444 447 447 451 452 447 452 456 456 453 447 413 465 465 464 464 465 465 469 469 469 465 477 477 477|471 477 477|471 477 477 477 469 479 469 481 479 484 484 484|481|482 484|481|482 484|481 484|481|482 465	Association
18558293	Disease	Gene	D001943	5728	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ PTEN @/GeneTgt$ ? [SEP] A novel mutation of the @GeneTgt$ PTEN @/GeneTgt$ gene in a Japanese patient with Cowden syndrome and @DiseaseSrc$ bilateral breast cancer @/DiseaseSrc$ . Cowden syndrome ( CS ) , also known as multiple hamartoma syndrome , is an autosomal dominant cancer syndrome associated with a high risk of breast and thyroid cancers . The @GeneTgt$ phosphatase and tensin homolog gene @/GeneTgt$ ( @GeneTgt$ PTEN @/GeneTgt$ ) encodes a lipid phosphatase that contains a PTPase domain and a C2 domain and plays a role as a tumor suppressor that negatively regulates the cell-survival signaling pathway initiated by phosphatidylinositol 3-kinase ( PI3 K ) . @GeneTgt$ PTEN @/GeneTgt$ inhibits angiogenesis , and germline mutations of the @GeneTgt$ PTEN @/GeneTgt$ gene are associated with CS . We screened for mutations in the @GeneTgt$ PTEN @/GeneTgt$ gene in two unrelated Japanese patients with CS . In one patient , who suffered from bilateral @DiseaseSrc$ breast cancer @/DiseaseSrc$ , thyroid adenoma , and gastric malignant lymphoma , we found a single-base substitution in exon 2 ( 115G > C ) of the @GeneTgt$ PTEN @/GeneTgt$ gene . This transversion results in a germline missense mutation ( A39P ) . To date , nine different mutations have been identified in exon 2 of the @GeneTgt$ PTEN @/GeneTgt$ gene in patients with CS and variant CS ; however , the A39P missense mutation has not been reported previously . We also detected a previously reported nonsense mutation , 697C > T , resulting in R233X .	3 3 3 8 8 8|5 8 8|5 3 12 12 12 3 15 15 12 15 17|15 17|15 17|15 17|15 17|15 3 25 42 27 25 27 25 31 25 35 35 35 31 25 42 42 42 42 42 42 42 47 47 47 43 49 47 49 49 49 42 55 54|55|65 54|55|65 54|55|65 54|55|65 54|55|65 55|65 54|55|65 62 55|56 55 55|56 62 65 68 68 65 70 68 73 73 70 73 77 77 73 70 70 81 79 85 85 85 79 88 88 85 92 92 92 88 92 96 96 93 99 99 96 99 65 103|106 106 103|106 106 106 107 107 111 118 116 116 112|116 116 112|116 111 118 106 120 118 106 125 125 127 125 132 132 132|129 132 132|129 127 137 137 137 137 132 139 137 125 144 144 163 144 147 144 150 150 149|150|147 149|150|147 150|147 149|150|147 150 155 150 150 150 160 160 150 163 163 163 166 166 163 168 166 168 173 173 173 168 173 179 179 174|179 179 174|179 168 163 184 185 185 190 190 190 190 185 192 190 192 185 196 203 203 200 200 203 203 203 203 205 203 205 211 211 211|208 211 211|208 205 213 211 215 213 215 215 215 203 229 229 223 225 225 229 229 229 229 203 229 203 235 235 235 240 238 240 240 235 240 244 244 240 240 240 248 246 235	Association
18558293	Disease	Gene	D013964	5728	True	0	What is [EMU_BC] between @DiseaseSrc$ thyroid adenoma @/DiseaseSrc$ and @GeneTgt$ PTEN @/GeneTgt$ ? [SEP] A novel mutation of the @GeneTgt$ PTEN @/GeneTgt$ gene in a Japanese patient with Cowden syndrome and bilateral breast cancer . Cowden syndrome ( CS ) , also known as multiple hamartoma syndrome , is an autosomal dominant cancer syndrome associated with a high risk of @DiseaseSrc$ breast and thyroid cancers @/DiseaseSrc$ . The @GeneTgt$ phosphatase and tensin homolog gene @/GeneTgt$ ( @GeneTgt$ PTEN @/GeneTgt$ ) encodes a lipid phosphatase that contains a PTPase domain and a C2 domain and plays a role as a tumor suppressor that negatively regulates the cell-survival signaling pathway initiated by phosphatidylinositol 3-kinase ( PI3 K ) . @GeneTgt$ PTEN @/GeneTgt$ inhibits angiogenesis , and germline mutations of the @GeneTgt$ PTEN @/GeneTgt$ gene are associated with CS . We screened for mutations in the @GeneTgt$ PTEN @/GeneTgt$ gene in two unrelated Japanese patients with CS . In one patient , who suffered from bilateral breast cancer , @DiseaseSrc$ thyroid adenoma @/DiseaseSrc$ , and gastric malignant lymphoma , we found a single-base substitution in exon 2 ( 115G > C ) of the @GeneTgt$ PTEN @/GeneTgt$ gene . This transversion results in a germline missense mutation ( A39P ) . To date , nine different mutations have been identified in exon 2 of the @GeneTgt$ PTEN @/GeneTgt$ gene in patients with CS and variant CS ; however , the A39P missense mutation has not been reported previously . We also detected a previously reported nonsense mutation , 697C > T , resulting in R233X .	3 3 3 8 8 8|5 8 8|5 3 12 12 12 3 15 15 12 15 19 19 15 3 23 40 25 23 25 23 29 23 33 33 33 29 23 40 40 40 40 40 40 40 45 45 45 41 47 45|46|47 45|46|47 45|46|47 45|46|47 45|47 45|46|47 40 55 54|55|65 54|55|65 54|55|65 54|55|65 54|55|65 55|65 54|55|65 62 55|56 55 55|56 62 65 68 68 65 70 68 73 73 70 73 77 77 73 70 70 81 79 85 85 85 79 88 88 85 92 92 92 88 92 96 96 93 99 99 96 99 65 103|106 106 103|106 106 106 107 107 111 118 116 116 112|116 116 112|116 111 118 106 120 118 106 125 125 127 125 132 132 132|129 132 132|129 127 137 137 137 137 132 139 137 125 144 144 163 144 147 144 151 151 151 147 151 151|152|153 151|152|153 151|153 151|152|153 151 151 160 160 151 163 163 163 166 166 163 168 166 168 173 173 173 168 173 179 179 174|179 179 174|179 168 163 184 185 185 190 190 190 190 185 192 190 192 185 196 203 203 200 200 203 203 203 203 205 203 205 211 211 211|208 211 211|208 205 213 211 215 213 215 215 215 203 229 229 223 225 225 229 229 229 229 203 229 203 235 235 235 240 238 240 240 235 240 244 244 240 240 240 248 246 235	Association
18558293	Disease	Gene	D006223	5728	True	0	What is [EMU_BC] between @DiseaseSrc$ multiple hamartoma syndrome @/DiseaseSrc$ and @GeneTgt$ PTEN @/GeneTgt$ ? [SEP] A novel mutation of the @GeneTgt$ PTEN @/GeneTgt$ gene in a Japanese patient with @DiseaseSrc$ Cowden syndrome @/DiseaseSrc$ and bilateral breast cancer . @DiseaseSrc$ Cowden syndrome @/DiseaseSrc$ ( CS ) , also known as @DiseaseSrc$ multiple hamartoma syndrome @/DiseaseSrc$ , is an autosomal dominant cancer syndrome associated with a high risk of breast and thyroid cancers . The @GeneTgt$ phosphatase and tensin homolog gene @/GeneTgt$ ( @GeneTgt$ PTEN @/GeneTgt$ ) encodes a lipid phosphatase that contains a PTPase domain and a C2 domain and plays a role as a tumor suppressor that negatively regulates the cell-survival signaling pathway initiated by phosphatidylinositol 3-kinase ( PI3 K ) . @GeneTgt$ PTEN @/GeneTgt$ inhibits angiogenesis , and germline mutations of the @GeneTgt$ PTEN @/GeneTgt$ gene are associated with CS . We screened for mutations in the @GeneTgt$ PTEN @/GeneTgt$ gene in two unrelated Japanese patients with CS . In one patient , who suffered from bilateral breast cancer , thyroid adenoma , and gastric malignant lymphoma , we found a single-base substitution in exon 2 ( 115G > C ) of the @GeneTgt$ PTEN @/GeneTgt$ gene . This transversion results in a germline missense mutation ( A39P ) . To date , nine different mutations have been identified in exon 2 of the @GeneTgt$ PTEN @/GeneTgt$ gene in patients with CS and variant CS ; however , the A39P missense mutation has not been reported previously . We also detected a previously reported nonsense mutation , 697C > T , resulting in R233X .	3 3 3 8 8 8|5 8 8|5 3 12 12 12 3 14 12|14 12|14 12|14 12|14 14 20 20 14 3 23|24|44 23|24|44 24|44 23|24|44 28 24 28 24 32 24 34 31|32|34 31|32|34 31|32|34 32|34 31|32|34 24 44 44 44 44 44 44 44 49 49 49 45 51 49 51 51 51 44 59 58|59|69 58|59|69 58|59|69 58|59|69 58|59|69 59|69 58|59|69 66 59|60 59 59|60 66 69 72 72 69 74 72 77 77 74 77 81 81 77 74 74 85 83 89 89 89 83 92 92 89 96 96 96 92 96 100 100 97 103 103 100 103 69 107|110 110 107|110 110 110 111 111 115 122 120 120 116|120 120 116|120 115 122 110 124 122 110 129 129 131 129 136 136 136|133 136 136|133 131 141 141 141 141 136 143 141 129 148 148 166 148 151 148 155 155 155 151 155 158 155 155 155 163 163 155 166 166 166 169 169 166 171 169 171 176 176 176 171 176 182 182 179|182 182 179|182 171 166 186 187 187 192 192 192 192 187 194 192 194 187 198 205 205 202 202 205 205 205 205 207 205 207 213 213 213|210 213 213|210 207 215 213 217 215 217 217 217 205 231 231 225 227 227 231 231 231 231 205 231 205 237 237 237 242 240 242 242 237 242 246 246 242 242 242 250 248 237	Association
12786840	Disease	Gene	D001943	7157	True	0	What is [EMU_BC] between @DiseaseSrc$ breast carcinomas @/DiseaseSrc$ and @GeneTgt$ p53 @/GeneTgt$ ? [SEP] Cowden 's disease : clinical and molecular genetic findings in a patient with a novel PTEN germline mutation . We report a 54-year-old woman with Cowden 's disease ( CD ) who was found to carry a novel germline mutation in the PTEN gene . The mutation ( c.334C-->G ) introduced a splice donor site within exon 5 that caused the expression of an aberrant transcript lacking 159 nucleotides corresponding to codons 112 - 164 . Clinically , the patient showed multiple benign hamartomatous lesions of the skin , papillomatosis of the lips and oral mucosa , polyposis coli and bilateral fibrocystic disease of the breast . In addition , she developed different types of malignant neoplasms , including bilateral carcinomas of the breast and malignant melanomas of the skin . Molecular genetic analysis of a benign skin hamartoma and an invasive ductal breast carcinoma revealed loss of heterozygosity ( LOH ) at microsatellite markers on chromosome 10 in the carcinoma but not in the hamartoma . The @DiseaseSrc$ breast carcinoma @/DiseaseSrc$ additionally carried a somatic @GeneTgt$ TP53 @/GeneTgt$ point mutation ( c.466C-->G ; R156 G ) that was associated with LOH on 17p and nuclear @GeneTgt$ p53 @/GeneTgt$ protein accumulation . Taken together , our findings indicate that benign hamartomas in CD may develop without loss of the second ( wild-type ) PTEN allele , whereas the pathogenesis of malignant tumours , such as @DiseaseSrc$ breast carcinomas @/DiseaseSrc$ , appears to require the complete inactivation of Pten as well as further alterations such as the loss of @GeneTgt$ p53-dependent @/GeneTgt$ growth control .	3 1 3 3 9 5 5 5 3 12 12 9 18 18 18 18 18 12 3 21 21 24 24 21 28 28 26 24 30 28 30 34 34 28 36 34 40 40 40 36 44 44 44 40 21 47 51 49 47 49 51 55 55 55 51 57 55 57 60 55 62 60 66 66 66 62 66 69 67 69 72 70 75 75 72 51 81 81 80 81 81 85 85 85 81 88 88 85 88 88 93 93 90 93 96 93 88 99 88 88 103 103 88 106 106 88 81 109 112 112 112 112 114 112 117 117 114 117 121 121 117 124 124 121 124 127 124 130 130 124 112 134 134 146 139 139 139 139 134 139 145 145 145 145 139 146 146 149 147 151 149 151 155 155 147 157 155 157 161 161 147 161 166 166 166 161 146 169 168|169|173 168|169|173 169|173 168|169|173 173 173 179 179 179|173 179 179|173 179 173 181 179 181 184 181 181 188 188 179 190 188 192 190 192 198 191|197 197 191|197 198 192 173 208 203 208 207 208 208 215 211 215 213 211 215 208 217 215 225 225 225 222 225 225 225 217 215 215 229 240 232 232 229 232 236 234 235|236|232 235|236|232 236|232 235|236|232 229 215 242 240 245 245 242 247 245 245 248 248 252 245 256 253 256 252 261 261|255 261 261|255 261 256 208	Association
11212236	Disease	Gene	D001943	7048	True	0	What is [EMU_BC] between @DiseaseSrc$ breast tumor @/DiseaseSrc$ and @GeneTgt$ TGFBR2 @/GeneTgt$ ? [SEP] Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human @DiseaseSrc$ breast cancer @/DiseaseSrc$ . Members of the transforming growth factor beta ( TGF-beta ) family are potent inhibitors of the growth of many epithelial cell types . Transmembrane signaling by TGF-beta occurs via a complex of the serine/threonine kinases TGF-beta type 1 receptor and TGF-beta type 2 receptor ( @GeneTgt$ TGFBR2 @/GeneTgt$ ) , and inactivating mutations in the latter have recently been detected in some primary tumors and in several types of tumor-derived cell lines . The most common mutations that have been identified in @GeneTgt$ TGFBR2 @/GeneTgt$ are frameshifts in a repetitive polyadenine region in replication error-positive colorectal carcinomas that result in a truncated protein and absence of receptor expression at the cell surface . A number of point mutations in the highly conserved serine/threonine kinase domain of @GeneTgt$ TGFBR2 @/GeneTgt$ have also been reported , some of which have been correlated with either loss of trans-phosphorylation of TGF-beta type 1 receptor or constitutive activation of trans-phosphorylation . No @GeneTgt$ TGFBR2 @/GeneTgt$ mutations have been reported in human @DiseaseSrc$ breast tumors @/DiseaseSrc$ , but anomalous expression of TGF-beta in @DiseaseSrc$ breast carcinomas @/DiseaseSrc$ suggests that TGF-beta signaling may be defective . We have therefore systematically examined unmatched sets of 17 primary and 17 recurrent @DiseaseSrc$ breast tumor @/DiseaseSrc$ samples for mutations in @GeneTgt$ TGFBR2 @/GeneTgt$ , restricted to those regions of the gene in which mutations have previously been reported . None of the previously reported mutations was detected , but four novel mutations ( V387 M , N435S , V447A , and L452 M ) were found in the kinase domain in recurrent tumors . No mutations were detected in primary tumors . TGF-beta signaling was significantly inhibited by each of the N435S , V447A , and L452 M mutations .	1 1 11 11 11 11 11 11 11 11 2 15 15 15 2|14|15 2|14|15 2|15 2|14|15 1 33 30 30 30 30 30 30 30 30 30 20 33 33 33 36 36 33 41 41 41 41 36 33 44 47 46 44 47 50 50 47 58 58 58 58 58 58 58 50 58 63 63 63 58 65 63|64 63 63|64 65 47 47 71 78 74 74 71 78 78 78 47 82 82 82 78 82 86 86 82 90 90 90 86 47 96 95 96 105 100 100 100 96 102 100|101 100 100|101 105 105 110 110 110 110 105 115 113 115 115 110 117 115 121 121 121 117 121 121 126 126 121 130 130 130 121 105 134 151 137 137 134 144 144 141 144 144 144 137 146 144|145 144 144|145 151 151 151 151 158 158 155 153 158 158 151 161 161 158 163 161 168 168 168 168 163 161 171 161 173 171 151 179 176|179 179 176|179 182 182 182 182 185 185 183|185|182 183|185|182 185|182 183|185|182 182 182 191 198 193 191 195 191|195 191|195 191|195 191|195 182 204 201 204 204 204 198 198 213 213 213 213 213 215 213 218 218 225 218 221 218 225|221 225|221 225 225|221 215 227 225 229 226|227 227 226|227 225 215 235 235 232 238 238 235 240 245 245 245 245 245 238 213 256 254 254 253 254 249 256 256 256 256 261 261 275 264 264 261 266 264 266 266 268 264 264 264 264 275 256 279 279 279 275 282 282 279 256 285 287 287 287 290 290 287 287 293 296 296 296 296 298 296 301 301 298 301 301 303 296 308 308 296 296	Association
15649950	Disease	Gene	D001943	11200	True	0	What is [EMU_BC] between @DiseaseSrc$ increases breast cancer @/DiseaseSrc$ and @GeneTgt$ CHEK2 @/GeneTgt$ ? [SEP] Functional and genomic approaches reveal an ancient @GeneTgt$ CHEK2 @/GeneTgt$ allele associated with @DiseaseSrc$ breast cancer @/DiseaseSrc$ in the Ashkenazi Jewish population . Functional and genomic approaches can be integrated to screen efficiently for pathogenic alleles in founder populations . We applied such approaches to analysis of the cancer-associated cell cycle regulator @GeneTgt$ CHEK2 @/GeneTgt$ in the Ashkenazi Jewish population . We first identified two extended haplotypes at @GeneTgt$ CHEK2 @/GeneTgt$ that co-segregated with @DiseaseSrc$ breast cancer @/DiseaseSrc$ in high-risk families . We sequenced @GeneTgt$ CHEK2 @/GeneTgt$ in a case representing each haplotype and discovered two novel amino acid substitutions , @GeneTgt$ CHEK2.S428F @/GeneTgt$ in the kinase domain and @GeneTgt$ CHEK2.P85L @/GeneTgt$ in the N-terminal region . To assay these alleles for loss of @GeneTgt$ CHEK2 @/GeneTgt$ function , we tested their capacity to complement Rad53 deletion in Saccharomyces cerevisiae . @GeneTgt$ CHEK2.S428F @/GeneTgt$ failed to complement @GeneTgt$ Rad53 @/GeneTgt$ and thus largely abrogates normal @GeneTgt$ CHEK2 @/GeneTgt$ function , whereas @GeneTgt$ CHEK2.P85L @/GeneTgt$ complemented @GeneTgt$ Rad53 @/GeneTgt$ as well as did wild-type @GeneTgt$ CHEK2 @/GeneTgt$ . Epidemiologic analyses were concordant with the functional tests . Frequencies of @GeneTgt$ CHEK2.S428F @/GeneTgt$ heterozygotes were 2.88 % ( 47/1632 ) among female @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients not selected for family history or age at diagnosis and 1.37 % ( 23/1673 ) among controls ( OR=2.13 , 95 % CI [ 1.26 , 3.69 ] , P=0.004 ) , whereas frequencies of @GeneTgt$ CHEK2.P85L @/GeneTgt$ were 0.92 % among cases and 0.83 % among controls . On the basis of the experience of mothers , sisters and daughters of probands , @DiseaseSrc$ breast cancer @/DiseaseSrc$ risk due to @GeneTgt$ CHEK2.S428F @/GeneTgt$ was estimated as 0.17 ( + /-0.08 ) by age 60 . We conclude that @GeneTgt$ CHEK2.S428F @/GeneTgt$ @DiseaseSrc$ increases breast cancer @/DiseaseSrc$ risk approximately 2-fold among Ashkenazi Jewish women , whereas @GeneTgt$ CHEK2.P85L @/GeneTgt$ is a neutral allele . In general , these results suggest that selecting probands with extended haplotypes that co-segregate with disease can improve the efficiency of resequencing efforts and that quantitative complementation tests in yeast can be used to evaluate variants in genes with highly conserved function .	4 1 1 5 5 10 10 10|7 10 10|7 5 10 13 11|13 11|13 11|13 11|13 20 20 20 20 13 5 27 24 24 30 30 30 30 32 30 32 36 36 32 39 39 36 30 42 42 44 42 46 42 53 53 53 53 52 53 52|46 46 52|46 59 59 59 59 46 42 64 64 64 67 67 64 69 67|68 67 67|68 72 67 74 72|74 72|74 72|74 72|74 79 79 74 64 84 84 84 84 84 89 89 84 89 92 90 84 84 99 99 99 99 94 99 99 99 99 106 106 106 101 101 101|105 101 101|105 113 113 113 108 84 119 119 121 119 123 121 127 127|124 127 127|124 123 130 130 119 132 130 136 136 136 132 139 139 136 130 141|144 144 141|144 144 146 144 145|146 146 145|146 144 144 152 144 156 151|156 156 151|156 152 144 144 161|155 161 161|155 144 157|161 161 157|161 161 164 164 161 169 167|163 167 167|163 144 179 181 181 181 185 185 185 181 181 194 191 188|191 191 188|191 187 194 194 194 196 194 196 203 203 203|198 203|198 203 203|198 194 205 203 208 208 205 208 208 212 205 205 215 205 217 215 217 220 215 222 220 222 225 226 222 230 230 228 226 230 222 222 222 194 243 243 239 235|237 237 235|237 243 243 194 245 243 243 248 243 250 248 194 257 257 273 260 260 257 262 260 262 262 264 264 268 264 273 270|273|269 270|273|269 270|273 270|273|269 279 276 274 273 273 273 279 279 281 279 281 281 281 281 287 279 287 279 293 293 297 294|297 297 294|297 293|301|295|297 293|301|295|297 293|301|295|297 293|301|297 293|301|295|297 297 303 301 307 307 307 301 297 315 315|305 315 315|305 315 315 315 297 293 325 320 325 324 325 325 327 325 337 331 331 328 333 331 335 333 337 327 339 337 342 342 339 337 352 347 347 352 349 347 352 352 337 354 352 354 357 355 361 360 361 357 325	Association
16280053	Disease	Gene	D001943	571	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ BACH1 @/GeneTgt$ ? [SEP] Mutation analysis of FANCD2 , @GeneTgt$ BRIP1/BACH1 @/GeneTgt$ , LMO4 and SFN in @DiseaseSrc$ familial breast cancer @/DiseaseSrc$ . INTRODUCTION : Mutations in known predisposition genes account for only about a third of all multiple-case @DiseaseSrc$ breast cancer @/DiseaseSrc$ families . We hypothesized that germline mutations in FANCD2 , @GeneTgt$ BRIP1/BACH1 @/GeneTgt$ , LMO4 and SFN may account for some of the unexplained multiple-case @DiseaseSrc$ breast cancer @/DiseaseSrc$ families . METHODS : The families used in this study were ascertained through the Kathleen Cuningham Foundation Consortium for Research into @DiseaseSrc$ Familial Breast Cancer @/DiseaseSrc$ ( kConFab ) . Denaturing high performance liquid chromatography ( DHPLC ) analysis of the coding regions of these four genes was conducted in the youngest affected cases of 30 to 267 non-BRCA1/2 @DiseaseSrc$ breast cancer @/DiseaseSrc$ families . In addition , a further 399 index cases were also screened for mutations in two functionally significant regions of the FANCD2 gene and 253 index cases were screened for two previously reported mutations in @GeneTgt$ BACH1 @/GeneTgt$ ( p. P47A and p. M299I ) . RESULTS : DHPLC analysis of FANCD2 identified six silent exonic variants , and a large number of intronic variants , which tagged two common haplotypes . One protein truncating variant was found in @GeneTgt$ BRIP1/BACH1 @/GeneTgt$ , as well as four missense variants , a silent change and a variant in the 3 ' untranslated region . No missense or splice site mutations were found in LMO4 or SFN . Analysis of the missense , silent and frameshift variants of FANCD2 and @GeneTgt$ BACH1 @/GeneTgt$ in relatives of the index cases , and in a panel of controls , found no evidence suggestive of pathogenicity . CONCLUSION : There is no evidence that highly penetrant exonic or splice site mutations in FANCD2 , @GeneTgt$ BRIP1/BACH1 @/GeneTgt$ , LMO4 or SFN contribute to @DiseaseSrc$ familial breast cancer @/DiseaseSrc$ . Large scale association studies will be necessary to determine whether any of the polymorphisms or haplotypes identified in these genes contributes to @DiseaseSrc$ breast cancer @/DiseaseSrc$ risk .	2 2 4 2 4 4|5 4 4|5 4 4 4 4 13 2|11|13 2|11|13 2|11|13 2|13 2|11|13 2 20 20 27 26 26 26 22 20 32 30 32 32 27 39 39 39 35|39 35|39 39 35|39 32 27 43 43 57 46 57 48 46 48 49|48 48 49|48 48 48 48 48 57 43 59 57 67 67 67 67 67|62 67|62 67 67|62 59 43 80 80 74 80 74 78 78 75 80 80 86 86 86 86 86 80 88 86 90 80|89|90 80|89|90 80|89|90 80|90 80|89|90 95 90 95 80 117 103 103 103 107 105 107 107 117 111 111 111 107 115 115 115 111 117 117 120 120 117 122 117 131 126 126 131 131 131|127 131|127 131 131|127 122 117 135 144 144 141 141 141 141 144 144 144 144 146 144 151 151 150 151 146 155 155 155 151 151 159 159 161 161 144 166 166 165 166 161 168 166|167 166 166|167 172 172 168 172 175 172 172 144 179 179 182 185 184 182 179 189 189 189 185 185 185 194 194 185 197 197 194 197 200 197 203 203 200 179 206 208 208 210 210 210 212 210|211 210 210|211 212 212 215 215 220 220 212 220 224 224 220 224 227 224 233 233 233 233 233 227 210 237 243 237 241 241 237 243 243 245 243 245 245 243 277 252 252 249 252 252 252 252 252 259 257 259 259|260 259 259|260 264 257 268 268 268 264 252 252 273 273 249 275 273 249 277 279 277 279 282 280 277 285 288 288 285 290 288 308 293 294 308 294 294 298 294 300 298 300 300|301 300 300|301 300 300 300 300 290 310 308|310 308|310 308|310 308|310 308|310 285 318 320 320 323 323 323 323 325 323 337 337 330 330 327 330 330 327 336 336 333 325 342 342|338|339 342|338|339 342|339 342|338|339 337 323	Association
9806478	Disease	Gene	D008545	1029	True	0	What is [EMU_BC] between @DiseaseSrc$ melanoma @/DiseaseSrc$ and @GeneTgt$ p16 @/GeneTgt$ ? [SEP] Screening for tumour suppressor @GeneTgt$ p16(CDKN2A @/GeneTgt$ ) germline mutations in Israeli @DiseaseSrc$ melanoma @/DiseaseSrc$ families . Approximately ten percent of patients with @DiseaseSrc$ malignant melanoma @/DiseaseSrc$ have family histories of the disease , suggesting a genetic predisposition . Germline mutations in tumour suppressor @GeneTgt$ p16 @/GeneTgt$ gene have been implicated as disease causing mutations in some of the @DiseaseSrc$ melanoma @/DiseaseSrc$ families . The frequency of families with @GeneTgt$ p16 @/GeneTgt$ germline mutations among @DiseaseSrc$ melanoma @/DiseaseSrc$ prone families varies from eight to fifty percent . The range of the variability is influenced apparently by the number of @DiseaseSrc$ melanoma @/DiseaseSrc$ affected individuals within the family , as well as by other , yet unidentified factors . Ethnic background is known to determine both the frequency and the nature of germline alterations . Recently , specific mutations in tumour suppressor genes involved in breast cancer and in colon cancer were found at elevated frequency among Ashkenazi Jews . This report describes results of a screening for @GeneTgt$ p16 @/GeneTgt$ germline alterations in a collection of @DiseaseSrc$ Israeli melanoma @/DiseaseSrc$ families . We have analyzed genomic DNA from thirty one Ashkenazi and non-Ashkenazi Jewish @DiseaseSrc$ melanoma @/DiseaseSrc$ families , as well as from thirty @DiseaseSrc$ melanoma @/DiseaseSrc$ patients without an apparent family history of the disease . The entire coding region of the @GeneTgt$ p16 @/GeneTgt$ gene was screened by single strand conformation polymorphism analysis and direct DNA sequencing . We have detected a number of carriers with the Ala148 Thr polymorphism at the end of the second exon and several instances of 500(G=>C ) substitution at the 3 ' untranslated portion of the gene .	1 5 5 5 1|4 1 1|4 5 9 1 14 14 10|14 14 10|14 9 1 19 20 27 22 20 24 22|23|24 22|23|24 22|24 22|23|24 27 29 27 32 32 29 27 27 37 37 34 27 41 50 47 47 47 47|44 47 47|44 41 50 50 50 53 53 50 53 56 54 61 61 57|61 61 57|61 56 50 66 79 68 66 73 73|69 73 73|69 73 68 78 73|77 77 73|77 78 73 79 84 83 83 84 79 79 89 94 92 92 89 94 94 94 98 98 102 100 98|99 98 98|99 94 102 106 106 103 103 102 108 108 116 116 112 112 116 102 94 120 122 122 122 124 122 127 127 124 127 130 127 133 133 130 122 152 152 138 152 142 142 142 138 142 146 146 143 146 150 150 146 152 152 155 155 152 158 158 155 152 161 162 162 162 166 166 163 171 167|171 171 167|171 171 166 174 174 163 179 179|174 179|174 179 179|174 174 162 185 185 185 187 185 191 190 191 187 191 194 191 194|197 197 194|197 191 191 187 199 199 206 206 206|202 206 206|202 187 211 211 211 211 185 214 214 211 185 221 221 221 228 226 226 226|223 226 226|223 221 228 228 234 234 234 234 234 228 234 238 238 234 228 243 243 243 245 243 247 245 252 252 252 252 247 255 255 245 259 259 259 255 245 262 245 266 266 266 262 272 272 272 272 272 245 275 275 272 243	Association
15101044	Disease	Gene	D001943	472	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ ATM @/GeneTgt$ ? [SEP] Functional consequences of @GeneTgt$ ATM @/GeneTgt$ sequence variants for chromosomal radiosensitivity . The @GeneTgt$ ATM @/GeneTgt$ [ for ataxia-telangiectasia ( A-T ) mutated ] protein plays a key role in the detection and cellular response to DNA double-strand breaks . Several single-nucleotide polymorphisms ( SNPs ) have been described in the @GeneTgt$ ATM @/GeneTgt$ gene ; however , their association with cancer risk or radiosensitivity remains to be fully established . In this study , the functional consequences of specific @GeneTgt$ ATM @/GeneTgt$ SNPs on in vitro radiosensitivity , as assessed by micronuclei ( MN ) formation , were measured in lymphoblastoid cell lines established from 10 @DiseaseSrc$ breast cancer @/DiseaseSrc$ ( BC ) patients carrying different @GeneTgt$ ATM @/GeneTgt$ missense SNPs , six A-T patients , six A-T heterozygotes ( A-T het ) , and six normal individuals . The BC , A-T het , and A-T cell line groups showed significantly higher mean levels of MN formation after exposure to ionizing radiation ( IR ) than did the group containing normal cell lines , with similar levels in the BC and A-T het groups . Within the BC lines studied , the group composed of the six carrying the linked 2572T > C ( 858F > L ) and 3161C > G ( 1054P > R ) variants had a higher level of MN after IR exposure compared to that observed in the remaining four BC or in the normal cell lines . This increase was not related to the constitutive @GeneTgt$ ATM @/GeneTgt$ mRNA level , which was similar in these BC and the normal cell lines . Our results indicate that alterations in the @GeneTgt$ ATM @/GeneTgt$ gene , including the presence of heterozygous mutations and the 2572C and 3161 G variant alleles , are associated with increased in vitro chromosomal radiosensitivity , perhaps by interfering with @GeneTgt$ ATM @/GeneTgt$ function in a dominant-negative manner .	2 2 7 3|7 7 3|7 7 2 10 10 7 2 14 13|25 25 13|25 14 24 24 20 18 20 24 24 14 25 28 28 25 31 31 25 31 34 31 38 38 38 31 25 43 43 49 45 43 45 49 49 49 54 54 51|54 54 51|54 49 49 65 65 59 65 61 59 61 62 62 49 69 69 69 65 49 74 74 99 99 78 78 99 83 83 80|83 83 80|83 78 87 87 85 78 78 90 78 96 96 94 92 94 90 78 99 99 103 103 103 99 103 107 107 105|107|113 105|107|113 113|107 105|107|113 111 113 111 104 113 119 119|112 119 119|112 119 114 119 123 123 119 123 127 127 123 130 130 127 130 119 119 136 136 119 99 142 152 142 145 152 145 145 145 151 151 145 152 154 156 156 152 159 159 156 161 152 164 164 161 166 164 166 169 152 171 169 171 175 175 172 169 179 179 169 182 182 179 182 182 186 182 152 191 191 191 221 191 191 195 191 195 199 199 196 199 203 203 200 205 195 209 209 209 205 209 205 191 214 220 220 215 216 220 220 191 221 224 224 221 226 224 229 229 221 232 232 229 232 238 238 238 238 233 232 244 244 244 244 232 221 247 250 250 250 250 257 257 257 253|257 257 253|257 257 250 257 261 261 257 264 264 261 264 269 269 269 264 250 273 274 274 299 299 281 281 281|278 281 281|278 276 281 285 285 276 288 288 285 285 291 285 291 291 295 296 291 276 299 274 305 305 305 302 305 299 299 309 309 299 313 313|309 313 313|309 309 317 317 317 309 274	Association
12810666	Disease	Gene	D010051	472	True	0	What is [EMU_BC] between @DiseaseSrc$ breast and ovarian cancer @/DiseaseSrc$ and @GeneTgt$ ATM @/GeneTgt$ ? [SEP] Contributions of @GeneTgt$ ATM @/GeneTgt$ mutations to familial breast and ovarian cancer . This study addresses the prevalence of @GeneTgt$ ATM @/GeneTgt$ mutations and the association with breast cancer in Austrian families selected for a history of @DiseaseSrc$ breast or ovarian cancer @/DiseaseSrc$ or both [ hereditary breast and ovarian cancer ( HBOC ) ] . In 270 HBOC families previously screened for BRCA1 and BRCA2 mutations , 137 different sequence alterations of @GeneTgt$ ATM @/GeneTgt$ were identified . Seven of these were mutations presumed to cause ataxia telangiectasia based on their effect on the @GeneTgt$ ATM @/GeneTgt$ protein , including five that caused a protein truncation and two missense mutations in the catalytic kinase domain of the highly conserved COOH terminus of the protein . The seven mutations were found in 10 families ( 3.7 % ) . In addition , one missense variant , L1420F , was observed in 13 HBOC families ( 4.8 % ) but was not observed in any of the 122 healthy volunteers with no history of breast cancer . In addition , the variant segregated with breast cancer in some of the families , suggesting that it may be pathogenic for breast cancer . Sixty-two additional variants of potential significance were observed in 65 HBOC families , but not in healthy controls . These variants included 24 sequence alterations with possible effects on splicing or protein-protein interactions . This study indicates that there is a significant prevalence of @GeneTgt$ ATM @/GeneTgt$ mutations in @DiseaseSrc$ breast and ovarian cancer @/DiseaseSrc$ families and adds to a growing body of evidence that @GeneTgt$ ATM @/GeneTgt$ mutations confer increased susceptibility to breast cancer .	1 5 2|5 5 2|5 1 8 8 1 8 11 8 1 15 16 16 18 16 22 22|19 22 22|19 18 18 25 18 28 28 25 31 31 25 31 35 35 32 37 37|35 37|35 37|35 37|35 37|35 37|35 37 46 45 46 37 46 49 46 51 49 51 16 16 60 60 60 77 62 60 64 62 64 64 64 77 72 72 72 77 74 72|73 72 72|73 77 77 77 84 82 80 84 84 84 87 85 89 87 89 93 93 90 98 98 95|98 98 95|98 93 98 101 98 103 101 106 106 103 106 110 110 106 115 115 115 115 110 121 121 119 121 121 115 124 124 121 85 129 129 131 131 131 134 134 131 137 137 134 137 131 141 150 150 145 145 150 145 145 145 150 150 154 154 154 150 157 157 154 157 150 162 162 150 164 162 169 169 169 169 164 172 172 164 175 175 172 150 178 182 182 181 182 182 185 185 182 187 182 190 190 187 182 182 197 197 197 197 192 200 200 197 182 204 204 209 207 207 204 209 209 213 213 213 209 213 213 219 219 219 213 209 222 223 223 226 226 223 229 229 226 231 229 231 231 231 223 237 238 238 241 241 238 244 244 241 248 245|248 248 245|248 244 250 255|248|250 255|248|250 255|248|250 255|248|250 255|248|250 255|248|250 250 241 241 261 261 261 257 263 261 268 259|267 267 259|267 268 263 238 269 273 273 270 238	Association
12810666	Disease	Gene	D001943	472	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ ATM @/GeneTgt$ ? [SEP] Contributions of @GeneTgt$ ATM @/GeneTgt$ mutations to familial breast and ovarian cancer . This study addresses the prevalence of @GeneTgt$ ATM @/GeneTgt$ mutations and the association with @DiseaseSrc$ breast cancer @/DiseaseSrc$ in Austrian families selected for a history of breast or ovarian cancer or both [ hereditary breast and ovarian cancer ( HBOC ) ] . In 270 HBOC families previously screened for BRCA1 and BRCA2 mutations , 137 different sequence alterations of @GeneTgt$ ATM @/GeneTgt$ were identified . Seven of these were mutations presumed to cause ataxia telangiectasia based on their effect on the @GeneTgt$ ATM @/GeneTgt$ protein , including five that caused a protein truncation and two missense mutations in the catalytic kinase domain of the highly conserved COOH terminus of the protein . The seven mutations were found in 10 families ( 3.7 % ) . In addition , one missense variant , L1420F , was observed in 13 HBOC families ( 4.8 % ) but was not observed in any of the 122 healthy volunteers with no history of @DiseaseSrc$ breast cancer @/DiseaseSrc$ . In addition , the variant segregated with @DiseaseSrc$ breast cancer @/DiseaseSrc$ in some of the families , suggesting that it may be pathogenic for @DiseaseSrc$ breast cancer @/DiseaseSrc$ . Sixty-two additional variants of potential significance were observed in 65 HBOC families , but not in healthy controls . These variants included 24 sequence alterations with possible effects on splicing or protein-protein interactions . This study indicates that there is a significant prevalence of @GeneTgt$ ATM @/GeneTgt$ mutations in breast and ovarian cancer families and adds to a growing body of evidence that @GeneTgt$ ATM @/GeneTgt$ mutations confer increased susceptibility to @DiseaseSrc$ breast cancer @/DiseaseSrc$ .	1 5 2|5 5 2|5 1 8 8 1 8 11 8 1 15 16 16 18 16 22 22|19 22 22|19 18 18 25 18 27 25|27 25|27 25|27 25|27 32 32 25 32 36 36 33 38 36 38 38 38 38 46 45 46 38 46 49 46 51 49 51 16 16 60 60 60 77 62 60 64 62 64 64 64 77 72 72 72 77 74 72|73 72 72|73 77 77 77 84 82 80 84 84 84 87 85 89 87 89 93 93 90 98 98 95|98 98 95|98 93 98 101 98 103 101 106 106 103 106 110 110 106 115 115 115 115 110 121 121 119 121 121 115 124 124 121 85 129 129 131 131 131 134 134 131 137 137 134 137 131 141 150 150 145 145 150 145 145 145 150 150 154 154 154 150 157 157 154 157 150 162 162 150 164 162 169 169 169 169 164 172 172 164 174 172|173|174 172|173|174 172|174 172|173|174 150 180 184 184 183 184 184 186 186|184|185 186|184|185 186|184 186|184|185 190 184 193 193 190 184 184 200 200 200 200 195 202 202|199|200 202|199|200 202|200 202|199|200 184 210 210 215 213 213 210 215 215 219 219 219 215 219 219 225 225 225 219 215 228 229 229 232 232 229 235 235 232 237 235 237 237 237 229 243 244 244 247 247 244 250 250 247 254 251|254 254 251|254 250 256 254 256 256 260 256 247 247 266 266 266 262 268 266 273 268|272 272 268|272 273 268 244 274 277 274|275|277 274|275|277 275|277 274|275|277 244	Association
15170666	Disease	Gene	D001943	5892	True	0	What is [EMU_BC] between @DiseaseSrc$ familial breast cancer @/DiseaseSrc$ and @GeneTgt$ RAD51D @/GeneTgt$ ? [SEP] The variant E233 G of the @GeneTgt$ RAD51D @/GeneTgt$ gene could be a low-penetrance allele in high-risk @DiseaseSrc$ breast cancer @/DiseaseSrc$ families without BRCA1/2 mutations . Six SNPs have been detected in the DNA repair genes RAD51C and @GeneTgt$ RAD51D @/GeneTgt$ , not previously characterized . The novel variant E233 G in @GeneTgt$ RAD51D @/GeneTgt$ is more highly represented in high-risk , site-specific , @DiseaseSrc$ familial breast cancer @/DiseaseSrc$ cases that are not associated with the BRCA1/2 genes , with a frequency of 5.74 % ( n = 174 ) compared to a control population ( n = 567 ) and another subset of @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients ( n = 765 ) with a prevalence of around 2 % only ( comparison to controls , OR = 2.6 , 95 % CI 1.12 - 6.03 ; p < 0.021 ) . We found that the immunohistochemical profile detected in available tumors from these patients differs slightly from those described in non-BRCA1/2 tumors . Finally , the structural prediction of the putative functional consequence of this change indicates that it can diminish protein stability and structure . This suggests a role for E233 G as a low-penetrance susceptibility gene in the specific subgroup of high-risk @DiseaseSrc$ familial breast cancer @/DiseaseSrc$ cases that are not related to BRCA1/2 .	4 4 4 14 9 9 9|6 9 9|6 4 14 14 14 14 14 20 20 20|15 20|15 20 20|15 14 23 23 20 14 28 31 31 31 31 36 36 36 36 31 36 37 37|38 37 37|38 36 44 44 36 31 51 51 51 51 58 53 51|52 51 51|52 58 57 58 58 68 68 60 60 60 62|64|68|60 62|64|68|60 62|64|68|60 64|68|60 62|64|68|60 58 72 72 72 68 76 76 76 72 68 80 80 58 83 83 80 85 86 83 86 86 80 93 93 93 89 96 96 93 96 96 93 101 93 106 98|106 98|106 106 98|106 101 108 106 108 109 108 114 114 93 118 117 118 114 121 121 118 123 121 58 126 58 131 131 130 131 126 134 134 131 137 137 131 137 58 58 145 145 157 149 149 157 149 153 153 150 156 156 153 145 157 160 157 160 164 164 161 145 179 179 170 170 179 175 175 175 175 170 178 178 175 179 183 183 183 179 183 184 185 185 179 190 190 192 190 195 195 192 200 200 200 200 192 204 204 204 200 211 211 206|211 206|211 206|211 211 206|211 204 215 215 215 211 217 215 190	Association
12516098	Disease	Gene	D001943	5727	True	0	What is [EMU_BC] between @DiseaseSrc$ breast carcinoma @/DiseaseSrc$ and @GeneTgt$ PTCH1 @/GeneTgt$ ? [SEP] The patched polymorphism Pro1315Leu ( C3944 T ) may modulate the association between use of oral contraceptives and @DiseaseSrc$ breast cancer @/DiseaseSrc$ risk . The gene coding for the human homologue of the Drosophila segment polarity gene patched ( @GeneTgt$ PTCH1 @/GeneTgt$ ) is mutated in several common human tumors . In mice , haplodeficiency at the Ptch1 locus results in severe histologic defects in mammary ductal structure . We found no mutations within the coding region of @GeneTgt$ PTCH1 @/GeneTgt$ in 17 human primary @DiseaseSrc$ breast carcinomas @/DiseaseSrc$ . However , the biallelic Pro1315Leu ( C3944 T ) polymorphism of @GeneTgt$ PTCH1 @/GeneTgt$ was significantly associated with @DiseaseSrc$ breast cancer @/DiseaseSrc$ in 41 Bavarian patients compared to 85 healthy controls . We investigated whether this variant influences susceptibility for @DiseaseSrc$ breast cancer @/DiseaseSrc$ in 611 @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients diagnosed by age 50 years and 1,057 controls matched by age and study region in Germany and in 1,093 @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients from the United Kingdom . Allele and genotype frequencies were not different between cases and controls . However , multivariate logistic regression analysis revealed an effect modification of oral contraceptive use ( OC ) on @DiseaseSrc$ breast cancer @/DiseaseSrc$ risk by Leu-carrier status . Compared to women who have Pro/Pro and never used OC , Pro/Pro OC users had an increased odds ratio for @DiseaseSrc$ breast cancer @/DiseaseSrc$ of 1.7 . The odds ratio was also 1.7 for Leu-carriers who never used OC , but this was attenuated among Leu-carriers who ever used OC by 20 % . The gene-environmental interaction was confirmed in case-only analysis of the German and British studies , yielding an interaction odds ratio of 0.7 for premenopausal women ( p = 0.06 ) . Longer duration of pill use was associated with a significantly greater risk reduction ( p for trend = 0.015 ) . Our novel observation of a differential effect of OC use on @DiseaseSrc$ breast cancer @/DiseaseSrc$ risk by @GeneTgt$ PTCH1 @/GeneTgt$ 1315Leu-carrier status suggests the interesting possibility of the Sonic hedgehog/Patched ( @GeneTgt$ SHH/PTCH1 @/GeneTgt$ ) signaling pathway being involved in hormone-induced development of @DiseaseSrc$ breast carcinoma @/DiseaseSrc$ .	4 4 4 10 7 7 4 7 10 10 12 10 14 12 17 17 14 17 18|19|22 18|19|22 19|22 18|19|22 14 10 26 38 26 31 31 31 27 37 37 37 37 37 31 44 40 38|39 38 38|39 40 44 44 49 49 49 49 44 44 53 60 60 60 59 59 59 55 60 64 64 64 60 68 68 68 64 60 71 71 73 71 77 77 77 73 79 77|78 77 77|78 85 85 85 85 85|77|83 85|77|83 85|77 85|77|83 71 106 106 95 95 106 100 100 100 100 95 102 100|101 100 100|101 106 106 106 108 106|108 106|108 106|108 106|108 114 114 114 108 106 119 119 119 115 106 124 124 128 127 128 124 128 131 130|131|129 130|131|129 131|129 130|131|129 139 139 139|133 139|133 139 139|133 129 139 142 140 144 128 144 147 144 147 150 148 150 153 150 155 150 150 162 162 154|162 154|162 162 154|162 150 166 166 166 162 124 177 171 171 177 177 177 177 179 177 179 179 177 189 189 188 185 188 189 189 192 192 189 196 196 196 192 198 196 198 204 200|201|204 200|201|204 201|204 200|201|204 192 207 207 189 189 224 212 210 214 212 214 215 218 215 215 224 223 223 224 224 228 228 228 224 230 228|229|230 228|229|230 228|230 228|229|230 234 230 224 239 239 242 242 242 242 244 242 247 247 244 247 242 242 253 253 242 255 253 258 258 255 258 262 262 258 253 266 266 268 268 268 271 271 268 277 277 277 274 274 271 268 268 283 282 283 279 285 283 288 288 283 291 291 283 291 291 268 296 301 299 299 296 301 301 307 307 305 307 307 301 309 307 311 309 311 312 309 301 318 318 336 322 322 322 318 325 325 322 330 326|327|330 326|327|330 327|330 326|327|330 325 335 334|329 334 334|329 335 322 336 339 339 336 349 349 349 349 349 341|349 349 341|349 349 349 339 351 349 354 354 351 356 356|351|354 356|351|354 356|354 356|351|354 336	Association
14683420	Disease	Gene	D001943	7157	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ TP53 @/GeneTgt$ ? [SEP] Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology . The number of reports investigating disease susceptibility based on the carriage of low-penetrance , high-frequency polymorphisms has steadily increased over the last years . Evidence based on meta-analyses of individual case-control studies is accumulating , defining specific individual variations in disease susceptibility . For example , genetic variations of the estradiol metabolism have been described as significant contributors to disease susceptibility with variations depending on ethnic background . In the field of obstetrics and gynecology , the genetic contribution of polymorphic markers to a series of disorders has been characterized . These disorders include recurrent pregnancy loss , pre-eclampsia , endometriosis , @DiseaseSrc$ breast cancer @/DiseaseSrc$ , and hormone replacement therapy (HRT)-related complications such as thrombosis . Among other genetic markers , thrombophilic genetic variants , such as the Factor V Leiden and prothrombin G20210A polymorphisms , as well as genetic variants of cytochrome P450 ( CYP ) enzymes , for example , CYP19 and CYP1B1 , have been established as genetic risk markers and disease modifiers of recurrent and sporadic pregnancy loss and HRT-independent and -dependent @DiseaseSrc$ breast cancer @/DiseaseSrc$ , respectively . In addition , meta-analyses of data in the literature established the TGFBR1 * 6A , GSTP I105V , and @GeneTgt$ TP53 @/GeneTgt$ R72P polymorphisms , as well as the GSTM1 gene deletion as low-penetrance genetic risk factors of sporadic @DiseaseSrc$ breast cancer @/DiseaseSrc$ . With respect to genetic modulation of therapeutic effects , beneficial effects of estrogen replacement therapy and HRT are modulated by the carriage of single nucleotide polymorphisms , for example , osteoprotection and blood lipid changes by the estrogen receptor-alpha ( ER-a ) PvuII polymorphism . Polymorphisms of the catechol-O-methyltransferase ( COMT ) , ER-alpha , IL-1 receptor antagonist , and Factor V genes have been demonstrated to modulate the timing of natural menopause . Lastly , a strong genetic contribution of polymorphisms to the development and the clinical course of endometriosis has been established with data pointing to polymorphisms of the COMT , GST , NAT-2 , and ER-alpha genes as susceptibility markers . In summary , the available evidence points to a number of polymorphisms of a wide variety of genes as strong hereditary determinants of the susceptibility to benign and malignant gynecologic and obstetric conditions .	1 3 1 3 3 7 3 7 7 1 12 29 14 12 14 17 15 21 21 21 12 23 21 23 23 23 29 29 29 33 33 33 29 29 44 35 38 36 42 42 42 38 44 44 44 44 49 49 46 52 52 49 44 55 65 65 58 65 62 62 62 58 65 65 65 68 68 65 71 71 68 73 71 77 77 77 65 65 81 81 100 83 81 83 83 100 89 89 100 92 92 89 95 95 89 97 95 100 100 100 100 103 104 104 107 107 104 107 107 109 109 109 109|112|113 109|112|113 109|113 109|112|113 113 107 120 120 122 122 107 125 123 122 104 131 131 131 170 131 134 135 131 135 142 137 142 142 142 135 142 145 146 142 146 142 148 148 152 142 159 159 159 157 159 159 152 159 162 152 142 142 164 164 131 170 170 170 174 174 174 170 174 177 174 179 177 179 179 183 179 179 179 185 185 187|188|179 187|188|179 179|188 187|188|179 170 170 170 196 204 204 204 200 198 203 203 200 204 217 208 208 217 208 211 208 208 208 213|208 208 213|208 217 204 217 217 219 219 225 224 225 217 230 230 230 230 225 233 233 230|231|233 230|231|233 230|233 230|231|233 204 240 257 243 243 240 246 246 243 257 249 257 253 253 253 249 253 253 257 257 260 260 257 264 264 264 260 264 267 260 269 267 269 269 273 260 282 282 277 282 279 277 279 282 273 257 304 287 287 284 289 287 289 287 287 292 296 296 292 287 287 300 301 287 304 304 304 306 304 308 306 311 311 308 304 332 332 318 318 318 332 320 318 323 323 318 323 327 327 323 329 327 332 332 332 334 332 334 337 335 340 340 337 340 340 340 340 340 340 348 340 351 351 332 332 354 359 359 359 359 359 359 362 362 359 364 362 368 368 368 364 370 368 374 374 374 362 377 377 374 379 385 379 379 379 382 382 377 359	Association
17541742	Disease	Gene	D010051	7157	True	0	What is [EMU_BC] between @DiseaseSrc$ ovarian cancer @/DiseaseSrc$ and @GeneTgt$ TP53 @/GeneTgt$ ? [SEP] Germline @GeneTgt$ TP53 @/GeneTgt$ mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families . About 40 % of French Canadian @DiseaseSrc$ breast and/or ovarian cancer @/DiseaseSrc$ families harbor germline BRCA1 or BRCA1 mutations where common mutations account for about 84 % of all mutations identified in cancer families . Within a series of BRCA1 and BRCA2 mutation-negative families , a germline @GeneTgt$ TP53 @/GeneTgt$ 13398 G > A ( Arg213Gln ) mutation was identified , which was selected for mutation analysis in this gene because of a family history consistent with Li-Fraumeni syndrome ( LFS ) . Given the founder effects in this population , the 13398 G > A mutation was screened in series of 52 BRCA1 and BRCA2 mutation-negative cancer families , and a mutation-positive family was identified . However , pedigree inspection and expansion of mutation-positive families with the same mutation revealed that they were closely related to each other . To further characterize the contribution of @GeneTgt$ TP53 @/GeneTgt$ in cancer families , mutation analysis was performed in the remaining BRCA1 and BRCA2 mutation-negative cancer families . Thirty sequence variants were identified , the majority of which occur in intronic sequences and are not predicted to affect the functionality of @GeneTgt$ TP53 @/GeneTgt$ . However , the 14538 G > A ( Arg290His ) mutation was identified in a family which did not exhibit features consistent with LFS or Li-Fraumeni-like ( LFL ) syndrome . Neither of the @GeneTgt$ TP53 @/GeneTgt$ mutations was detected in 381 French Canadian women with breast cancer diagnosed before 50 years of age not selected for family history of cancer . In all , germline @GeneTgt$ TP53 @/GeneTgt$ mutations were identified in two of 52 ( 3.8 % ) cancer families , suggesting that @GeneTgt$ TP53 @/GeneTgt$ is not a major contributor to BRCA1 and BRCA2 mutation-negative breast and/or @DiseaseSrc$ ovarian cancer @/DiseaseSrc$ families of French Canadian descent .	4 1|4 4 1|4 4 6 14 6 6 14 14 14 14 14 4 4 18 19 29 23 23 23 19|28|22|23 19|28|22|23 19|28|22|23 19|28|22|23 19|28|23 19|28|22|23 23 29 31 29 31 34 31 38 37 38 31 42 41 42 38 45 45 42 45 49 49 46 29 54 54 75 56 54 56 59 56 56 56 67 67 67|63 67 67|63 67 56 56 73 71 73 73 75 75 75 75 79 79 75 82 82 79 85 85 82 90 86 90 90 79 90 94 94 91 96 94 96 75 103 103 103 115 106 106 103 106 110 110 103 103 113 115 115 115 117 115 120 120 117 120 123 120 125 120 125 120 130 130 120 132 115 115 147 147 137 147 137 137 142 142 139 146 146 146 137 147 152 152 152 152 147 155 155 152 147 159 159 172 161 159 163 161|162 161 161|162 167 167 161 172 170 172 172 172 181 181 176 181 176 179 176 181 172 172 186 186 188 188 188 194 191 194 193 191 188 197 197 194 194 201 201 194 203 201 205 203 207 205|206 205 205|206 194 223 223 215 215 223 215 221 219 217 219 223 223 223 226 226 223 230 230 230 226 230 231 234 232 234 240 238 236 238 234 223 249 247 247 244|247 247 244|247 242 249 249 254 254 254 254 249 257 257 254 257 261 261 258 263 261 265 254 268 268 265 270 268 249 274 281 281 279 276|279 279 276|279 281 281 281 283 281 285 291 288 288 291 291 291 283 281 281 301 301|293 301 301|293 301 301 301 301 293 303 301 303 306 303 303 307 312|306 312|306 312 312|306 303 316 316 316 303 281	Association
17541742	Disease	Gene	D001943	7157	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ TP53 @/GeneTgt$ ? [SEP] Germline @GeneTgt$ TP53 @/GeneTgt$ mutations in BRCA1 and BRCA2 mutation-negative French Canadian @DiseaseSrc$ breast cancer @/DiseaseSrc$ families . About 40 % of French Canadian breast and/or ovarian cancer families harbor germline BRCA1 or BRCA1 mutations where common mutations account for about 84 % of all mutations identified in cancer families . Within a series of BRCA1 and BRCA2 mutation-negative families , a germline @GeneTgt$ TP53 @/GeneTgt$ 13398 G > A ( Arg213Gln ) mutation was identified , which was selected for mutation analysis in this gene because of a family history consistent with Li-Fraumeni syndrome ( LFS ) . Given the founder effects in this population , the 13398 G > A mutation was screened in series of 52 BRCA1 and BRCA2 mutation-negative cancer families , and a mutation-positive family was identified . However , pedigree inspection and expansion of mutation-positive families with the same mutation revealed that they were closely related to each other . To further characterize the contribution of @GeneTgt$ TP53 @/GeneTgt$ in cancer families , mutation analysis was performed in the remaining BRCA1 and BRCA2 mutation-negative cancer families . Thirty sequence variants were identified , the majority of which occur in intronic sequences and are not predicted to affect the functionality of @GeneTgt$ TP53 @/GeneTgt$ . However , the 14538 G > A ( Arg290His ) mutation was identified in a family which did not exhibit features consistent with LFS or Li-Fraumeni-like ( LFL ) syndrome . Neither of the @GeneTgt$ TP53 @/GeneTgt$ mutations was detected in 381 French Canadian women with @DiseaseSrc$ breast cancer @/DiseaseSrc$ diagnosed before 50 years of age not selected for family history of cancer . In all , germline @GeneTgt$ TP53 @/GeneTgt$ mutations were identified in two of 52 ( 3.8 % ) cancer families , suggesting that @GeneTgt$ TP53 @/GeneTgt$ is not a major contributor to BRCA1 and BRCA2 mutation-negative breast and/or ovarian cancer families of French Canadian descent .	4 1|4 4 1|4 4 6 15 6 6 15 15 15 10|15 10|15 15 10|15 4 4 20 21 30 25 25 25 21 25 29 29 25 30 32 30 32 35 32 39 38 39 32 43 42 43 39 46 46 43 46 50 50 47 30 54 54 75 56 54 56 59 56 56 56 67 67 67|63 67 67|63 67 56 56 73 71 73 73 75 75 75 75 79 79 75 82 82 79 85 85 82 90 86 90 90 79 90 94 94 91 96 94 96 75 103 103 103 115 106 106 103 106 110 110 103 103 113 115 115 115 117 115 120 120 117 120 123 120 125 120 125 120 130 130 120 132 115 115 147 147 137 147 137 137 142 142 139 146 146 146 137 147 152 152 152 152 147 155 155 152 147 159 159 172 161 159 163 161|162 161 161|162 167 167 161 172 170 172 172 172 181 181 176 181 176 179 176 181 172 172 186 186 188 188 188 194 191 194 193 191 188 197 197 194 194 201 201 194 203 201 205 203 207 205|206 205 205|206 194 223 223 215 215 223 215 221 219 217 219 223 223 223 226 226 223 230 230 230 226 230 231 234 232 234 240 238 236 238 234 223 249 247 247 244|247 247 244|247 242 249 249 254 254 254 254 249 256 254|256 254|256 254|256 254|256 256 262 262 259 264 262 266 254 269 269 266 271 269 249 276 283 283 281 278|281 281 278|281 283 283 283 285 283 287 293 290 290 293 293 293 285 283 283 303 303|295 303 303|295 303 303 303 303 295 305 303 305 308 305 305 309 313 313 305 317 317 317 305 283	Association
17550384	Disease	Gene	D001943	8678	True	0	What is [EMU_BC] between @DiseaseSrc$ breast carcinoma @/DiseaseSrc$ and @GeneTgt$ BECN1 @/GeneTgt$ ? [SEP] Somatic mutations of @GeneTgt$ BECN1 @/GeneTgt$ , an autophagy-related gene , in human cancers . Evasion of programmed cell death ( PCD ) is one of the hallmarks of human cancers . It is well known that not only apoptosis , but also autophagy , acts as an action mechanism of PCD . @GeneTgt$ BECN1 @/GeneTgt$ protein is a key regulator of autophagic PCD . The @GeneTgt$ BECN1 @/GeneTgt$ gene that encodes @GeneTgt$ BECN1 @/GeneTgt$ protein acts as a haploinsufficient tumor-suppressor gene . However , to date , data on @GeneTgt$ BECN1 @/GeneTgt$ mutation in human cancer tissues are lacking . To explore the possibility that somatic mutation of the @GeneTgt$ BECN1 @/GeneTgt$ gene might contribute to the development of human cancers , we analyzed the entire coding region and all splice sites of the human @GeneTgt$ BECN1 @/GeneTgt$ gene for detection of somatic mutations in 180 gastric carcinomas , 94 @DiseaseSrc$ breast carcinomas @/DiseaseSrc$ , 50 acute leukemias , 50 colorectal carcinomas , 50 hepatocellular carcinomas , and 124 non-small cell lung cancers by single-strand conformation polymorphism ( SSCP ) and DNA sequencing . Overall , we detected 11 somatic mutations of the @GeneTgt$ BECN1 @/GeneTgt$ gene , including 3 missense mutations ( N8 K , P350R and R389C ) in coding sequences and 8 mutations in introns . The mutations were observed in five gastric , three colorectal , one lung and one @DiseaseSrc$ breast carcinoma @/DiseaseSrc$ ( s ) . We expressed the three mutations ( N8 K , P350R and R389C ) in HT1080 cells , and found that two ( P350R and R389C ) of them showed only slightly decreased cell death activities compared to the wild-type @GeneTgt$ BECN1 @/GeneTgt$ . This is the first report on @GeneTgt$ BECN1 @/GeneTgt$ gene mutations in human cancer tissues , and the data suggest that point mutations are a rare event in common human cancers and probably do not play a major role in cancer pathogenesis .	2 2 4 2|3 2 2|3 4 9 9 4 4 13 13 2 2 25 20 20 20 16 22 20 22 25 25 28 28 25 31 31 28 25 36 36 36 36 46 39 40 46 40 40 44 40 46 36 50 50 50 46 52 50 36 53|56 56 53|56 60 60 60 60 60 63 63 60 60 69 66|69 69 66|69 75 71 69 74|70 74 74|70 71 75 80 80 80 80 75 75 99 99 87 99 99 99 93 93|90 93 93|90 89 97 97 97 93 99 99 99 103 103 105 103 115 108 115 113 113 110|113 113 110|113 108 115 105 118 118 115 121 121 118 124 124 103 128 128 128 124 128 132 132 128 138 138 138 134|138 138 134|138 132 140 132 143 143 140 147 147 147 140 147 150 150|147 150|147 150|147 150|147 124 156 156 124 156 160 160 156 156 164 164 156 156 156 171 171 171 171 156 175 175 175 171 177 175 177 175 181 175 124 189 189 189 189 192 192 189 197 197 194|197 197 194|197 192 197 202 202 202 197 205 205 202 205 205 205 205 205 212 213 202 213 216 213 218 213 189 222 224 224 224 227 227 224 227 230 227 230 233 230 233 236 236|240|235 236|240|235 236|240 236|240|235 240 233 240 224 245 245 248 248 245 251 251 248 251 251 253 253 251 259 259 248 245 245 245 272 272 266 264 266 266 266 271 264 262 274 275 278 278 278 272 262 283 283 283 279|282 279 279|282 245 291 291 291 291 291 296 296|292 296 296|292 296 291 300 300 300 296 291 291 304 305 291 312 308 312 312 312 312 305 316 316 316 312 312 321 321 321 312 324 324 321 327 327 321 305	Association
17550384	Disease	Gene	D002289	8678	True	0	What is [EMU_BC] between @DiseaseSrc$ non-small cell lung cancers @/DiseaseSrc$ and @GeneTgt$ BECN1 @/GeneTgt$ ? [SEP] Somatic mutations of @GeneTgt$ BECN1 @/GeneTgt$ , an autophagy-related gene , in human cancers . Evasion of programmed cell death ( PCD ) is one of the hallmarks of human cancers . It is well known that not only apoptosis , but also autophagy , acts as an action mechanism of PCD . @GeneTgt$ BECN1 @/GeneTgt$ protein is a key regulator of autophagic PCD . The @GeneTgt$ BECN1 @/GeneTgt$ gene that encodes @GeneTgt$ BECN1 @/GeneTgt$ protein acts as a haploinsufficient tumor-suppressor gene . However , to date , data on @GeneTgt$ BECN1 @/GeneTgt$ mutation in human cancer tissues are lacking . To explore the possibility that somatic mutation of the @GeneTgt$ BECN1 @/GeneTgt$ gene might contribute to the development of human cancers , we analyzed the entire coding region and all splice sites of the human @GeneTgt$ BECN1 @/GeneTgt$ gene for detection of somatic mutations in 180 gastric carcinomas , 94 breast carcinomas , 50 acute leukemias , 50 colorectal carcinomas , 50 hepatocellular carcinomas , and 124 @DiseaseSrc$ non-small cell lung cancers @/DiseaseSrc$ by single-strand conformation polymorphism ( SSCP ) and DNA sequencing . Overall , we detected 11 somatic mutations of the @GeneTgt$ BECN1 @/GeneTgt$ gene , including 3 missense mutations ( N8 K , P350R and R389C ) in coding sequences and 8 mutations in introns . The mutations were observed in five gastric , three colorectal , one lung and one breast carcinoma ( s ) . We expressed the three mutations ( N8 K , P350R and R389C ) in HT1080 cells , and found that two ( P350R and R389C ) of them showed only slightly decreased cell death activities compared to the wild-type @GeneTgt$ BECN1 @/GeneTgt$ . This is the first report on @GeneTgt$ BECN1 @/GeneTgt$ gene mutations in human cancer tissues , and the data suggest that point mutations are a rare event in common human cancers and probably do not play a major role in cancer pathogenesis .	2 2 4 2|3 2 2|3 4 9 9 4 4 13 13 2 2 25 20 20 20 16 22 20 22 25 25 28 28 25 31 31 28 25 36 36 36 36 46 39 40 46 40 40 44 40 46 36 50 50 50 46 52 50 36 53|56 56 53|56 60 60 60 60 60 63 63 60 60 69 66|69 69 66|69 75 71 69 74|70 74 74|70 71 75 80 80 80 80 75 75 99 99 87 99 99 99 93 93|90 93 93|90 89 97 97 97 93 99 99 99 103 103 105 103 115 108 115 113 113 110|113 113 110|113 108 115 105 118 118 115 121 121 118 124 124 103 128 128 128 124 128 132 132 128 138 138 138 134|138 138 134|138 132 140 132 143 143 140 147 147 147 140 147 151 151 147 124 155 155 124 155 159 159 155 155 163 163 155 155 155 167 167|155|164 167|155|164 167|155|164 167|155|164 167|155 167|155|164 175 175 175 167 177 175 177 175 181 175 124 189 189 189 189 192 192 189 197 197 194|197 197 194|197 192 197 202 202 202 197 205 205 202 205 205 205 205 205 212 213 202 213 216 213 218 213 189 222 224 224 224 227 227 224 227 230 227 230 233 230 233 237 237 239 239 233 239 224 243 243 246 246 243 249 249 246 249 249 251 251 249 257 257 246 243 243 243 270 270 264 262 264 264 264 269 262 260 272 273 276 276 276 270 260 281 281 281 277|280 277 277|280 243 289 289 289 289 289 294 294|290 294 294|290 294 289 298 298 298 294 289 289 302 303 289 310 306 310 310 310 310 303 314 314 314 310 310 319 319 319 310 322 322 319 325 325 319 303	Association
17550384	Disease	Gene	D013274	8678	True	0	What is [EMU_BC] between @DiseaseSrc$ gastric carcinomas @/DiseaseSrc$ and @GeneTgt$ BECN1 @/GeneTgt$ ? [SEP] Somatic mutations of @GeneTgt$ BECN1 @/GeneTgt$ , an autophagy-related gene , in human cancers . Evasion of programmed cell death ( PCD ) is one of the hallmarks of human cancers . It is well known that not only apoptosis , but also autophagy , acts as an action mechanism of PCD . @GeneTgt$ BECN1 @/GeneTgt$ protein is a key regulator of autophagic PCD . The @GeneTgt$ BECN1 @/GeneTgt$ gene that encodes @GeneTgt$ BECN1 @/GeneTgt$ protein acts as a haploinsufficient tumor-suppressor gene . However , to date , data on @GeneTgt$ BECN1 @/GeneTgt$ mutation in human cancer tissues are lacking . To explore the possibility that somatic mutation of the @GeneTgt$ BECN1 @/GeneTgt$ gene might contribute to the development of human cancers , we analyzed the entire coding region and all splice sites of the human @GeneTgt$ BECN1 @/GeneTgt$ gene for detection of somatic mutations in 180 @DiseaseSrc$ gastric carcinomas @/DiseaseSrc$ , 94 breast carcinomas , 50 acute leukemias , 50 colorectal carcinomas , 50 hepatocellular carcinomas , and 124 non-small cell lung cancers by single-strand conformation polymorphism ( SSCP ) and DNA sequencing . Overall , we detected 11 somatic mutations of the @GeneTgt$ BECN1 @/GeneTgt$ gene , including 3 missense mutations ( N8 K , P350R and R389C ) in coding sequences and 8 mutations in introns . The mutations were observed in five gastric , three colorectal , one lung and one breast carcinoma ( s ) . We expressed the three mutations ( N8 K , P350R and R389C ) in HT1080 cells , and found that two ( P350R and R389C ) of them showed only slightly decreased cell death activities compared to the wild-type @GeneTgt$ BECN1 @/GeneTgt$ . This is the first report on @GeneTgt$ BECN1 @/GeneTgt$ gene mutations in human cancer tissues , and the data suggest that point mutations are a rare event in common human cancers and probably do not play a major role in cancer pathogenesis .	2 2 4 2|3 2 2|3 4 9 9 4 4 13 13 2 2 25 20 20 20 16 22 20 22 25 25 28 28 25 31 31 28 25 36 36 36 36 46 39 40 46 40 40 44 40 46 36 50 50 50 46 52 50 36 53|56 56 53|56 60 60 60 60 60 63 63 60 60 69 66|69 69 66|69 75 71 69 74|70 74 74|70 71 75 80 80 80 80 75 75 99 99 87 99 99 99 93 93|90 93 93|90 89 97 97 97 93 99 99 99 103 103 105 103 115 108 115 113 113 110|113 113 110|113 108 115 105 118 118 115 121 121 118 124 124 103 128 128 128 124 128 132 132 128 138 138 138 134|138 138 134|138 132 140 132 143 143 140 146 146 143|146|140 143|146|140 146|140 143|146|140 146 152 152 146 124 156 156 124 156 160 160 156 156 164 164 156 156 156 171 171 171 171 156 175 175 175 171 177 175 177 175 181 175 124 189 189 189 189 192 192 189 197 197 194|197 197 194|197 192 197 202 202 202 197 205 205 202 205 205 205 205 205 212 213 202 213 216 213 218 213 189 222 224 224 224 227 227 224 227 230 227 230 233 230 233 237 237 239 239 233 239 224 243 243 246 246 243 249 249 246 249 249 251 251 249 257 257 246 243 243 243 270 270 264 262 264 264 264 269 262 260 272 273 276 276 276 270 260 281 281 281 277|280 277 277|280 243 289 289 289 289 289 294 294|290 294 294|290 294 289 298 298 298 294 289 289 302 303 289 310 306 310 310 310 310 303 314 314 314 310 310 319 319 319 310 322 322 319 325 325 319 303	Association
17550384	Disease	Gene	D015179	8678	True	0	What is [EMU_BC] between @DiseaseSrc$ colorectal @/DiseaseSrc$ and @GeneTgt$ BECN1 @/GeneTgt$ ? [SEP] Somatic mutations of @GeneTgt$ BECN1 @/GeneTgt$ , an autophagy-related gene , in human cancers . Evasion of programmed cell death ( PCD ) is one of the hallmarks of human cancers . It is well known that not only apoptosis , but also autophagy , acts as an action mechanism of PCD . @GeneTgt$ BECN1 @/GeneTgt$ protein is a key regulator of autophagic PCD . The @GeneTgt$ BECN1 @/GeneTgt$ gene that encodes @GeneTgt$ BECN1 @/GeneTgt$ protein acts as a haploinsufficient tumor-suppressor gene . However , to date , data on @GeneTgt$ BECN1 @/GeneTgt$ mutation in human cancer tissues are lacking . To explore the possibility that somatic mutation of the @GeneTgt$ BECN1 @/GeneTgt$ gene might contribute to the development of human cancers , we analyzed the entire coding region and all splice sites of the human @GeneTgt$ BECN1 @/GeneTgt$ gene for detection of somatic mutations in 180 gastric carcinomas , 94 breast carcinomas , 50 acute leukemias , 50 @DiseaseSrc$ colorectal carcinomas @/DiseaseSrc$ , 50 hepatocellular carcinomas , and 124 non-small cell lung cancers by single-strand conformation polymorphism ( SSCP ) and DNA sequencing . Overall , we detected 11 somatic mutations of the @GeneTgt$ BECN1 @/GeneTgt$ gene , including 3 missense mutations ( N8 K , P350R and R389C ) in coding sequences and 8 mutations in introns . The mutations were observed in five gastric , three @DiseaseSrc$ colorectal @/DiseaseSrc$ , one lung and one breast carcinoma ( s ) . We expressed the three mutations ( N8 K , P350R and R389C ) in HT1080 cells , and found that two ( P350R and R389C ) of them showed only slightly decreased cell death activities compared to the wild-type @GeneTgt$ BECN1 @/GeneTgt$ . This is the first report on @GeneTgt$ BECN1 @/GeneTgt$ gene mutations in human cancer tissues , and the data suggest that point mutations are a rare event in common human cancers and probably do not play a major role in cancer pathogenesis .	2 2 4 2|3 2 2|3 4 9 9 4 4 13 13 2 2 25 20 20 20 16 22 20 22 25 25 28 28 25 31 31 28 25 36 36 36 36 46 39 40 46 40 40 44 40 46 36 50 50 50 46 52 50 36 53|56 56 53|56 60 60 60 60 60 63 63 60 60 69 66|69 69 66|69 75 71 69 74|70 74 74|70 71 75 80 80 80 80 75 75 99 99 87 99 99 99 93 93|90 93 93|90 89 97 97 97 93 99 99 99 103 103 105 103 115 108 115 113 113 110|113 113 110|113 108 115 105 118 118 115 121 121 118 124 124 103 128 128 128 124 128 132 132 128 138 138 138 134|138 138 134|138 132 140 132 143 143 140 147 147 147 140 147 151 151 147 124 155 155 124 155 158 158|155 158|155 158|155 158|155 155 164 164 155 155 155 171 171 171 171 155 175 175 175 171 177 175 177 175 181 175 124 189 189 189 189 192 192 189 197 197 194|197 197 194|197 192 197 202 202 202 197 205 205 202 205 205 205 205 205 212 213 202 213 216 213 218 213 189 222 224 224 224 227 227 224 227 230 229|227 227 229|227 230 234 230 234 238 238 240 240 234 240 224 245 245 248 248 245 251 251 248 251 251 253 253 251 259 259 248 245 245 245 272 272 266 264 266 266 266 271 264 262 274 275 278 278 278 272 262 283 283 283 279|282 279 279|282 245 291 291 291 291 291 296 296|292 296 296|292 296 291 300 300 300 296 291 291 304 305 291 312 308 312 312 312 312 305 316 316 316 312 312 321 321 321 312 324 324 321 327 327 321 305	Association
16061562	Disease	Gene	D010051	580	True	0	What is [EMU_BC] between @DiseaseSrc$ ovarian tumour @/DiseaseSrc$ and @GeneTgt$ BARD1 @/GeneTgt$ ? [SEP] Identification and characterization of missense alterations in the BRCA1 associated RING domain ( @GeneTgt$ BARD1 @/GeneTgt$ ) gene in @DiseaseSrc$ breast and ovarian cancer @/DiseaseSrc$ . BACKGROUND : BRCA1 associated RING domain protein ( @GeneTgt$ BARD1 @/GeneTgt$ ) was originally identified due to its interaction with the RING domain of BRCA1 . @GeneTgt$ BARD1 @/GeneTgt$ is required for S phase progression , contact inhibition and normal nuclear division , as well as for BRCA1 independent , p53 dependent apoptosis . METHODS : To investigate whether alterations in @GeneTgt$ BARD1 @/GeneTgt$ are involved in human breast and ovarian cancer , we used single strand conformation polymorphism analysis and sequencing on 35 breast tumours and cancer cell lines and on 21 @DiseaseSrc$ ovarian tumours @/DiseaseSrc$ . RESULTS : Along with the G2355C ( S761N ) missense mutation previously identified in a uterine cancer , we found two other variants in breast cancers , T2006C ( C645R ) and A2286 G ( I738V ) . The T2006C ( C645R ) mutation was also found in one @DiseaseSrc$ ovarian tumour @/DiseaseSrc$ . A variant of uncertain consequence , G1743C ( C557S ) , was found to be homozygous or hemizygous in an @DiseaseSrc$ ovarian tumour @/DiseaseSrc$ . Eleven variants of @GeneTgt$ BARD1 @/GeneTgt$ were characterised with respect to known functions of @GeneTgt$ BARD1 @/GeneTgt$ . None of the variants appears to affect localisation or interaction with BRCA1 ; however , putative disease associated alleles appear to affect the stability of p53 . These same mutations also appear to abrogate the growth suppressive and apoptotic activities of @GeneTgt$ BARD1 @/GeneTgt$ . CONCLUSIONS : These activities allowed us to identify one of the rare variants ( A2286 G ; I738V ) as a neutral polymorphism rather than a detrimental mutation , and suggested that G1743C ( C557S ) is not a polymorphism but may contribute to the cancer phenotype .	1 1 1 6 6 1 17 17 17 17 12 17 17 17|13 17 17|13 17 1 19 17|19 17|19 17|19 17|19 17|19 17|19 1 27 27 33 33 33 33 40 35 34|33 33 34|33 35 40 40 27 44 41 44 40 48 48 48 44 50 48 27 52|56 56 52|56 56 56 60 60 60 56 60 63 60 63 67 67 63 60 60 69 69 74 74 78 77 77 78 60 56 84 84 84 84 91 91 88 86|87 86 86|87 91 84 94 94 91 94 97 94 100 100 84 105 104 104 105 100 105 105 111 111 111 107 111 115 115 111 111 119 119 119|117|111 119|117|111 119|111 119|117|111 84 125 125 135 135 135 135 132 135 135 135 144 137 135 141 141 141 137 144 144 125 147 147 144 150 150 147 150 150 154 152 154 152 158 150 160 158 160 125 168 168 166 164 166 171 171 171 171 174 174 171|173|174 171|173|174 171|174 171|173|174 171 180 191 183 183 180 183 183 187 185 187 183 191 191 194 194 191 194 194 199 199 194|198|199 194|198|199 194|199 194|198|199 191 205 210 207 205|206 205 205|206 210 210 212 210 215 215 212 217 215 215 215 210 226 225 225 222 226 228 226 228 229 229 233 229 226 239 239 238 239 240 241 226 243 241 245 243 247 245 226 251 251 253 253 253 255 253 257 255 257 258 258 257 263 261|262 261 261|262 253 267 267 270 271 267 271 274 271 274 279 279 279 275 282 282 279 284 282 284 289 289 289 274 289 290 294 294 289 271 271 271 306 306 301 299 301 306 306 306 297 271 309 271 313 313 313 309 267	Association
16061562	Disease	Gene	D001943	580	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancers @/DiseaseSrc$ and @GeneTgt$ BARD1 @/GeneTgt$ ? [SEP] Identification and characterization of missense alterations in the BRCA1 associated RING domain ( @GeneTgt$ BARD1 @/GeneTgt$ ) gene in breast and ovarian cancer . BACKGROUND : BRCA1 associated RING domain protein ( @GeneTgt$ BARD1 @/GeneTgt$ ) was originally identified due to its interaction with the RING domain of BRCA1 . @GeneTgt$ BARD1 @/GeneTgt$ is required for S phase progression , contact inhibition and normal nuclear division , as well as for BRCA1 independent , p53 dependent apoptosis . METHODS : To investigate whether alterations in @GeneTgt$ BARD1 @/GeneTgt$ are involved in human breast and ovarian cancer , we used single strand conformation polymorphism analysis and sequencing on 35 @DiseaseSrc$ breast tumours @/DiseaseSrc$ and cancer cell lines and on 21 ovarian tumours . RESULTS : Along with the G2355C ( S761N ) missense mutation previously identified in a uterine cancer , we found two other variants in @DiseaseSrc$ breast cancers @/DiseaseSrc$ , T2006C ( C645R ) and A2286 G ( I738V ) . The T2006C ( C645R ) mutation was also found in one ovarian tumour . A variant of uncertain consequence , G1743C ( C557S ) , was found to be homozygous or hemizygous in an ovarian tumour . Eleven variants of @GeneTgt$ BARD1 @/GeneTgt$ were characterised with respect to known functions of @GeneTgt$ BARD1 @/GeneTgt$ . None of the variants appears to affect localisation or interaction with BRCA1 ; however , putative disease associated alleles appear to affect the stability of p53 . These same mutations also appear to abrogate the growth suppressive and apoptotic activities of @GeneTgt$ BARD1 @/GeneTgt$ . CONCLUSIONS : These activities allowed us to identify one of the rare variants ( A2286 G ; I738V ) as a neutral polymorphism rather than a detrimental mutation , and suggested that G1743C ( C557S ) is not a polymorphism but may contribute to the cancer phenotype .	1 1 1 6 6 1 17 17 17 17 12 17 17 17|13 17 17|13 17 1 19 17 19 19 19 1 25 25 31 31 31 31 38 33 32|31 31 32|31 33 38 38 25 42 39 42 38 46 46 46 42 48 46 25 50|54 54 50|54 54 54 58 58 58 54 58 61 58 61 65 65 61 58 58 67 67 72 72 76 75 75 76 58 54 82 82 82 82 89 89 86 84|85 84 84|85 89 82 92 92 89 92 95 92 98 98 82 103 102 102 103 98 103 103 108 108 105|106|108 105|106|108 105|108 105|106|108 108 114 114 108 108 119 119 119 108 82 123 123 133 133 133 133 130 133 133 133 142 135 133 139 139 139 135 142 142 123 145 145 142 147 146|147|145 146|147|145 147|145 146|147|145 147 147 153 151 153 151 157 147 159 157 159 123 168 168 166 164 166 171 171 171 171 175 175 175 171 171 178 189 181 181 178 181 181 185 183 185 181 189 189 192 192 189 192 192 198 198 198 192 189 201 206 203 201|202 201 201|202 206 206 208 206 211 211 208 213 211 211 211 206 222 221 221 218 222 224 222 224 225 225 229 225 222 235 235 234 235 236 237 222 239 237 241 239 243 241 222 247 247 249 249 249 251 249 253 251 253 254 254 253 259 257|258 257 257|258 249 263 263 266 267 263 267 270 267 270 275 275 275 271 278 278 275 280 278 280 285 285 285 270 285 286 290 290 285 267 267 267 302 302 297 295 297 302 302 302 293 267 305 267 309 309 309 305 263	Association
18565893	Disease	Gene	D004701	472	True	0	What is [EMU_BC] between @DiseaseSrc$ endocrine tumors @/DiseaseSrc$ and @GeneTgt$ ATM @/GeneTgt$ ? [SEP] Risk of cancer by @GeneTgt$ ATM @/GeneTgt$ missense mutations in the general population . PURPOSE : Truncating and missense mutations in the @GeneTgt$ ATM @/GeneTgt$ gene , which cause insufficient DNA damage surveillance , allow damaged cells to proceed into mitosis , which eventually results in increased cancer susceptibility . We tested the hypotheses that @GeneTgt$ ATM @/GeneTgt$ Ser49Cys and @GeneTgt$ ATM @/GeneTgt$ Ser707Pro heterozygosity increase the risk of cancer overall , of breast cancer , and of 26 other cancer subtypes in the general population . PATIENTS AND METHODS : We genotyped 10,324 individuals from the Danish general population who were observed prospectively for 36 years , during which 2,056 developed cancer . RESULTS : Multifactorially adjusted hazard ratios for @GeneTgt$ ATM @/GeneTgt$ Ser49Cys heterozygotes versus noncarriers were 1.2 ( 95 % CI , 0.9 to 1.5 ) for cancer overall , 0.8 ( 95 % CI , 0.3 to 2.0 ) for breast cancer , 4.8 ( 95 % CI , 2.2 to 11 ) for melanoma , 2.3 ( 95 % CI , 1.1 to 5.0 ) for prostate cancer , and 3.4 ( 95 % CI , 1.1 to 11 ) for cancer of the oral cavity/pharynx . Multifactorially adjusted hazard ratios for @GeneTgt$ ATM @/GeneTgt$ Ser707Pro heterozygotes versus noncarriers were 0.8 ( 95 % CI , 0.6 to 1.2 ) for cancer overall , 0.6 ( 95 % CI , 0.2 to 1.6 ) for breast cancer , 10 ( 95 % CI , 1.1 to 93 ) for thyroid/other @DiseaseSrc$ endocrine tumors @/DiseaseSrc$ , and 2.7 ( 95 % CI , 1.0 to 7.6 ) for cancer of corpus uteri . CONCLUSION : @GeneTgt$ ATM @/GeneTgt$ missense mutations do not increase the risk of cancer overall or of breast cancer in the general population ; however , we observed in exploratory analyses that @GeneTgt$ ATM @/GeneTgt$ missense mutations may be associated with an increased risk of other cancer subtypes . As we did multiple comparisons , some of these findings could represent chance findings rather than real phenomena .	1 3 1 8 8|4 8 8|4 8 1 12 12 12 8 1 34 15 15 17 17 17 25 25 22|25 25 22|25 17 17 28 17 32 32 32 28 17 34 36 38 38 34 40 38 40 44 44 40 48 48 48 44 34 52 52 54 52 64 58|55 58 58|55 64 58 58 58 58 63 58 54 66 64 68 66 64 69 73 73 69 64 64 80 80 80 80 64 84 84 84 80 52 88 88 88 93 93 88 95 93 100 100 100 100 95 103 103 95 103 107 107 103 93 110 112 112 93 112 93 133 115 118 115 120 118 125 125|121 125 125|121 125 120 125 125 133 133 132 132 129 133 137 137 137 133 137 140 147 147 147 147 147 146 147 115 147 151 151 147 151 155 155 151 155 161 160 160 161 133 161 165 165 161 165 168 161 168 174 173 173 174 168 174 178 178 174 174 182 182 174 182 182 189 188 188 189 168 189 193 193 189 193 196 168 200 200 200 196 133 204 204 206 204 211 211|207 211 211|207 211 206 211 211 219 219 218 218 219 204 223 223 223 219 223 226 233 233 233 233 233 232 233 204 237 237 237 233 237 241 241 233 241 247 246 246 247 233 247 251 251 247 251 255 255 251|253|255 251|253|255 251|255 251|253|255 251 247 264 263 263 264 247 264 268 268 264 268 271 264 274 274 271 204 278 286 279|283 283 279|283 283 286 286 286 278 288 286 290 288 286 291 295 295 291 299 299 299 286 286 304 304 304 286 307 307 304 315 312|307 312 312|307 312 315 315 315 304 319 319 319 315 323 323 323 319 278 329 329 338 331 329 338 338 336 336 333 338 338 340 338 340 341 344 340 338	Association
18565893	Disease	Gene	D001943	472	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ ATM @/GeneTgt$ ? [SEP] Risk of cancer by @GeneTgt$ ATM @/GeneTgt$ missense mutations in the general population . PURPOSE : Truncating and missense mutations in the @GeneTgt$ ATM @/GeneTgt$ gene , which cause insufficient DNA damage surveillance , allow damaged cells to proceed into mitosis , which eventually results in increased cancer susceptibility . We tested the hypotheses that @GeneTgt$ ATM @/GeneTgt$ Ser49Cys and @GeneTgt$ ATM @/GeneTgt$ Ser707Pro heterozygosity increase the risk of cancer overall , of @DiseaseSrc$ breast cancer @/DiseaseSrc$ , and of 26 other cancer subtypes in the general population . PATIENTS AND METHODS : We genotyped 10,324 individuals from the Danish general population who were observed prospectively for 36 years , during which 2,056 developed cancer . RESULTS : Multifactorially adjusted hazard ratios for @GeneTgt$ ATM @/GeneTgt$ Ser49Cys heterozygotes versus noncarriers were 1.2 ( 95 % CI , 0.9 to 1.5 ) for cancer overall , 0.8 ( 95 % CI , 0.3 to 2.0 ) for @DiseaseSrc$ breast cancer @/DiseaseSrc$ , 4.8 ( 95 % CI , 2.2 to 11 ) for melanoma , 2.3 ( 95 % CI , 1.1 to 5.0 ) for prostate cancer , and 3.4 ( 95 % CI , 1.1 to 11 ) for cancer of the oral cavity/pharynx . Multifactorially adjusted hazard ratios for @GeneTgt$ ATM @/GeneTgt$ Ser707Pro heterozygotes versus noncarriers were 0.8 ( 95 % CI , 0.6 to 1.2 ) for cancer overall , 0.6 ( 95 % CI , 0.2 to 1.6 ) for @DiseaseSrc$ breast cancer @/DiseaseSrc$ , 10 ( 95 % CI , 1.1 to 93 ) for thyroid/other endocrine tumors , and 2.7 ( 95 % CI , 1.0 to 7.6 ) for cancer of corpus uteri . CONCLUSION : @GeneTgt$ ATM @/GeneTgt$ missense mutations do not increase the risk of cancer overall or of @DiseaseSrc$ breast cancer @/DiseaseSrc$ in the general population ; however , we observed in exploratory analyses that @GeneTgt$ ATM @/GeneTgt$ missense mutations may be associated with an increased risk of other cancer subtypes . As we did multiple comparisons , some of these findings could represent chance findings rather than real phenomena .	1 3 1 8 8|4 8 8|4 8 1 12 12 12 8 1 34 15 15 17 17 17 25 25 22|25 25 22|25 17 17 28 17 32 32 32 28 17 34 36 38 38 34 40 38 40 44 44 40 48 48 48 44 34 52 52 54 52 64 58|55 58 58|55 64 58 58 58 58 63 58 54 66 64 68 66 64 69 72 69|72 69|72 69|72 69|72 64 64 81 81 81 81 64 85 85 85 81 52 90 90 90 95 95 90 97 95 102 102 102 102 97 105 105 97 105 109 109 105 95 112 114 114 95 114 95 135 117 120 117 122 120 127 127|123 127 127|123 127 122 127 127 135 135 134 134 131 135 139 139 139 135 139 142 149 149 149 149 149 148 149 117 149 153 153 149 153 156 156|153|154 156|153|154 156|153 156|153|154 156 164 163 163 164 135 164 168 168 164 168 171 164 171 177 176 176 177 171 177 181 181 177 177 185 185 177 185 185 192 191 191 192 171 192 196 196 192 196 199 171 203 203 203 199 135 208 208 210 208 215 215|211 215 215|211 215 210 215 215 223 223 222 222 223 208 227 227 227 223 227 230 237 237 237 237 237 236 237 208 241 241 241 237 241 244 242|244|237 242|244|237 244|237 242|244|237 244 252 251 251 252 237 252 256 256 252 256 261 261 261 256 256 252 268 267 267 268 252 268 272 272 268 272 275 268 278 278 275 208 282 290 283|287 287 283|287 287 290 290 290 282 292 290 294 292 290 295 298 298|295|296 298|295|296 298|295 298|295|296 304 304 304 290 290 309 309 309 290 312 312 309 320 317|310 317 317|310 317 320 320 320 309 324 324 324 320 328 328 328 324 282 335 335 344 337 335 344 344 342 342 339 344 344 346 344 346 347 350 346 344	Association
17889706	Disease	Gene	D001943	8994	True	0	What is [EMU_BC] between @DiseaseSrc$ breast tumors @/DiseaseSrc$ and @GeneTgt$ LIMD1 @/GeneTgt$ ? [SEP] Identification of rare variants in the @GeneTgt$ hLIMD1 @/GeneTgt$ gene in @DiseaseSrc$ breast cancer @/DiseaseSrc$ . The @GeneTgt$ hLIMD1 @/GeneTgt$ gene is located at chromosome 3p21 and was identified as a putative tumor suppressor gene using an elimination test assay . Chromosome 3p21 loci are frequently deleted in a number of cancers , including breast . The 3p21.3 locus harbors a number of tumor suppressor candidates , including @GeneTgt$ LIMD1 @/GeneTgt$ , a member of the ZYXIN family of genes . @GeneTgt$ LIMD1 @/GeneTgt$ directly interacts with RB and is thought to play a role in suppressing tumor growth . To investigate whether mutations in the @GeneTgt$ LIMD1 @/GeneTgt$ gene could potentially be involved in @DiseaseSrc$ breast cancer @/DiseaseSrc$ , we used single-stranded conformation polymorphism analysis on DNA from 235 @DiseaseSrc$ breast cancers @/DiseaseSrc$ and 95 controls . We identified four novel coding region alterations , including two amino acid substitutions at positions 255 and 302 . The two remaining novel variants were found at amino acid positions 246 and 647 and encoded silent alterations . The rare Ser255Arg variant was identified in only sporadic @DiseaseSrc$ breast tumors @/DiseaseSrc$ ( 2/165 tumors ) . Some ZYXIN proteins are phosphorylated by serine/threonine kinases , and the Ser255Arg change is located in a region phosphorylated on serine residues . Together , the data suggest that this variant may warrant further characterization .	1 4 4 1 9 9 9|6 9 9|6 4 11 9|11 9|11 9|11 9|11 1 20 17|20 20 17|20 22 22 22 25 25 22 22 28 22 34 34 34 34 34 28 34 39 39 39 35 22 44 44 47 47 47 47 50 50 47 52 50 52 55 52 47 59 59 60 60 62 60 66 66 66 62 66 69 66|68 66 66|68 69 73 69 77 77 77 73 79 77 60 81|85 85 81|85 85 85 87 85 85 90 85 92 90 94 92 96 92 98 96 85 102 102 113 113 109 109 109|106 109 109|106 104 113 113 113 102 115 113|115 113|115 113|115 113|115 120 120 102 124 124 124 120 126 124 129 129 125|126|129 125|126|129 126|129 125|126|129 129 134 129 120 140 140 145 145 145 145 140 145 151 151 151 151 145 153 151 153 154 154 140 159 160 164 162 160 164 164 168 168 168 164 168 169 169 164 164 175 173 164 180 180 180 182 182 182 186 186 186 185|186|182 185|186|182 186|182 185|186|182 191 191 186 191 182 197 197 199 199 199 202 202 199 199 199 207 207 209 209 199 212 212 209 212 216 216 213 209 222 222 221 222 222 227 225 227 227 222 229 227 222	Association
15665273	Disease	Gene	D001943	580	False	1	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ BARD1 @/GeneTgt$ ? [SEP] Down-regulation of @GeneTgt$ BRCA1-BARD1 @/GeneTgt$ ubiquitin ligase by CDK2 . BRCA1 , a @DiseaseSrc$ breast and ovarian tumor @/DiseaseSrc$ suppressor , is a phosphoprotein whose cellular expression level is regulated in a cell cycle-dependent manner . BRCA1 interacts with @GeneTgt$ BARD1 @/GeneTgt$ to generate significant ubiquitin ligase activity which catalyzes nontraditional Lys-6-linked polyubiquitin chains . However , it is not clear how the activity is regulated and how this affects BRCA1 's multiple cellular functions . Here we show that the ubiquitin ligase activity of @GeneTgt$ BRCA1-BARD1 @/GeneTgt$ is down-regulated by CDK2 . During the cell cycle , @GeneTgt$ BARD1 @/GeneTgt$ expression can largely be categorized into three patterns : moderately expressed in a predominantly unphosphorylated form in early G(1 ) phase , expressed at low levels in both phosphorylated and unphosphorylated forms during late G(1 ) and S phases , and highly expressed in its phosphorylated form during mitosis coinciding with BRCA1 expression . CDK2-cyclin A1/E1 and CDK1-cyclin B1 phosphorylate @GeneTgt$ BARD1 @/GeneTgt$ on its NH(2 ) terminus in vivo and in vitro . Intriguingly , the @GeneTgt$ BRCA1-BARD1-mediated @/GeneTgt$ in vivo ubiquitination of nucleophosmin/B23 ( NPM ) and autoubiquitination of BRCA1 are dramatically disrupted by coexpression of CDK2-cyclin A1/E1 , but not by CDK1-cyclin B1 . The inhibition of ubiquitin ligase activity is not due to the direct effect of the kinases on @GeneTgt$ BARD1 @/GeneTgt$ because an unphosphorylatable mutant of @GeneTgt$ BARD1 @/GeneTgt$ , S148A/S251A/S288A/T299A , is still inhibited by CDK2-cyclin E1 . Alternatively , BRCA1 and @GeneTgt$ BARD1 @/GeneTgt$ are likely exported to the cytoplasm and their expressions are remarkably reduced by CDK2-cyclin E1 coexpression . Recognizing the importance of cyclin E1 overexpression in @DiseaseSrc$ breast cancer @/DiseaseSrc$ development , these results suggest a CDK2-BRCA1-NPM pathway that coordinately functions in cell growth and tumor progression pathways .	1 6 2|6 6 2|6 6 1 8 1 1 23 11 14 11|13|14|19 11|13|14|19 11|13|14|19 11|13|14|19 11|14|19 11|13|14|19 14 11 23 23 23 27 27 27 29 29 23 34 34 33 34 29 23 38 38 40 38|39 38 38|39 43 38 47 47 47 43 49 47 53 53 53 49 38 61 61 61 61 61 61 66 64 66 66 61 66 70 70 66 75 75 75 75 70 61 79 79 79 89 84 83 84 89 86 84|85 84 84|85 89 79 91 89 79 97 97 97 105 105 101|98 101 101|98 105 105 105 105 105 108 108 105 105 111 105 116 116 115 116 111 121 121 118 121 116 116 116 126 126 123 129 129 132 129 129 123 135 135 123 135 135 139 135 139 111 143 111 147 147 147 143 149 143 149 153 153 150 105 157 161 157 160 157 161 161 161 161 168 168 168 168 161 170 171 161 173 171 161 195 195 183 183|178 183 183|178 183 181 195 187 187 187 183 187 183 183 192 190 195 195 195 197 195 200 200 197 200 197 206 206 206 197 195 210 221 214 214 214 210 221 221 221 217 221 221 240 224 224 221 226 225|221 221 225|221 231 231 231 221 233 231 231 231 233 233 221 240 240 240 243 243 240 240 255 255 255 249 249|250 249 249|250 255 255 255 258 258 255 255 261 264 264 264 255 268 268 268 264 264 286 273 271 277 277 277 273 282 278|279|282 278|279|282 279|282 278|279|282 277 286 285 286 286 289 289 286 292 292 289 295 295 292 295 299 299 295 286	Association
16123141	Disease	Gene	D001943	26994	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ RNF11 @/GeneTgt$ ? [SEP] Molecular characterization of @GeneTgt$ ring finger protein 11 @/GeneTgt$ . Ring finger proteins serve many vital functions within the cell . We have identified @GeneTgt$ RNF11 @/GeneTgt$ , a novel 154-amino acid ring finger-containing protein , which is elevated in @DiseaseSrc$ breast cancer @/DiseaseSrc$ . Within its ring finger domain , @GeneTgt$ RNF11 @/GeneTgt$ contains an AKT phosphorylation site ( T135 ) that is situated within a 14 - 3 - 3 binding domain . In WM239 cells with constitutively active AKT , @GeneTgt$ RNF11 @/GeneTgt$ exhibits seven distinct phosphopeptides as measured using two-dimensional phosphopeptide mapping . Upon inhibition of the AKT pathway or mutation of T135 , the phosphorylation at one of these sites is virtually eliminated , suggesting that AKT may phosphorylate @GeneTgt$ RNF11 @/GeneTgt$ at T135 . Moreover , @GeneTgt$ RNF11 @/GeneTgt$ is phosphorylated by AKT in vitro and is recognized by phospho-AKT substrate antibodies . @GeneTgt$ RNF11 @/GeneTgt$ shows enhanced binding to 14 - 3 - 3 in WM239 cells compared with that seen in the parental WM35 cells which have low AKT activity . Furthermore , treatment of WM239 cells with LY294002 reduces @GeneTgt$ RNF11/14 @/GeneTgt$ - 3 - 3 interactions suggesting that @GeneTgt$ RNF11/14 @/GeneTgt$ - 3 - 3 binding is regulated by AKT . In addition , @GeneTgt$ RNF11/14 @/GeneTgt$ - 3 - 3 binding is enhanced by constitutively active AKT and is diminished by dominant-negative AKT . There is also reduced 14 - 3 - 3 binding to T135E @GeneTgt$ RNF11 @/GeneTgt$ . @GeneTgt$ RNF11 @/GeneTgt$ localization was altered from the cytoplasm to the nucleus by activated AKT . Thus , phosphorylation of @GeneTgt$ RNF11 @/GeneTgt$ by AKT either causes its nuclear localization or induces degradation of cytoplasmic @GeneTgt$ RNF11 @/GeneTgt$ . In addition , T135E @GeneTgt$ RNF11 @/GeneTgt$ , which does not bind 14 - 3 - 3 and is not phosphorylated by AKT , causes a greater enhancement of transforming growth factor-beta signaling than wild-type @GeneTgt$ RNF11 @/GeneTgt$ . It is clear that @GeneTgt$ RNF11 @/GeneTgt$ function , localization , and potentially , degradation are regulated by AKT . Disregulation of proper @GeneTgt$ RNF11 @/GeneTgt$ function by AKT may prove to be detrimental to patient outcomes , making @GeneTgt$ RNF11 @/GeneTgt$ a potential target for novel cancer therapeutics .	2 2 4 2|3|4 2|3|4 2|3|4 2|3|4 2|4 2|3|4 2 12 13 14 14 17 17 14 20 20 17 14 24 24 24 24 24 24 25 34 34 34 34 34 34 25 34 38 38 34 40 38|40 38|40 38|40 38|40 24 50 50 50 50 54 54 54|51 54 54|51 54 58 58 58 54 60 58 60 64 64 58 73 73 69 69 71 71 73 73 64 54 78 78 86 82 81 82 78 86 83|86 86 83|86 86 89 89 86 91 86 91 95 95 92 86 99 118 103 103 103 99 99 99 107 105 107 110 118 112 110 115 115 112 118 118 118 118 118 124 124 124 120 124 124 124 128 124 118 136 136 132|136 136 132|136 136 136 138 136 140 136 136 143 136 147 147 147 143 136 149|152 152 149|152 153 153 153 160 158 158 160 160 154 163 163 154 166 166 154 166 172 172 172 172 167 174 172 177 177 174 153 188 188 188 185 185 182 187 182 188 188|194 194 188|194 192 194 194 195 188 195 206 196|201 201 196|201 201 204 203 201 206 206 196 208 206 188 213 223 223 214|218 218 214|218 218 221 220 218 223 223 223 227 226 227 223 223 230 223 233 233 230 223 239 239 239 239 242 242 244 244 245 248 247 245 247|239 239 247|239 239 251|254 254 251|254 256 256 256 259 259 256 262 262 259 265 265 256 256 277 277 277 272 270|271 270 270|271 275 270 270 277 280 280 277 277 277 282 285 286 283|284 283 283|284 277 292 314 314 295 314|294 314 314|294 295 301 301 301 295 304 304 306 304 301 301 310 310 301 312 310 314 314 317 317 314 322 322 322 322 317 325 325 322|323 322 322|323 314 331 331 331 345 345|333 345 345|333 334 336 336 338 336 336 345 345 345 332 347 345 331 359 355 355 352|355 355 352|355 350 357 350 359 359 362 362 359 364 362 364 362 362 366|372 372 366|372 372 372 367 376 376 376 372 359	Association
9815913	Disease	Gene	D001943	7157	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ p53 @/GeneTgt$ ? [SEP] @GeneTgt$ p53 @/GeneTgt$ mutation and tamoxifen resistance in @DiseaseSrc$ breast cancer @/DiseaseSrc$ . A substantial portion of patients with estrogen receptor-positive @DiseaseSrc$ breast cancer @/DiseaseSrc$ fail to respond to estrogen depletion or to the antiestrogen tamoxifen . The molecular changes that lead to tamoxifen resistance and estrogen-independent growth are unknown . To test the hypothesis that a @GeneTgt$ p53 @/GeneTgt$ mutation could result in tamoxifen resistance and estrogen-independent growth , the MCF-7 cell line was transfected with @GeneTgt$ p53 @/GeneTgt$ cDNA which was mutated at codon 179 ( histidine to glutamine ) . MCF-7 is an estrogen receptor-positive , estrogen-dependent , tamoxifen-sensitive cell line with only wild-type @GeneTgt$ p53 @/GeneTgt$ . The presence of transfected mutant @GeneTgt$ p53 @/GeneTgt$ cDNA was verified by the PCR , and overexpression of @GeneTgt$ p53 @/GeneTgt$ protein was assessed by Western blotting . Five separate mutant-transfected clones were selected and tested in subsequent growth experiments . In monolayer culture , there was no consistent evidence of estrogen-independent growth or tamoxifen resistance in the mutant transfectants compared with vector-only controls or the parental cell line . In soft agar growth experiments , four of five mutant transfectants remained sensitive to tamoxifen in a dose-dependent manner . In the presence of wild-type @GeneTgt$ p53 @/GeneTgt$ , mutant 179 @GeneTgt$ p53 @/GeneTgt$ protein does not result in estrogen-independent growth or tamoxifen resistance . These results do not exclude the possibility that other @GeneTgt$ p53 @/GeneTgt$ mutational types could result in tamoxifen resistance , or that loss of the remaining wild-type allele may be necessary to result in this phenotype .	0|3 3 0|3 3 3 6 3 8 8|3|6 8|3|6 8|3 8|3|6 3 16 16 25 18 16 22 22 22 21|22|18 21|22|18 22|18 21|22|18 25 27 25 30 30 27 30 35 35 35 30 25 40 40 50 42 40 45 45 42 45 48 45 50 50 50 53 75 55 53 62 60 60|57 60 60|57 62 62 55 65 65 62 65 68 65 75 73 73 73 75 75 75 79 75|79 79 75|79 75 82 82 79 87 87 84 87 82 89 87 87 75 104 104 104 104 104 98 98 98 98 104 104 108 108 108 104|107 104 104|107 104 113 121 119 119 119 119|116 119 119|116 113 121 121 124 124 121 121 121 133 131 127|131 131 127|131 127 133 121 136 136 133 121 143 143 143 145 145 145 145 145 151 151 151 147 145 155 155 158 158 158 158 161 161 158 164 164 161 164 167 164 171 171 171 164 175 175 175 158 175 180 180 180 175 158 186 186 186 186 193 193 193 192 192 192 188 193 193 196 194 200 200 200 193 193 204 204 217 207 207 204|206 204 204|206 217 214 214 210|214 214 210|214 217 217 217 217 220 220 217 220 223 220 217 228 231 231 231 231 233 231 241 239 235|239 239 235|239 239 241 241 233 244 244 241 241 241 256 256 253 253 253 253 248 256 256 241 258 256 261 261 258 231	Association
17130833	Disease	Gene	D001943	7157	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ p53 @/GeneTgt$ ? [SEP] Negative regulation of chemokine receptor CXCR4 by tumor suppressor @GeneTgt$ p53 @/GeneTgt$ in @DiseaseSrc$ breast cancer @/DiseaseSrc$ cells : implications of @GeneTgt$ p53 @/GeneTgt$ mutation or isoform expression on @DiseaseSrc$ breast cancer @/DiseaseSrc$ cell invasion . Chemokine receptor CXCR4 and its ligand CXCL12 are suggested to be involved in migration , invasion and metastasis of breast cancer cells . Mutation of the tumor suppressor gene @GeneTgt$ p53 @/GeneTgt$ in @DiseaseSrc$ breast cancer @/DiseaseSrc$ is associated with metastasis and aggressive clinical phenotype . In this report , we demonstrate that wild type but not the dominant-negative mutant ( V143A ) or cancer-specific mutants ( R175H or R280 K ) of @GeneTgt$ p53 @/GeneTgt$ repress CXCR4 expression . Recently described cancer-specific @GeneTgt$ p53 @/GeneTgt$ isoform , Delta133p53 , also failed to repress CXCR4 promoter activity . Short-interfering RNA-mediated depletion of @GeneTgt$ p53 @/GeneTgt$ increased endogenous CXCR4 expression in MCF-7 @DiseaseSrc$ breast cancer @/DiseaseSrc$ cells that contain wild-type @GeneTgt$ p53 @/GeneTgt$ . Basal CXCR4 promoter activity in HCT116 colon carcinoma cells deleted of @GeneTgt$ p53 @/GeneTgt$ [ HCT116(p53KO ) ] was 10-fold higher compared to that in parental HCT116 cells with functional wild-type @GeneTgt$ p53 @/GeneTgt$ . Deletion analysis of CXCR4 promoter identified a seven-base pair @GeneTgt$ p53-repressor @/GeneTgt$ element homologous to cyclic AMP/AP-1 response ( CRE/AP-1 ) element . Electrophoretic mobility shift and chromatin immunoprecipitation assays revealed binding of ATF-1 and cJun to the CRE/AP-1 element . The @GeneTgt$ p53 @/GeneTgt$ rescue drug PRIMA-1 reduced CXCR4 mRNA and cell surface expression in MDA-MB-231 cells , which express R280 K mutant @GeneTgt$ p53 @/GeneTgt$ . CP-31398 , another @GeneTgt$ p53 @/GeneTgt$ rescue drug , similarly reduced cell surface levels of CXCR4 . PRIMA-1-mediated decrease in CXCR4 expression correlated with reduced invasion of MDA-MB-231 cells through matrigel . These results suggest a mechanism for elevated CXCR4 expression and metastasis of breast cancers with @GeneTgt$ p53 @/GeneTgt$ mutations or isoform expression . We propose that @GeneTgt$ p53 @/GeneTgt$ rescue drugs either alone or in combination with chemotherapeutic drugs may be effective in reducing CXCR4-mediated metastasis .	2 2 6 6 6 2 10 10 10 9|2 2 9|2 16 16|11 16|11 16 16|11 10 2 2 22 16|22 22 16|22 18 22 25 22 31 22|31 22|31 31 22|31 31 22 2 39 39 45 39 43 43 39 45 45 48 48 45 50 48 50 50 50 50 58 58 58 50 45 73 66 66 66 66 66 60|65 60 60|65 69 67|60|69 67|60|69 60|69 67|60|69 73 73 75 73 75 79 79 75 73 85 85 88 88 88 88 112 91 112 93 91 96 96 91 98 96 98 96 102 96 104 112 104 107 104 107 110 109|104 104 109|104 88 114 112 88 118 118 122 119|122 122 119|122 127 122 122 122 127 118 129 127 132 132 129 127 137 137 141 139 137|138 137 137|138 141 144 144 141 150 150 150|145 150|145 150 150|145 144 152 150 154 150|152 152 150|152 141 163 163 163 179 168 168 168 168 163 168 174 170|174 174 170|174 174 169 174 174 179 179 179 182 182 179 186 186 186 182 190 190 190 186|188 186 186|188 179 196 200 199 199 196 200 206 206 206 203|206 206 203|206 200 206 215 210 215 210 213 215 215 207 200 220 220 225 220 224 224 225 225 225 228 226 228 228 234 234 234 226 225 241 236|241 241 236|241 240 241 242 242 244 242 244 248 248 244 251 251 244 251 254 251 258 258 258 254|256 254 254|256 242 272 263 269 265|269 269 265|269 269 263 272 272 272 275 275 272 277 275 272 281 285 284 284 281 285 288 288 285 291 291 288 293 288 285 296 297 297 299 297 303 303 303 299 303 303 308 308 303 312 312|309 312 312|309 303 312 315 312 297 319 319 335 320|324 324 320|324 324 335 326 324 326 329 326 332 332 329 335 335 319 337 335 339 337 319	Association
18431743	Disease	Gene	D010051	675	True	0	What is [EMU_BC] between @DiseaseSrc$ ovarian cancer @/DiseaseSrc$ and @GeneTgt$ BRCA2 @/GeneTgt$ ? [SEP] Consortium analysis of 7 candidate SNPs for @DiseaseSrc$ ovarian cancer @/DiseaseSrc$ . The @DiseaseSrc$ Ovarian Cancer @/DiseaseSrc$ Association Consortium selected 7 candidate single nucleotide polymorphisms ( SNPs ) , for which there is evidence from previous studies of an association with variation in @DiseaseSrc$ ovarian cancer @/DiseaseSrc$ or breast cancer risks . The SNPs selected for analysis were F31I ( rs2273535 ) in AURKA , N372H ( rs144848 ) in @GeneTgt$ BRCA2 @/GeneTgt$ , rs2854344 in intron 17 of RB1 , rs2811712 5 ' flanking CDKN2A , rs523349 in the 3 ' UTR of SRD5A2 , D302H ( rs1045485 ) in CASP8 and L10P ( rs1982073 ) in TGFB1 . Fourteen studies genotyped 4,624 invasive epithelial ovarian cancer cases and 8,113 controls of white non-Hispanic origin . A marginally significant association was found for RB1 when all studies were included [ ordinal odds ratio ( OR ) 0.88 ( 95 % confidence interval ( CI ) 0.79 - 1.00 ) p = 0.041 and dominant OR 0.87 ( 95 % CI 0.76 - 0.98 ) p = 0.025 ] ; when the studies that originally suggested an association were excluded , the result was suggestive although no longer statistically significant ( ordinal OR 0.92 , 95 % CI 0.79 - 1.06 ) . This SNP has also been shown to have an association with decreased risk in breast cancer . There was a suggestion of an association for AURKA , when one study that caused significant study heterogeneity was excluded [ ordinal OR 1.10 ( 95 % CI 1.01 - 1.20 ) p = 0.027 ; dominant OR 1.12 ( 95 % CI 1.01 - 1.24 ) p = 0.03 ] . The other 5 SNPs in @GeneTgt$ BRCA2 @/GeneTgt$ , CDKN2A , SRD5A2 , CASP8 and TGFB1 showed no association with @DiseaseSrc$ ovarian cancer @/DiseaseSrc$ risk ; given the large sample size , these results can also be considered to be informative . These null results for SNPs identified from relatively large initial studies shows the importance of replicating associations by a consortium approach .	2 2 6 6 6 2 8 8|2|7 8|2|7 8|2 8|2|7 2 18 13|18 13|18 18 13|18 18 19 19 24 24 24 24 19 26 24 26 24 30 32 32 24 32 36 36 33 39 39 36 41 39 43 40|41|43 40|41|43 41|43 40|41|43 43 49 49 43 19 54 59 54 57 55 59 59 61 59 61 64 59 64 64 68 66 68 71 70|64 64 70|64 71 71 76 74 76 79 76 79 64 81 85 85 64 85 85 92 92 92 92 87 94 92 94 94 98 96 98 101 92 101 101 105 103 105 108 101 59 112 113 113 119 119 119 119 119 113 119 122 119 126 126 126 122 113 131 130 131 133 133 133 135 133 140 138 140 140 133 144 144 144 195 146 144 146 146 153 151 153 153 146 155 153 155 159 159 162 162 162 153 162 162 162 165 166 171 170 171 177 174 174 177 177 177 162 177 162 153 190 183 190 186 186 183 188 186 190 195 195 193 195 195 133 200 198 200 200 195 202 200 202 202 202 207 208 202 211 209 202 202 133 215 219 219 219 219 219 221 219 223 221 226 226 223 229 229 226 219 232 232 234 232 237 237 234 239 237 234 250 243 241 245 243 248 248 250 250 234 252 250 252 252 258 257 258 264 261 261 264 264 264 252 264 264 250 267 268 273 272 273 279 276 276 279 279 279 267 279 234 232 286 286 286 298 288 286|287 286 286|287 288 288 288 288 288 288 288 288 298 300 298 305 300|305 300|305 305 300|305 300 298 311 311 311 311 318 318 314 318 318 318 318 298 321 321 318 298 326 327 336 329 327 329 335 333 335 335 330 336 338 336 341 341 338 345 345 345 336 336	Association
18431743	Disease	Gene	D010051	6790	False	1	What is [EMU_BC] between @DiseaseSrc$ ovarian cancer @/DiseaseSrc$ and @GeneTgt$ AURKA @/GeneTgt$ ? [SEP] Consortium analysis of 7 candidate SNPs for @DiseaseSrc$ ovarian cancer @/DiseaseSrc$ . The @DiseaseSrc$ Ovarian Cancer @/DiseaseSrc$ Association Consortium selected 7 candidate single nucleotide polymorphisms ( SNPs ) , for which there is evidence from previous studies of an association with variation in @DiseaseSrc$ ovarian cancer @/DiseaseSrc$ or breast cancer risks . The SNPs selected for analysis were F31I ( rs2273535 ) in @GeneTgt$ AURKA @/GeneTgt$ , N372H ( rs144848 ) in BRCA2 , rs2854344 in intron 17 of RB1 , rs2811712 5 ' flanking CDKN2A , rs523349 in the 3 ' UTR of SRD5A2 , D302H ( rs1045485 ) in CASP8 and L10P ( rs1982073 ) in TGFB1 . Fourteen studies genotyped 4,624 invasive epithelial ovarian cancer cases and 8,113 controls of white non-Hispanic origin . A marginally significant association was found for RB1 when all studies were included [ ordinal odds ratio ( OR ) 0.88 ( 95 % confidence interval ( CI ) 0.79 - 1.00 ) p = 0.041 and dominant OR 0.87 ( 95 % CI 0.76 - 0.98 ) p = 0.025 ] ; when the studies that originally suggested an association were excluded , the result was suggestive although no longer statistically significant ( ordinal OR 0.92 , 95 % CI 0.79 - 1.06 ) . This SNP has also been shown to have an association with decreased risk in breast cancer . There was a suggestion of an association for @GeneTgt$ AURKA @/GeneTgt$ , when one study that caused significant study heterogeneity was excluded [ ordinal OR 1.10 ( 95 % CI 1.01 - 1.20 ) p = 0.027 ; dominant OR 1.12 ( 95 % CI 1.01 - 1.24 ) p = 0.03 ] . The other 5 SNPs in BRCA2 , CDKN2A , SRD5A2 , CASP8 and TGFB1 showed no association with @DiseaseSrc$ ovarian cancer @/DiseaseSrc$ risk ; given the large sample size , these results can also be considered to be informative . These null results for SNPs identified from relatively large initial studies shows the importance of replicating associations by a consortium approach .	2 2 6 6 6 2 8 8|2|7 8|2|7 8|2 8|2|7 2 18 13|18 13|18 18 13|18 18 19 19 24 24 24 24 19 26 24 26 24 30 32 32 24 32 36 36 33 39 39 36 41 39 43 40|41|43 40|41|43 41|43 40|41|43 43 49 49 43 19 54 59 54 57 55 59 59 61 59 61 64 63|59 59 63|59 64 64 69 67 69 72 64 72 72 76 74 76 79 76 79 64 81 85 85 64 85 85 92 92 92 92 87 94 92 94 94 98 96 98 101 92 101 101 105 103 105 108 101 59 112 113 113 119 119 119 119 119 113 119 122 119 126 126 126 122 113 131 130 131 133 133 133 135 133 140 138 140 140 133 144 144 144 195 146 144 146 146 153 151 153 153 146 155 153 155 159 159 162 162 162 153 162 162 162 165 166 171 170 171 177 174 174 177 177 177 162 177 162 153 190 183 190 186 186 183 188 186 190 195 195 193 195 195 133 200 198 200 200 195 202 200 202 202 202 207 208 202 211 209 202 202 133 215 219 219 219 219 219 221 219 223 221 226 226 223 229 229 226 219 232 232 234 232 237 237 234 239 238|237 237 238|237 234 251 244 242 246 244 249 249 251 251 234 253 251 253 253 259 258 259 265 262 262 265 265 265 253 265 265 251 268 269 274 273 274 280 277 277 280 280 280 268 280 234 232 288 288 288 299 290 288 290 290 290 290 290 290 290 290 299 301 299 306 302|306 302|306 306 302|306 301 299 312 312 312 312 319 319 315 319 319 319 319 299 322 322 319 299 326 327 336 329 327 329 335 333 335 335 330 336 338 336 341 341 338 345 345 345 336 336	Association
18241035	Disease	Gene	D001943	8038	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ ADAM12 @/GeneTgt$ ? [SEP] @DiseaseSrc$ Breast cancer-associated @/DiseaseSrc$ mutations in metalloprotease disintegrin @GeneTgt$ ADAM12 @/GeneTgt$ interfere with the intracellular trafficking and processing of the protein . @GeneTgt$ ADAM12 @/GeneTgt$ has recently emerged as a Candidate Cancer Gene in a comprehensive genetic analysis of human @DiseaseSrc$ breast cancers @/DiseaseSrc$ . Three somatic mutations in @GeneTgt$ ADAM12 @/GeneTgt$ were observed at significant frequencies in @DiseaseSrc$ breast cancers @/DiseaseSrc$ : D301H , G479E and L792F . The first 2 of these mutations involve highly conserved residues in @GeneTgt$ ADAM12 @/GeneTgt$ , and our computational sequence analysis confirms that they may be cancer-related . We show that the corresponding mutations in mouse ADAM12 inhibit the proteolytic processing and activation of ADAM12 in NIH3T3 , COS-7 , CHO-K1 cells and in @DiseaseSrc$ MCF-7 breast cancer @/DiseaseSrc$ cells . The D/H and G/E @GeneTgt$ ADAM12 @/GeneTgt$ mutants exert a dominant-negative effect on the processing of the wild-type @GeneTgt$ ADAM12 @/GeneTgt$ . Immunofluorescence analysis and cell surface biotinylation experiments demonstrate that the D/H and G/E mutants are retained inside the cell and are not transported to the cell surface . Consequently , the D/H and G/E mutants , unlike the wild-type @GeneTgt$ ADAM12 @/GeneTgt$ , are not capable of shedding Delta-like l , a ligand for Notch receptor , at the cell surface , or of stimulating cell migration . Our results suggest that the @DiseaseSrc$ breast cancer-associated @/DiseaseSrc$ mutations interfere with the intracellular trafficking of @GeneTgt$ ADAM12 @/GeneTgt$ and result in loss of the functional @GeneTgt$ ADAM12 @/GeneTgt$ at the cell surface .	0|1|4 0|1|4 1|4 0|1|4 10 8 8 8 4|5 4 4|5 10 14 14 14 10 14 14 19 19 14 10 22|27 27 22|27 27 27 27 32 32 32 32 27 37 37 37 37 27 40 40 38|40|37 38|40|37 40|37 38|40|37 27 48 48 53 50 48|49 48 48|49 53 53 56 56 53 58 56|58 56|58 56|58 56|58 58 58 62 62 62 62 53 72 72 76 75 75 72 76 78 79 76 81 79|80 79 79|80 76 76 88 88 88 89 76 94 94 94 94 89 89 98 98 106 102 102 106 105 105 102 98 109 109 106 109 109 113 111 115 111 115 115 115 120 115 115 127 122|127 122|127 122|127 127 122|127 115 98 131 137 131 131 133|136 136 133|136 131 137 140 140 137 143 143 140 147 147 147 145|143 143 145|143 137 153 159 153 158 158 158 153 159 167 162 167 162 162 162 167 159 170 170 167 167 174 174 167 178 178 178 174 159 196 196 183 196 183 183 183 183 191 191 191 190|183 183 190|183 183 196 196 196 198 196 200 198 200 203 200 206 206 203 200 211 211 211 200 211 211 215 211 217 215 196 221 222 222 229 228 228|224|225 228|224|225 228|225 228|224|225 229 222 233 233 233 229 235 232|233 233 232|233 229 229 240 238 244 244 244 240 240 240 249 249 249 240 222	Association
16825437	Disease	Gene	D001943	580	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ BARD1 @/GeneTgt$ ? [SEP] Nordic collaborative study of the @GeneTgt$ BARD1 @/GeneTgt$ Cys557Ser allele in 3956 patients with cancer : enrichment in familial BRCA1/BRCA2 mutation-negative @DiseaseSrc$ breast cancer @/DiseaseSrc$ but not in other malignancies . BACKGROUND : @GeneTgt$ BARD1 @/GeneTgt$ was originally identified as a BRCA1-interacting protein but has also been described in tumour-suppressive functions independent of BRCA1 . Several studies have indicated that the @GeneTgt$ BARD1 @/GeneTgt$ gene is a potential target for germline changes predisposing to breast and ovarian cancer . The C-terminal Cys557Ser change has previously been uncovered to associate with an increased risk of @DiseaseSrc$ breast cancer @/DiseaseSrc$ and was recently shown to result in defective apoptotic activities . AIM AND METHODS : Conformation-sensitive gel electrophoresis , minisequencing , TaqMan assays , denaturing high-performance liquid chromatography analysis and DNA sequencing were used to investigate the prevalence of the Cys557Ser allele in a large Nordic case-control study cohort consisting of 2906 patients with breast or ovarian cancer , 734 with prostate cancer , 188 with colorectal cancer , 128 men with @DiseaseSrc$ breast cancer @/DiseaseSrc$ , and 3591 controls from Finland , Iceland , Denmark , Sweden and Norway . RESULTS : The frequency of the @GeneTgt$ BARD1 @/GeneTgt$ Cys557Ser variant seemed to increase among patients from families with breast or ovarian cancer lacking BRCA1 or BRCA2 mutations : a significant difference was obtained compared with controls ( 6.8 % v 2.7 % ; p<0.001 ; odds ratio ( OR ) 2.6 ; 95 % confidence interval ( CI ) 1.7 to 4.0 ) and with patients from BRCA1/BRCA2 mutation-positive families ( 6.8 % v 2.2 % ; p = 0.01 ; OR 3.2 ; 95 % CI 1.2 to 8.3 ) . In contrast , no major association with male breast , ovarian , colorectal or prostate cancer was observed . Additionally , a novel @GeneTgt$ BARD1 @/GeneTgt$ allele resulting in Ser558Pro was identified in @DiseaseSrc$ familial breast cancer @/DiseaseSrc$ cases . CONCLUSION : These results provide further evidence that @GeneTgt$ BARD1 @/GeneTgt$ Cys557Ser confers a slightly increased risk of @DiseaseSrc$ breast cancer @/DiseaseSrc$ in women .	3 3 3 9 9 9|5 9 9|5 9 3 12 12 9 14 12 3 3 21 21 21 21 16|19|21 16|19|21 16|21 16|19|21 21 28 28 28 21 3 38 32 33|38 38 33|38 38 38 38 42 42 42 38 38 47 47 47 38 50 50 47 50 53 51 38 57 59 59 59 68 64 64|61 64 64|61 68 68 68 68 59 70 71 68 71 74 72 74 74 74 59 83 83 83 87 87 87 87 87 89 87 93 93 93 89 95 95|93|94 95|93|94 95|93 95|93|94 87 101 101 87 103 101 107 107 107 103 87 110 110 110 110 116 116 132 116 116 118 121 116 116 116 127 127 127 123 127 130 127 132 110 134 132 136 134 140 140 140 136 147 147 147 147 147 147 136 147 151 151 148 153 151 153 156 153 151 151 161 161 151 151 151 166 166 151 151 169 151 171 169|170|171 169|170|171 169|171 169|170|171 169 169 177 169 179 177 179 179 181 181 183 183 185 185 132 190 190 193 200 199 199 199|195 199 199|195 199 193 190 202 200 204 202 206 204 208 206 208 211 208 204 212 213 213 213 190 220 220 222 222 190 222 225 223 228 228 225 231 231 228 228 228 228 236 245 238 245 245 245 240 243 245 245 228 247 245 247 251 251 247 247 245 255 245 259 259 259 255 262 262 255 265 265 262 268 268 262 268 268 262 262 262 275 276 262 279 279 276 262 190 284 300 300 288 288 300 291 291 288 291 291 293 293 293 298 291 300 300 300 313 313 308 308 305|308 308 305|308 313 308 311 309 313 313 319 319|313 319|313 319|313 319 319|313 313 313 323 323 326 327 323 329 327 334 330|333 333 330|333 334 329 338 337 338 334 340 338|340 338|340 338|340 338|340 344 338 327	Association
12100746	Disease	Gene	D001943	6716	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ SRD5A2 @/GeneTgt$ ? [SEP] A49 T , V89L and TA repeat polymorphisms of steroid 5alpha-reductase type II and @DiseaseSrc$ breast cancer @/DiseaseSrc$ risk in Japanese women . BACKGROUND : @DiseaseSrc$ Breast cancer @/DiseaseSrc$ is hormone related , as are cancers of the endometrium , ovary , and prostate . Several studies have suggested that higher extracellular levels of androgens are associated with @DiseaseSrc$ breast cancer @/DiseaseSrc$ risk , while biological evidence indicates that androgens are protective . The codon 49 alanine to threonine substitution ( A49 T ) , codon 89 valine to leucine substitution ( V89L ) and TA repeat polymorphisms of the steroid 5alpha-reductase type II ( @GeneTgt$ SRD5A2 @/GeneTgt$ ) gene are considered functional with respect to enzyme activity converting testosterone into dihydrotestosterone . To test the hypothesis that these three polymorphisms are associated with risk of @DiseaseSrc$ breast cancer @/DiseaseSrc$ , a case-control study was conducted with patients of Aichi Cancer Center Hospital . METHODS : The cases were 237 patients histologically diagnosed with @DiseaseSrc$ breast cancer @/DiseaseSrc$ , and the controls were 185 noncancer outpatients . DNA from peripheral blood was genotyped by PCR methods . RESULTS : The threonine allele of A49 T was not found in our subjects . Compared with the V/V genotype of V89L , the L/L genotype was associated with a decreased risk ( crude odds ratio [ OR ] = 0.61 , 95 % confidence interval [ CI ] = 0.36 - 1.05 ) . This was also the case for the TA(9/9 ) genotype , with an OR of 0.58 ( 95 % CI = 0.13 - 2.63 ) relative to TA(0/0 ) . Among women with the TA(0/0 ) genotype , however , the OR for the L/L genotype was 0.46 ( 95 % CI = 0.24 - 0.88 ) compared with the V/V genotype , and those with the V/V and TA(0/0 ) genotypes had the highest risk . The haplotype with the L and TA(9 ) repeat alleles was not found . CONCLUSION : This study is the first to our knowledge focusing on Japanese women , suggesting that @GeneTgt$ SRD5A2 @/GeneTgt$ polymorphisms might have an association with @DiseaseSrc$ breast cancer @/DiseaseSrc$ risk . Further large-sample studies will be required to confirm the association and to assess any interactions with environmental factors .	2 8 2 2 4 4 8 18 12 12 12 18 12 12 18|14|15 18|14|15 18|15 18|14|15 18 21 21 18 18 24 24 31|25|26 31|25|26 31|26 31|25|26 31 31 24 31 31 33 33 38 38 35 38 38 38 38 38 31 47 49 49 49 57 53 53 57 55 53 57 49 62 62|58|59 62|58|59 62|59 62|58|59 57 57 67 66 67 57 71 71 71 67 49 77 77 77 111 80 80 77 83 83 80 83 80 88 88 80 91 91 77 93 91 93 91 98 98 91 109 109 109 109 109 109 106 105|109 109 105|109 109 98 111 111 111 114 112 117 117 114 111 118 121 118 111 125 145 127 125 133 131 131 133 133 127 135 133 137 135|136|137 135|136|137 135|137 135|136|137 145 143 143 145 145 145 147 145 152 152 151 152 147 145 161 161 158 161 161 161 161 163 161 165 163|164|165 163|164|165 163|165 163|164|165 161 161 171 175 175 175 175 161 161 183 181 181 178 183 183 186 186 183 183 188 188 192 192 198 195 195 192 198 198 188 201 201 198 188 207 207 207 207 215 209 207 215 213 213 215 215 215 219 219 219 215 223 222 223 219 223 223 225 223 227 228 231 233 233 223 235 233 235 233 237 240 237 223 215 247 247 247 247 247 252 250 252 252 247 247 256 256 247 258 256 261 261 262 256 262 266 266 263 263 270 270 256 247 247 274 294 279 277 279 279 274 294 294 294 284 290 288 288 288 284 290 294 293 293 294 294 294 298 298 295 295 294 304 304 304 300 304 294 315 310 310 307 310 310 312 310 294 318 318 315 315 321 332 329 329 323 324 324 329 329 321 332 332 332 332 340 340 337 340 340 340 340 343 343 340 343 347 347 344 340 340 355 350|353 353 350|353 355 355 349 357 355 362 357|359|362 357|359|362 359|362 357|359|362 357 340 368 368 371 371 371 371 373 371 375 373 373 378 373 380 378 383 383 380 371	Association
17217814	Disease	Gene	D001943	1312	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ COMT @/GeneTgt$ ? [SEP] [ Prevalence of Val158Met polymorphism in @GeneTgt$ COMT @/GeneTgt$ gene on non-BRCA1/2 @DiseaseSrc$ hereditary breast cancer @/DiseaseSrc$ ] . OBJECTIVE : To explore the prevalence of Val158Met polymorphism in @GeneTgt$ Catechol-O-methyltransferase @/GeneTgt$ ( @GeneTgt$ COMT @/GeneTgt$ ) gene and its effect on genetic susceptibility for @DiseaseSrc$ breast cancer @/DiseaseSrc$ in Shanghai population . METHODS : A total of 114 patients with BRCA1/BRCA 2 negative hereditary @DiseaseSrc$ breast cancer @/DiseaseSrc$ from independent families and 121 age-matched healthy controls were analyzed . Genotype analysis was conducted by polymerase chain reaction ( PCR ) and then DNA direct sequencing . The odd ratios ( OR ) and 95 % confidence intervals ( CI ) were calculated by unconditional logistic regression model . RESULTS : The frequency of Val158Met polymorphism GG , GA and AA genotype in case group and control was 0.58 ( 65 ) , 0.32 ( 36 ) , 0.10 ( 11 ) and 0.60 ( 66 ) , 0.35 ( 41 ) , 0.03 ( 3 ) , respectively . The frequency of allele-containing genotypes is significantly higher in early-onset @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients ( 0.57 ) than in familial ones ( 0.35 ) . Compared with GG ( Val/Val ) genotype , AA ( Met/Met ) genotype confers a significantly increased risk for @DiseaseSrc$ breast cancer @/DiseaseSrc$ ( adjusted OR = 3.15 ; 95 % CI , 0.70 - 14.19 ) , especially among premenopausal women ( adjusted OR = 9.98 ; 95 % CI , 1.00 - 99.64 ) . Borderline significantly association was found between AA genotype ( adjusted OR = 7.57 ; 95 % CI , 0.57 - 101.28 ) and susceptibility for @DiseaseSrc$ breast cancer @/DiseaseSrc$ in BMI < or = 23 kg/m(2 ) group . CONCLUSIONS : Val158Met polymorphism in @GeneTgt$ COMT @/GeneTgt$ gene could be a candidate for low penetrance @DiseaseSrc$ breast cancer @/DiseaseSrc$ susceptibility in Shanghai population , especially among premenopausal women and early-onset @DiseaseSrc$ breast cancer @/DiseaseSrc$ patients .	2 2 5 5 2 9 9|6 9 9|6 5 12 12 9|10|12 9|10|12 9|10|12 9|12 9|10|12 2 2 20 23 23 20 25 23 28 28 25 36 36|29 36 36|29 33 36|31 36 36|31 36 28 25 39 25 42 42 39 44 44|41|42 44|41|42 44|42 44|41|42 49 49 44 20 78 78 57 78 60 60 57 66 66 66 66 66 65|66|60 65|66|60 66|60 65|66|60 71 71 66 71 76 76 76 71 78 78 78 82 84 84 84 88 88 88 84 90 88 90 88 96 96 96 88 84 100 100 113 102 100 102 100 106 108 108 100 110 108 110 113 113 118 118 118 118 113 113 120 120 123 139 127 127 127 123 127 127 129 129 123 135 135 132 135 135 139 120 141 139 141 139 139 146 144 146 139 139 151 149 151 139 139 156 154 156 139 139 161 159 161 139 139 166 164 166 139 139 120 172 178 175 175 172 178 178 178 184 184 180|184 180|184 184 180|184 178 186 184 186 191 191 191 178 193 191 193 178 203 203 203 203 203 203 210 210 209 207 209 209 210 210 214 213 214 210 216 214|215|216 214|215|216 214|216 214|215|216 220 216 220 220 222 222 226 227 210 227 231 231 227 231 227 237 237 237 227 239 237 239 239 241 241 245 246 237 250 250 250 246 227 210 255 256 258 258 258 261 261 258 263 261 263 263 265 265 269 270 263 270 274 274 270 270 263 263 279 277|278|279 277|278|279 277|279 277|278|279 284 284 279 263 263 290 290 290 286 258 293 293 296 304 300 300|297 300 300|297 296 304 304 304 293 311 311 311 311|306 311|306 311 311|306 304 314 314 311 311 319 319 319 311 319 325 325|318 325|318 325 325|318 319 293	Association
18083510	Disease	Gene	D001943	3292	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ HSD17B1 @/GeneTgt$ ? [SEP] Characterization of @GeneTgt$ HSD17B1 @/GeneTgt$ sequence variants in @DiseaseSrc$ breast cancer @/DiseaseSrc$ cases from French Canadian families with high risk of breast and ovarian cancer . A family history of disease and estrogen exposure are risk factors for @DiseaseSrc$ breast cancer @/DiseaseSrc$ . The @GeneTgt$ HSD17B1 @/GeneTgt$ gene encodes a key steroidogenic enzyme that catalyses the final step of estradiol biosynthesis , rendering it a good candidate gene for @DiseaseSrc$ breast cancer @/DiseaseSrc$ susceptibility . The current study was designed to screen for @GeneTgt$ HSD17B1 @/GeneTgt$ germline mutations potentially involved in @DiseaseSrc$ breast cancer @/DiseaseSrc$ susceptibility . DNA samples from 50 individuals affected with @DiseaseSrc$ breast cancer @/DiseaseSrc$ from non-BRCA1/2 French Canadian families with a high risk of breast and ovarian cancer were screened for sequence variants in @GeneTgt$ HSD17B1 @/GeneTgt$ . Our study identified 28 sequence variants , including three non-synonymous variants , p. Ala238Val , p. Arg259His , p. Ser313Gly , one of which ( p. Arg259His ) was not previously reported . Functional assays failed to show changes in either activity or recombinant proteins levels for all three variants . Thus , our resequencing analysis does not support the existence of deleterious , gain-of-function or transcription mutations in @GeneTgt$ HSD17B1 @/GeneTgt$ , which could explain the clustering of @DiseaseSrc$ breast cancer @/DiseaseSrc$ cases in non-BRCA1/2 high-risk French Canadian families . However , a haplotype-based approach was used to establish tSNPs , providing a valuable tool for further searches of common disease-associated variants in this gene , using large cohorts .	1 6 2|6 6 2|6 6 1 11 11|6 11|6 11 11|6 6 15 15 15 11 18 18 1 20 18 20 23 20 1 29 29 37 31 29 31 31 31 37 37 37 39 37|38|39 37|38|39 37|39 37|38|39 37 47 44|47 47 44|47 48 48 52 52 52 48 54 52 57 57 54 60 60 57 54 54 67 67 67 67 62 72 67|69|72 67|69|72 69|72 67|69|72 67 48 78 78 80 80 80 82 80 87 83|87 87 83|87 87 82 89 87 94 91|94|89 91|94|89 91|94 91|94|89 89 80 99 123 102 102 99 102 105 105|103|104 105|103|104 105|103 105|103|104 112 112 112 112 105 116 116 116 103 118 116 118 121 118 123 123 126 126 123 128 125|126 126 125|126 123 134 135 135 138 138 135 138 143 143 143 138 143 146 143 146 149 143 143 143 135 164 164 156 154 159 159 154 154 164 164 164 135 135 167 168 168 170 168 170 174 174 171 174 177 174 171 182 181 182 178 168 191 191 188 188 191 191 191 191 193 191 200 200 195 195 197 195 193 202 200|201 200 200|201 202 207 207 200 209 207 214 209|214 209|214 214 209|214 209 220 220 220 220 220 209 191 230 230 228 228 230 230 230 232 230 232 232 232 238 238 235 241 241 238 245 245 245 241 248 248 245 232 232 252 250 230	Association
10485478	Disease	Gene	D001943	3482	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancers @/DiseaseSrc$ and @GeneTgt$ M6P/IGF2R @/GeneTgt$ ? [SEP] Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers . The @GeneTgt$ M6P/IGF2R @/GeneTgt$ gene , encoding the insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor ( @GeneTgt$ IGF2R @/GeneTgt$ ) , is frequently inactivated during carcinogenesis . @GeneTgt$ M6P/IGF2R @/GeneTgt$ is postulated to be a tumor suppressor gene due to its ability to bind and degrade the mitogen IGF-II , promote activation of the growth inhibitor transforming growth factor beta , and regulate the targeting of lysosomal enzymes . In this study , we determined the effects of four @GeneTgt$ M6P/IGF2R @/GeneTgt$ missense mutations associated with loss of heterozygosity in hepatocellular and @DiseaseSrc$ breast cancers @/DiseaseSrc$ on the ligand binding properties of full-length membrane-bound receptors . Site-directed mutagenesis was used to prepare COOH-terminal , c-myc epitope-tagged human @GeneTgt$ IGF2R @/GeneTgt$ cDNA expression constructs bearing point mutations that lead to the substitutions I1572 T , G1464E , G1449V , and Q1445H , all of which are located in the receptor 's extracytoplasmic domain . Ligand binding was measured in plasma membranes from 293 T cells expressing full-length receptors . No binding of 125I-IGF-II to I1572 T mutant receptors was observed . Binding to G1449V mutant receptors was decreased by 50 % relative to wild-type ( WT ) . However , IGF-II binding to the G1464E and Q1445H mutant receptors was equivalent to WT when plasma membranes were assayed immediately after preparation . The phosphomannosylated pseudoglycoprotein pentamannose 6-phosphate-BSA ( PMP-BSA ) was synthesized as a ligand for the M6P binding site . Binding of 125I-PMP-BSA was equivalent to WT for the I1572 T , G1464E , and Q1445H mutations , but there was a 60 % reduction in PMP-BSA binding to the G1449V mutant receptor . Thus , several missense mutations in @GeneTgt$ M6P/IGF2R @/GeneTgt$ disrupt the ligand binding functions of the intact @GeneTgt$ IGF2R @/GeneTgt$ , lending further support to the hypothesis that the @GeneTgt$ M6P/IGF2R @/GeneTgt$ is a tumor suppressor gene .	3 3 3 10 10 10 10 10 10 3 10 13 11 16 16 11 3 21 18|21 21 18|21 39 21 21 27 27 27 23 27 33 31 33 33 27|31 27 27|31 33 27 39 39 39 41 39 39 44|48 48 44|48 48 48 54 54 54 54 54 48 58 55 58 54 60 58 60 60 65 65 62 54 48 67 76 76 76 76 76 76 76 68 48 48 48 81 79 84 84 81 48 89 89 92 92 92 92 94 92 100 100 96|100 100 96|100 100 94 100 103 101 105 103 107 103 107 107 107 107 107 116 116 116 116 103 120 120 120 116 92 125 127 127 127 129 127 139 133 133 130 139 139|134 139 139|134 139 139 129 139 142 140 144 142 149 149 149 149 144 149 149 149 149 149 149 149 162 162 160 158 162 127 168 165 168 165 168 162 162 172 174 174 174 177 177 174 181 181 181 177 181 184 182 174 187 196 189 187 194 194 194 194 187 196 196 196 204 202 202 202 198 204 204 207 207 204 207 210 208 212 210 212 204 227 227 227 217 221 221 218 221 221 225 221 227 227 229 227 234 232 234 234 227 234 237 234 227 243 243 243 243 248 245 243 245 248 248 251 251 248 256 256 256 256 251 248 262 260 258 262 262 264 262 268 268 268 264 268 268 268 264 264 264 262 262 278 262 282 281 282 278 285 285 282 290 290 290 290 285 278 300 300 296 296 300 298 296|297 296 296|297 300 304 304 304 300 308 308 308 304|306 304 304|306 300 300 313 311 316 316 311 325 319 316|325 325 316|325 325 325 325 325 316 300	Association
18036263	Disease	Gene	D001943	672	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ BRCA1 @/GeneTgt$ ? [SEP] Identification of @GeneTgt$ BRCA1 @/GeneTgt$ missense substitutions that confer partial functional activity : potential moderate risk variants ? INTRODUCTION : Many of the DNA sequence variants identified in the @DiseaseSrc$ breast cancer @/DiseaseSrc$ susceptibility gene @GeneTgt$ BRCA1 @/GeneTgt$ remain unclassified in terms of their potential pathogenicity . Both multifactorial likelihood analysis and functional approaches have been proposed as a means to elucidate likely clinical significance of such variants , but analysis of the comparative value of these methods for classifying all sequence variants has been limited . METHODS : We have compared the results from multifactorial likelihood analysis with those from several functional analyses for the four @GeneTgt$ BRCA1 @/GeneTgt$ sequence variants A1708E , G1738R , R1699Q , and A1708V . RESULTS : Our results show that multifactorial likelihood analysis , which incorporates sequence conservation , co-inheritance , segregation , and tumour immunohistochemical analysis , may improve classification of variants . For A1708E , previously shown to be functionally compromised , analysis of oestrogen receptor , cytokeratin 5/6 , and cytokeratin 14 tumour expression data significantly strengthened the prediction of pathogenicity , giving a posterior probability of pathogenicity of 99 % . For G1738R , shown to be functionally defective in this study , immunohistochemistry analysis confirmed previous findings of inconsistent ' @GeneTgt$ BRCA1-like @/GeneTgt$ ' phenotypes for the two tumours studied , and the posterior probability for this variant was 96 % . The posterior probabilities of R1699Q and A1708V were 54 % and 69 % , respectively , only moderately suggestive of increased risk . Interestingly , results from functional analyses suggest that both of these variants have only partial functional activity . R1699Q was defective in foci formation in response to DNA damage and displayed intermediate transcriptional transactivation activity but showed no evidence for centrosome amplification . In contrast , A1708V displayed an intermediate transcriptional transactivation activity and a normal foci formation response in response to DNA damage but induced centrosome amplification . CONCLUSION : These data highlight the need for a range of functional studies to be performed in order to identify variants with partially compromised function . The results also raise the possibility that A1708V and R1699Q may be associated with a low or moderate risk of cancer . While data pooling strategies may provide more information for multifactorial analysis to improve the interpretation of the clinical significance of these variants , it is likely that the development of current multifactorial likelihood approaches and the consideration of alternative statistical approaches will be needed to determine whether these individually rare variants do confer a low or moderate risk of @DiseaseSrc$ breast cancer @/DiseaseSrc$ .	1 6 2|6 6 2|6 6 1 8 6 11 11 8 1 16 16 16 1 1 19 19 37 26 26 26 26 21 26 35 35 35|29 35|29 35 35|29 35 35 27|32 27 27|32 19 37 40 38 44 44 44 40 37 51 51 51 57 51 54 51 57 57 57 60 60 57 62 60 65 63 62 68 68 65 57 57 86 75 75 75 71 78 78 75 80 71 83 83 80 86 86 57 86 92 92 92 92 92 94 92 98 98 98 94 100 98 104 104 104 100 111 111 111 111|107 111 111|107 111 104 111 112 112 112 112 112 112 112 92 122 122 125 126 122 147 130 130 147 130 133 130 135 133 135 135 137 137 137 135 144 144 135 147 147 126 147 150 148 122 153 156 156 156 156 160 160 160 156 177 177 165 165 162 165 165 167 165 165 175 171 175 175 177 177 156 179 177 181 179 177 177 186 186 183 188 186 191 191 188 177 194 196 196 207 200 200 200 196 203 203 200 207 206 207 207 209 207 216 216 216 216|212 216 216|212 216 209 220 220 220 216 216 207 207 226 226 232 229 229 226 232 232 207 207 237 237 244 239 237 239 239 244 244 244 244 247 244 247 247 253 252 253 244 256 256 253 253 264 264 264 263 263 260 264 270 270 269 269 266 264 274 274 274 270 264 278 278 278 281 281 278 283 281 286 286 283 278 278 292 292 292 288 278 278 296 294 299 299 296 278 302 305 305 305 305 310 310 310 310 305 310 314 314 316 316 310 318 305 321 321 318 305 305 325 323 305 327 331 330 331 327 333 331 336 336 333 339 339 336 342 342 333 344 342 346 344 346 351 350 351 347 327 354 356 356 356 358 356 365 365 360 360 365 365 358 371 371 371 368 368 365 373 371 356 380 378 378 380 380 400 382 380 385 385 382 387 385 389 387 393 393 393 389 396 396 393 400 400 400 400 418 403 418 408 408 408 408 403 403 411 403 415 415 415 411 418 418 400 420 418 427 425 424 425 427 427 420 432 432 429 429 427 434 432|433|434 432|433|434 432|434 432|433|434 400	Association
18307025	Disease	Gene	D012516	7157	False	2	What is [EMU_BC] between @DiseaseSrc$ Osteosarcoma @/DiseaseSrc$ and @GeneTgt$ p53 @/GeneTgt$ ? [SEP] A Japanese patient with Li-Fraumeni syndrome who had nine primary malignancies associated with a germline mutation of the @GeneTgt$ p53 @/GeneTgt$ tumor-suppressor gene . We describe a patient who had nine primary malignant tumors and a germline mutation in the @GeneTgt$ p53 @/GeneTgt$ tumor-suppressor gene , characteristically found in the Li-Fraumeni syndrome ( LFS ) . A 15-year-old girl with no family history of cancer was referred to our hospital because of pain and swelling of the right knee . @DiseaseSrc$ Osteosarcoma @/DiseaseSrc$ was diagnosed . The patient received chemotherapy followed by surgery and had a remission . After the age of 28 years , nine primary malignant tumors developed successively , including right breast cancer , colon cancer , malignant fibrous histiocytoma ( MFH ) of the abdominal wall , right lung double cancers , bilateral breast cancers , and MFH of the left thigh . This is the second highest number of types of primary malignant tumors to be reported in LFS . All tumors were treated by a multidisciplinary approach , including surgery . Genetic analysis revealed a germline missense mutation in the @GeneTgt$ p53 @/GeneTgt$ gene ( c.659 A > G ) , resulting in Y220C , which has been reported in three families with LFS . The patient died of lung metastasis from MFH at the age of 37 years . Despite the multiple tumors , repeated induction of remissions resulted in long survival . Our findings suggest that a multidisciplinary approach to treatment , including surgery , is beneficial in patients with LFS .	3 3 3 6 6 3 8 6 11 11 8 11 16 16 16 12 22 22 18|22 22 18|22 22 16 3 26 26 28 26 30 28 34 34 34 30 34 38 38 34 44 44 40|44 44 40|44 44 38 26 47 26 51 51 51 47 53 51 53 26 59 59 67 63 63 63 59 65 63 67 67 70 70 67 73 71 67 73 73 79 79 79 73 67 80|84 84 80|84 84 84 84 88 89 89 89 90 93 91 89 89 97 95 89 101 101 110 104 104 101 110 109 109 109 110 110 110 110 116 116 116 110 116 119 116 119 123 123 116 125 123 125 130 130 130 123 116 135 135 135 116 135 139 139 135 139 116 116 146 146 146 142 110 153 153 153 153 153 153 155 153 159 159 159 155 162 162 153 164 162 153 167 169 169 169 173 173 173 169 173 176 173 169 179 180 180 184 184 184 180 189 189 186|189 189 186|189 184 194 194 194 194 189 194 180 180 199 197 199 204 204 204 199 207 207 204 209 207 180 213 214 214 217 217 214 219 217 222 222 214 225 225 222 214 230 230 230 236 236 233 236 235 233 236 239 239 236 236 242 243 243 255 247 247 255 249 247 249 252 249 247 255 243 257 255 259 257 243	Association
18307025	Disease	Gene	D008175	7157	False	3	What is [EMU_BC] between @DiseaseSrc$ right lung double cancers @/DiseaseSrc$ and @GeneTgt$ p53 @/GeneTgt$ ? [SEP] A Japanese patient with Li-Fraumeni syndrome who had nine primary malignancies associated with a germline mutation of the @GeneTgt$ p53 @/GeneTgt$ tumor-suppressor gene . We describe a patient who had nine primary malignant tumors and a germline mutation in the @GeneTgt$ p53 @/GeneTgt$ tumor-suppressor gene , characteristically found in the Li-Fraumeni syndrome ( LFS ) . A 15-year-old girl with no family history of cancer was referred to our hospital because of pain and swelling of the right knee . Osteosarcoma was diagnosed . The patient received chemotherapy followed by surgery and had a remission . After the age of 28 years , nine primary malignant tumors developed successively , including right breast cancer , colon cancer , malignant fibrous histiocytoma ( MFH ) of the abdominal wall , @DiseaseSrc$ right lung double cancers @/DiseaseSrc$ , bilateral breast cancers , and MFH of the left thigh . This is the second highest number of types of primary malignant tumors to be reported in LFS . All tumors were treated by a multidisciplinary approach , including surgery . Genetic analysis revealed a germline missense mutation in the @GeneTgt$ p53 @/GeneTgt$ gene ( c.659 A > G ) , resulting in Y220C , which has been reported in three families with LFS . The patient died of lung metastasis from MFH at the age of 37 years . Despite the multiple tumors , repeated induction of remissions resulted in long survival . Our findings suggest that a multidisciplinary approach to treatment , including surgery , is beneficial in patients with LFS .	3 3 3 6 6 3 8 6 11 11 8 11 16 16 16 12 22 22 18|22 22 18|22 22 16 3 26 26 28 26 30 28 34 34 34 30 34 38 38 34 44 44 40|44 44 40|44 44 38 26 47 26 51 51 51 47 53 51 53 26 59 59 67 63 63 63 59 65 63 67 67 70 70 67 73 71 67 73 73 79 79 79 73 67 83 83 83 83 86 87 87 87 88 91 89 87 87 95 93 87 99 99 108 102 102 99 108 107 107 107 108 108 108 108 114 114 114 108 114 117 114 117 121 121 114 123 121 123 128 128 128 121 114 129|130|114 129|130|114 129|130|114 129|130|114 130|114 129|130|114 130 138 138 130 138 114 114 145 145 145 141 108 153 153 153 153 153 153 155 153 159 159 159 155 162 162 153 164 162 153 167 169 169 169 173 173 173 169 173 176 173 169 179 180 180 184 184 184 180 189 189 186|189 189 186|189 184 194 194 194 194 189 194 180 180 199 197 199 204 204 204 199 207 207 204 209 207 180 213 214 214 217 217 214 219 217 222 222 214 225 225 222 214 230 230 230 236 236 233 236 235 233 236 239 239 236 236 242 243 243 255 247 247 255 249 247 249 252 249 247 255 243 257 255 259 257 243	Association
18307025	Disease	Gene	D001943	7157	False	3	What is [EMU_BC] between @DiseaseSrc$ bilateral breast cancers @/DiseaseSrc$ and @GeneTgt$ p53 @/GeneTgt$ ? [SEP] A Japanese patient with Li-Fraumeni syndrome who had nine primary malignancies associated with a germline mutation of the @GeneTgt$ p53 @/GeneTgt$ tumor-suppressor gene . We describe a patient who had nine primary malignant tumors and a germline mutation in the @GeneTgt$ p53 @/GeneTgt$ tumor-suppressor gene , characteristically found in the Li-Fraumeni syndrome ( LFS ) . A 15-year-old girl with no family history of cancer was referred to our hospital because of pain and swelling of the right knee . Osteosarcoma was diagnosed . The patient received chemotherapy followed by surgery and had a remission . After the age of 28 years , nine primary malignant tumors developed successively , including right @DiseaseSrc$ breast cancer @/DiseaseSrc$ , colon cancer , malignant fibrous histiocytoma ( MFH ) of the abdominal wall , right lung double cancers , @DiseaseSrc$ bilateral breast cancers @/DiseaseSrc$ , and MFH of the left thigh . This is the second highest number of types of primary malignant tumors to be reported in LFS . All tumors were treated by a multidisciplinary approach , including surgery . Genetic analysis revealed a germline missense mutation in the @GeneTgt$ p53 @/GeneTgt$ gene ( c.659 A > G ) , resulting in Y220C , which has been reported in three families with LFS . The patient died of lung metastasis from MFH at the age of 37 years . Despite the multiple tumors , repeated induction of remissions resulted in long survival . Our findings suggest that a multidisciplinary approach to treatment , including surgery , is beneficial in patients with LFS .	3 3 3 6 6 3 8 6 11 11 8 11 16 16 16 12 22 22 18|22 22 18|22 22 16 3 26 26 28 26 30 28 34 34 34 30 34 38 38 34 44 44 40|44 44 40|44 44 38 26 47 26 51 51 51 47 53 51 53 26 59 59 67 63 63 63 59 65 63 67 67 70 70 67 73 71 67 73 73 79 79 79 73 67 83 83 83 83 86 87 87 87 88 91 89 87 87 95 93 87 99 99 108 102 102 99 108 107 107 107 108 108 108 108 113 113 112|113|108 112|113|108 113|108 112|113|108 113 118 113 118 122 122 113 124 122 124 129 129 129 122 113 134 134 134 113 134 136|133|134 136|133|134 136|133|134 136|134 136|133|134 136 113 113 146 146 146 142 108 155 155 155 155 155 155 157 155 161 161 161 157 164 164 155 166 164 155 169 171 171 171 175 175 175 171 175 178 175 171 181 182 182 186 186 186 182 191 191 188|191 191 188|191 186 196 196 196 196 191 196 182 182 201 199 201 206 206 206 201 209 209 206 211 209 182 215 216 216 219 219 216 221 219 224 224 216 227 227 224 216 232 232 232 238 238 235 238 237 235 238 241 241 238 238 244 245 245 257 249 249 257 251 249 251 254 251 249 257 245 259 257 261 259 245	Association
18307025	Disease	Gene	D051677	7157	False	3	What is [EMU_BC] between @DiseaseSrc$ malignant fibrous histiocytoma @/DiseaseSrc$ and @GeneTgt$ p53 @/GeneTgt$ ? [SEP] A Japanese patient with Li-Fraumeni syndrome who had nine primary malignancies associated with a germline mutation of the @GeneTgt$ p53 @/GeneTgt$ tumor-suppressor gene . We describe a patient who had nine primary malignant tumors and a germline mutation in the @GeneTgt$ p53 @/GeneTgt$ tumor-suppressor gene , characteristically found in the Li-Fraumeni syndrome ( LFS ) . A 15-year-old girl with no family history of cancer was referred to our hospital because of pain and swelling of the right knee . Osteosarcoma was diagnosed . The patient received chemotherapy followed by surgery and had a remission . After the age of 28 years , nine primary malignant tumors developed successively , including right breast cancer , colon cancer , @DiseaseSrc$ malignant fibrous histiocytoma @/DiseaseSrc$ ( MFH ) of the abdominal wall , right lung double cancers , bilateral breast cancers , and MFH of the left thigh . This is the second highest number of types of primary malignant tumors to be reported in LFS . All tumors were treated by a multidisciplinary approach , including surgery . Genetic analysis revealed a germline missense mutation in the @GeneTgt$ p53 @/GeneTgt$ gene ( c.659 A > G ) , resulting in Y220C , which has been reported in three families with LFS . The patient died of lung metastasis from MFH at the age of 37 years . Despite the multiple tumors , repeated induction of remissions resulted in long survival . Our findings suggest that a multidisciplinary approach to treatment , including surgery , is beneficial in patients with LFS .	3 3 3 6 6 3 8 6 11 11 8 11 16 16 16 12 22 22 18|22 22 18|22 22 16 3 26 26 28 26 30 28 34 34 34 30 34 38 38 34 44 44 40|44 44 40|44 44 38 26 47 26 51 51 51 47 53 51 53 26 59 59 67 63 63 63 59 65 63 67 67 70 70 67 73 71 67 73 73 79 79 79 73 67 83 83 83 83 86 87 87 87 88 91 89 87 87 95 93 87 99 99 108 102 102 99 108 107 107 107 108 108 108 108 114 114 114 108 114 117 114 117 114|118|119 114|118|119 114|118|119 114|119 114|118|119 124 119 124 129 129 129 119 114 134 134 134 114 134 138 138 134 138 114 114 145 145 145 141 108 153 153 153 153 153 153 155 153 159 159 159 155 162 162 153 164 162 153 167 169 169 169 173 173 173 169 173 176 173 169 179 180 180 184 184 184 180 189 189 186|189 189 186|189 184 194 194 194 194 189 194 180 180 199 197 199 204 204 204 199 207 207 204 209 207 180 213 214 214 217 217 214 219 217 222 222 214 225 225 222 214 230 230 230 236 236 233 236 235 233 236 239 239 236 236 242 243 243 255 247 247 255 249 247 249 252 249 247 255 243 257 255 259 257 243	Association
17531442	Disease	Gene	D001943	672	True	0	What is [EMU_BC] between @DiseaseSrc$ MCF-7 breast cancer @/DiseaseSrc$ and @GeneTgt$ BRCA1 @/GeneTgt$ ? [SEP] Identification of sequences that target @GeneTgt$ BRCA1 @/GeneTgt$ to nuclear foci following alkylative DNA damage . @GeneTgt$ BRCA1 @/GeneTgt$ is a tumor suppressor involved in the maintenance of genome integrity . @GeneTgt$ BRCA1 @/GeneTgt$ co-localizes with DNA repair proteins at nuclear foci in response to DNA double-strand breaks caused by ionizing radiation ( IR ) . The response of @GeneTgt$ BRCA1 @/GeneTgt$ to agents that elicit DNA single-strand breaks ( SSB ) is poorly defined . In this study , we compared chemicals that induce SSB repair and observed the most striking nuclear redistribution of @GeneTgt$ BRCA1 @/GeneTgt$ following treatment with the alkylating agent methyl methanethiosulfonate ( MMTS ) . In @DiseaseSrc$ MCF-7 breast cancer @/DiseaseSrc$ cells , MMTS induced movement of endogenous @GeneTgt$ BRCA1 @/GeneTgt$ into distinctive nuclear foci that co-stained with the SSB repair protein XRCC1 , but not the DSB repair protein gamma-H2AX . XRCC1 did not accumulate in foci after ionizing radiation . Moreover , we showed by deletion mapping that different sequences target @GeneTgt$ BRCA1 @/GeneTgt$ to nuclear foci induced by MMTS or by ionizing radiation . We identified two core MMTS-responsive sequences in @GeneTgt$ BRCA1 @/GeneTgt$ : the N-terminal BARD1-binding domain ( aa1 - 304 ) and the C-terminal sequence aa1078 - 1312 . These sequences individually are ineffective , but together they facilitated @GeneTgt$ BRCA1 @/GeneTgt$ localization at MMTS-induced foci . Site-directed mutagenesis of two SQ/TQ motif serines ( S1143A and S1280A ) in the @GeneTgt$ BRCA1 @/GeneTgt$ fusion protein reduced , but did not abolish , targeting to MMTS-inducible foci . This is the first report to describe co-localization of @GeneTgt$ BRCA1 @/GeneTgt$ with XRCC1 at SSB repair foci . Our results indicate that @GeneTgt$ BRCA1 @/GeneTgt$ requires BARD1 for targeting to different types of DNA lesion , and that distinct C-terminal sequences mediate selective recruitment to sites of double- or single-strand DNA damage .	1 3 1 5 3 5 5 5 10 10 5 14 14 14 5 1 16|22 22 16|22 22 22 22 22 22 26 26 23 29 29 26 22 31|34 34 31|34 34 38 38 38 34 41 41 34 43 34 47 47 47 43 47 51 51 48 53 51 53 34 58 74 60 58|59 58 58|59 63 58 65 63 68 68 65 70 68 70 74 74 74 74 79 79 82 82 82 82 82 85 83 87 85 85 85 94 92 94 94 89 96 94|95 94 94|95 99 94 105 105 103 105 105 99 107 105 107 82 116 111|116 111|116 111|116 116 111|116 119 119 119 119 119 123 123 119|120 120 119|120 128 128 128 120 130 128 136 136 136 136 136 130 136 139 136 144 144 144 144 136 119 151 151 151 151 153 151 156 156 153 151 161 161 161 161 164 164 161 168 167 168 164 168 168 168 173 173 168 173 176 174 176 180 180 176 161 184 184 188 188 188 184 190 188|189 188 188|189 188 196 196 196 188 198 196 198 198 198 196 206 206 206 196 206 206 184 212 215 215 215 215 215 215 220 220 215 220|223 223 220|223 220 226 226 220 220 230 247 235 235 235 235 230 237 235 237 237 237 246 246 246|242 246 246|242 246 235 247 247 247 252 252 247 252 252 257 257 254 247 264 264 264 264 264 266 264 266 269 267|268 267 267|268 272 267 276 276 276 267 264 280 281 281 285 282|285 285 282|285 281 285 288 285 291 291 288 294 294 291 285 285 301 300 300 301 285 303 301 305 303 307 311 307 307 311 303 281	Association
15235021	Disease	Gene	D013274	999	True	0	What is [EMU_BC] between @DiseaseSrc$ gastric cancer @/DiseaseSrc$ and @GeneTgt$ CDH1 @/GeneTgt$ ? [SEP] Germline @GeneTgt$ E-cadherin @/GeneTgt$ mutations in hereditary diffuse @DiseaseSrc$ gastric cancer @/DiseaseSrc$ : assessment of 42 new families and review of genetic screening criteria . BACKGROUND : Mutations in the @GeneTgt$ E-cadherin @/GeneTgt$ ( @GeneTgt$ CDH1 @/GeneTgt$ ) gene are a well documented cause of @DiseaseSrc$ hereditary diffuse gastric cancer @/DiseaseSrc$ ( @DiseaseSrc$ HDGC @/DiseaseSrc$ ) . Development of evidence based guidelines for @GeneTgt$ CDH1 @/GeneTgt$ screening for @DiseaseSrc$ HDGC @/DiseaseSrc$ have been complicated by its rarity , variable penetrance , and lack of founder mutations . METHODS : Forty three new @DiseaseSrc$ gastric cancer @/DiseaseSrc$ ( GC ) families were ascertained from multiple sources . In 42 of these families at least one @DiseaseSrc$ gastric cancer @/DiseaseSrc$ was pathologically confirmed to be a diffuse @DiseaseSrc$ gastric cancer @/DiseaseSrc$ ( DGC ) ; the other family had @DiseaseSrc$ intestinal type gastric cancers @/DiseaseSrc$ . Screening of the entire coding region of the @GeneTgt$ CDH1 @/GeneTgt$ gene and all intron/exon boundaries was performed by bi-directional sequencing . RESULTS : Novel mutations were found in 13 of the 42 DGC families ( 31 % overall ) . Twelve of these mutations occur among the 25 families with multiple cases of @DiseaseSrc$ gastric cancer @/DiseaseSrc$ and with pathologic confirmation of diffuse @DiseaseSrc$ gastric cancer @/DiseaseSrc$ phenotype in at least one individual under the age of 50 years . The mutations found include small insertions and deletions , splice site mutations , and three non-conservative amino acid substitutions ( A298 T , W409R , and R732Q ) . All three missense mutations conferred loss of @GeneTgt$ E-cadherin @/GeneTgt$ function in in vitro assays . Multiple cases of breast cancers including pathologically confirmed @DiseaseSrc$ lobular breast cancers @/DiseaseSrc$ were observed both in mutation positive and negative families . CONCLUSION : Germline truncating @GeneTgt$ CDH1 @/GeneTgt$ mutations are found in 48 % of families with multiple cases of @DiseaseSrc$ gastric cancer @/DiseaseSrc$ and at least one documented case of DGC in an individual under 50 years of age . We recommend that these criteria be used for selecting families for @GeneTgt$ CDH1 @/GeneTgt$ mutational analysis .	4 1|4 4 1|4 4 8 8 8 8|4|6 8|4|6 8|4 8|4|6 4 4 16 16 16 12 12 12 22 22 22 18 4 26 26 42 37 37 37|30 37 37|30 37 37|32 37 37|32 37 28 42 42 41 42 26 44 41|42|44 41|42|44 41|42|44 41|42|44 42|44 41|42|44 50 43|44 44 43|44 50 26 72 60 58 62 60 66 66|63 66 66|63 62 68 66 66 66 72 72 72 75 75 72 75 78 75 75 75 75 84 84 81 72 101 101 91 99 99 99|92 99|92 99 99|92 97 99 97 101 101 101 104 104 101 101 108 120 111 111 108 113 114 115 114|115|120 114|115|120 115|120 114|115|120 120 120 120 125 125 125 125 122|125|120 122|125|120 125|120 122|125|120 129 125 129 125 134 134 135 120 131|135|136 131|135|136 131|135|136 131|135|136 135|136 131|135|136 120 161 150 150 150 150 145 155 155 152|155 155 152|155 150 150 159 159 150 161 161 164 164 161 161 167 167 170 172 172 167 174 172 179 179 179 179 174 183 182 183 172 183 172 190 189 189 186 190 194 194 194 190 197 197 194 199 197|198|199 197|198|199 197|199 197|198|199 194 205 205 194 211 211 211|205 211|205 211 211|205 205 216 214 215 216 205 219 219 205 222 222 219 190 227 229 227 229 231 229 231 231 233 237 237 233 231 231 244 244 244 244 231 247 247 244 247 247 247 247 247 247 229 256 258 258 259 259 259 264 264|261 264 264|261 260 268 268 266 259 259 272 284 275 275 272 279 278 279 278|279|275 278|279|275 278|279|275 279|275 278|279|275 284 284 288 288 288 284 288 288 288 284 302 294 297 294 297|300 300 297|300 297 302 302 305 305 302 307 305 310 310 307 312 310|312 310|312 310|312 310|312 305 317 318 319 302 319 322 320 325 325 320 328 328 319 330 328 302 335 335 340 338 340 340 335 342 340 342 348 344|348 348 344|348 348 343 335	Association
15235021	Disease	Gene	D001943	999	False	1	What is [EMU_BC] between @DiseaseSrc$ breast cancers @/DiseaseSrc$ and @GeneTgt$ CDH1 @/GeneTgt$ ? [SEP] Germline @GeneTgt$ E-cadherin @/GeneTgt$ mutations in hereditary diffuse gastric cancer : assessment of 42 new families and review of genetic screening criteria . BACKGROUND : Mutations in the @GeneTgt$ E-cadherin @/GeneTgt$ ( @GeneTgt$ CDH1 @/GeneTgt$ ) gene are a well documented cause of hereditary diffuse gastric cancer ( HDGC ) . Development of evidence based guidelines for @GeneTgt$ CDH1 @/GeneTgt$ screening for HDGC have been complicated by its rarity , variable penetrance , and lack of founder mutations . METHODS : Forty three new gastric cancer ( GC ) families were ascertained from multiple sources . In 42 of these families at least one gastric cancer was pathologically confirmed to be a diffuse gastric cancer ( DGC ) ; the other family had intestinal type gastric cancers . Screening of the entire coding region of the @GeneTgt$ CDH1 @/GeneTgt$ gene and all intron/exon boundaries was performed by bi-directional sequencing . RESULTS : Novel mutations were found in 13 of the 42 DGC families ( 31 % overall ) . Twelve of these mutations occur among the 25 families with multiple cases of gastric cancer and with pathologic confirmation of diffuse gastric cancer phenotype in at least one individual under the age of 50 years . The mutations found include small insertions and deletions , splice site mutations , and three non-conservative amino acid substitutions ( A298 T , W409R , and R732Q ) . All three missense mutations conferred loss of @GeneTgt$ E-cadherin @/GeneTgt$ function in in vitro assays . Multiple cases of @DiseaseSrc$ breast cancers @/DiseaseSrc$ including pathologically confirmed lobular breast cancers were observed both in mutation positive and negative families . CONCLUSION : Germline truncating @GeneTgt$ CDH1 @/GeneTgt$ mutations are found in 48 % of families with multiple cases of gastric cancer and at least one documented case of DGC in an individual under 50 years of age . We recommend that these criteria be used for selecting families for @GeneTgt$ CDH1 @/GeneTgt$ mutational analysis .	4 1|4 4 1|4 4 9 9 9 9 4 4 4 15 15 15 11 11 11 21 21 21 17 4 24 24 40 35 35 35|28 35 35|28 35 35|30 35 35|30 35 26 40 40 39 40 24 45 45 45 45 40 47 45 47 24 65 54 52 56 54 60 60|57 60 60|57 56 62 60 65 65 65 68 68 65 68 71 68 68 68 68 77 77 74 65 92 92 83 90 90 90 90 88 90 88 92 92 92 95 95 92 92 98 109 101 101 98 103 104 106 106 109 109 109 109 115 115 115 115 115 109 117 115 117 115 122 122 123 109 127 127 127 123 109 145 134 134 134 134 129 139 139 136|139 139 136|139 134 134 143 143 134 145 145 148 148 145 145 151 151 154 156 156 151 158 156 163 163 163 163 158 167 166 167 156 167 156 174 173 173 170 174 178 178 178 174 181 181 178 184 184 181 178 188 188 178 193 193 193 193 188 198 196 197 198 188 201 201 188 204 204 201 174 207 209 207 209 211 209 211 211 213 217 217 213 211 211 224 224 224 224 211 227 227 224 227 227 227 227 227 227 209 236 238 238 239 239 239 244 244|241 244 244|241 240 248 248 246 239 239 252 264 254 252|253|254 252|253|254 252|254 252|253|254 262 259 262 262 262 254 264 264 268 268 268 264 268 268 268 264 282 274 277 274 277|280 280 277|280 277 282 282 285 285 282 287 285 290 290 287 293 293 290 285 296 297 298 282 298 301 299 304 304 299 307 307 298 309 307 282 313 313 318 316 318 318 313 320 318 320 326 322|326 326 322|326 326 321 313	Association
16652348	Disease	Gene	D001943	472	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ ATM @/GeneTgt$ ? [SEP] The @GeneTgt$ ATM @/GeneTgt$ missense mutation p. Ser49Cys ( c.146C > G ) and the risk of @DiseaseSrc$ breast cancer @/DiseaseSrc$ . Homozygous mutation in the @GeneTgt$ ATM @/GeneTgt$ gene causes ataxia telangiectasia and heterozygous mutation carriers may be at increased risk of @DiseaseSrc$ breast cancer @/DiseaseSrc$ . We studied a total of 22 @GeneTgt$ ATM @/GeneTgt$ variants ; 18 variants were analyzed in one of two large population-based studies from the U.S. and Poland , and four variants were analyzed in all 2,856 @DiseaseSrc$ breast cancer @/DiseaseSrc$ cases and 3,344 controls from the two studies . The missense mutation Ser49Cys ( c.146C > G , p. S49C ) , carried by approximately 2 % of subjects , was more common in cases than controls in both study populations , combined odds ratio ( OR ) 1.69 ( 95 % CI , 1.19 - 2.40 ; P=0.004 ) . Another missense mutation at approximately 2 % frequency , Phe858Leu ( c.2572T > C , p. F858L ) , was associated with a significant increased risk in the U.S. study but not in Poland , and had a combined OR of 1.44 ( 95 % CI , 0.98 - 2.11 ; P=0.06 ) . These analyses provide the most convincing evidence thus far that missense mutations in @GeneTgt$ ATM @/GeneTgt$ , particularly p. S49C , may be @DiseaseSrc$ breast cancer @/DiseaseSrc$ susceptibility alleles . Because of their low frequency , even larger sample sizes are required to more firmly establish these associations .	15 1|15 15 1|15 7 7 7 2 9 7 11 9 9 7 15 15 17 17|15 17|15 17|15 17|15 15 24 30 29 29 26|29 29 26|29 24 30 32 41 32 36 36 32 41 41 41 41 30 43 41|43 41|43 41|43 41|43 30 50 50 52 50 57 57 57|54 57 57|54 52 50 60 62 62 50 64 62 69 69 69 69 64 72 72 69 72 72 62 62 78 80 80 62 87 87 87 82|87 82|87 87 82|87 80 80 90 80 94 94 94 90 62 101 101 101 105 103 105 105 121 105 108 105 105 105 105 115 114 115 111 117 115 121 121 121 121 123 121 125 123 129 129 129 125 121 133 133 121 135 133 137 135 141 140 141 135 141 145 145 141 141 141 141 121 152 152 170 157 155 156 157 152 170 170 166 166 166 166 166 166 159 166 159 170 170 175 175 175 175 170 179 179 179 175 175 183 183 175 170 170 170 189 189 186 191 195 194 194 195 186 195 195 197 197 195 195 195 170 205 206 206 210 209 210 206 212 206 230 215 230 217 215|216 215 215|216 217 222 222 217 217 230 230 230|224 230|224 230 230|224 230 212 206 238 234 238 238 245 245 241 243 243 245 245 245 249 248 249 245 251 249 245	Association
9407971	Disease	Gene	D001943	7157	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ p53 @/GeneTgt$ ? [SEP] Abrogation of wild-type @GeneTgt$ p53-mediated @/GeneTgt$ transactivation is insufficient for mutant @GeneTgt$ p53-induced @/GeneTgt$ immortalization of normal human mammary epithelial cells . The @GeneTgt$ p53 @/GeneTgt$ protein has become a subject of intense interest since the discovery that about 50 % of human cancers carry @GeneTgt$ p53 @/GeneTgt$ mutations . Mutations in the @GeneTgt$ p53 @/GeneTgt$ gene are the most frequent genetic lesions in @DiseaseSrc$ breast cancer @/DiseaseSrc$ , suggesting a critical role for @GeneTgt$ p53 @/GeneTgt$ protein in normal mammary epithelial cell ( MEC ) growth control . We previously demonstrated that abrogation of the @GeneTgt$ p53 @/GeneTgt$ function by a cancer-derived @GeneTgt$ p53 @/GeneTgt$ mutant , del239 , was sufficient to induce immortalization of normal MECs . To further extend these findings and to examine the mechanism of mutant @GeneTgt$ p53-induced @/GeneTgt$ immortalization of MECs , we tested the immortalizing ability of four selected @GeneTgt$ p53 @/GeneTgt$ mutants ( R175H , R248W , R249S , and R273H ) , which involve residues that cluster close to N239 in the three-dimensional structure and which are critical for the DNA-binding function of @GeneTgt$ p53 @/GeneTgt$ . Interestingly , two of these mutants ( R175H and R249S ) reproducibly immortalized 76N normal MECs , whereas the other two mutants ( R248W and R273H ) induced an extension of life span but not immortalization . These results further substantiate that selective ablation of @GeneTgt$ p53 @/GeneTgt$ function with dominant-negative mutants is sufficient for immortalization of MECs . To determine whether abrogation of the transactivation function of endogenous @GeneTgt$ p53 @/GeneTgt$ was important for the differential immortalizing ability of @GeneTgt$ p53 @/GeneTgt$ mutants , we measured the effects of mutant @GeneTgt$ p53 @/GeneTgt$ on the endogenous wild-type @GeneTgt$ p53-mediated @/GeneTgt$ transactivation of a chloramphenicol acetyltransferase reporter linked to a consensus @GeneTgt$ p53 @/GeneTgt$ binding DNA sequence in transiently transfected 76N MECs . All of the mutants , regardless of their immortalizing phenotype , abrogated the endogenous wild-type @GeneTgt$ p53-mediated @/GeneTgt$ transactivation to a similar extent . Thus , abrogation of transactivation function is not sufficient for mutant @GeneTgt$ p53-induced @/GeneTgt$ immortalization of normal MECs . The @GeneTgt$ p53-immortalized @/GeneTgt$ MECs showed substantial telomerase activity ; however , induction of telomerase activity occurred at late passages and was undetectable in mutant @GeneTgt$ p53-expressing @/GeneTgt$ cells prior to immortalization . We suggest that mechanisms other than abrogation of transactivation and induction of telomerase activity determine the differential MEC-immortalizing behavior of various @GeneTgt$ p53 @/GeneTgt$ mutants .	8 6 6 3|6 6 3|6 1 8 8 13 13 9|10 10 9|10 8 19 19 19 19 19 13 8 26 23|26 26 23|26 28 28 28 30 28 33 33 30 36 36 30 44 39 40 44 43 43 40 36 47|43 47 47|43 44 28 62 56 56 53|56 56 53|56 51 62 62 60 62 62 62 64 62|64 62|64 62|64 62|64 62 62 71 71 68 75 75|69 75 75|69 71 80 80 80 80 85 82 85 82 85 71 62 92 92 92 110 110 99 99 99|96 99 99|96 94 105 105 105 105|101 105 105|101 94 105 105 105 110 92 112 110 112 116 116 113 92 122 122 122 124 122 122 127 122 129 127 134 134 131|134 134 131|134 129 136 134 139 139 122 142 142 139 148 148 148 144|148 148 144|148 142 150 148 150 150 150 150 150 150 150 150 148 161 148 161 164 162 164 167 165 171 171 171 164 164 175 175 162 179 179 179 175 181 178|179 179 178|179 139 199 199 199 192 192 189 194 192 194 194 194 199 199 202 202 199 199 199 208 208 208 214 210 208 210 210 210 199 216 214 218 219 216 221 219 219 214 225 227 227 227 239 230 239 234 231|234 234 231|234 230 237 237 234 239 227 241 239 243 241 227 247 271 259 259 253 253 253 249 256 256 253|255 253 253|255 259 247 264 264 264 264 259 268 264|268 268 264|268 264 271 271 271 273 271 276 276 273 273 273 284 284 284 284 278|281 281 278|281 273 289 289 289 289 284 284 298 298 298 289|298 298 289|298 298 298 290 303 301 303 303 298 271 321 313 313 310 310 310 319 319 319 315 310 321 327 327 327 324 324 324 321 331 331 331 321 321 342 342 342 339 339 336 342 342 342 347 347 344 344 344 342 350 350 347 342 356 353|356 356 353|356 357 357 360 360 357 357 368 368 368 367 367 364 357 371 371 368 368 374 368 379 379 379|375 379 379|375 374 382 382 374 357 387 387 400 400 389 392 390 394 392 394 394 399 399 396 387 404 404 404 400 409 409 409|406 409 409|406 404 387	Association
12645254	Disease	Gene	D001943	672	True	0	What is [EMU_BC] between @DiseaseSrc$ familial breast cancer @/DiseaseSrc$ and @GeneTgt$ BRCA1 @/GeneTgt$ ? [SEP] [ Studies of mutations in @GeneTgt$ BRCA1 @/GeneTgt$ transactivation domain by visualization of chromatin structure ] . Mutations in @DiseaseSrc$ breast cancer @/DiseaseSrc$ susceptibility gene @GeneTgt$ 1(BRCA1 @/GeneTgt$ ) account for approximately 40%-50 % of @DiseaseSrc$ familial breast cancer @/DiseaseSrc$ cases and for more than 80 % of inherited breast and ovarian cancer cases . Many cancer-predisposing mutations are located in the C-terminal region that functions as a transcriptional activation domain , but most of the mutations in the transactivation domain identified to date can not be readily distinguished as either disease-associated mutations or benign polymorphisms . Because chromatin structure regulation is an early event in gene transcription control , the chromatin unfolding activities of different transactivation domain variants were compared with that of the wild-type transactivation domain by use of an approach that allows visualization of large-scale chromatin structure through lac repressor/lac operator recognition . To do this , different constructs of the transactivation domain were selected as follows : ( a ) the wild-type transactivation domain ; ( b ) two polymorphisms ( S1613 G and M1652I ) ; and ( c ) four cancer-predisposing mutations ( A1708E , M1775R , W1837R and Y1853 term ) . All of the constructs were made by fusing in frame with lac repressor . Western blot analysis indicated that all of the fusion proteins were expressed in A03 1 cells , in which multiple copies of the lac operator were integrated to produce a heterochromatic region of the genome . The chromatin unfolding assay showed that , like the wild-type transactivation domain , two variants that represent benign polymorphisms did not induce chromatin unfolding or only induced subtle change . Contrary to the behaviors of the wild type and two benign variants , four cancer-predisposing mutations in the transactivation domain superactivate the chromatin unfolding . The results suggest that the chromatin unfolding assay can aid in the characterization of deterious mutations in the C-terminal transactivation domain of @GeneTgt$ BRCA1 @/GeneTgt$ and may provide more reliable presymptomatic risk assessment .	2 2 4 2 9 9|5 9 9|5 9 4 11 2 14 14 11 2 2 28 24 19|24 19|24 24 19|24 24 25 18|22 18 18|22 25 28 32 31 32 28 38 38|30 38|30 38|30 38 38|30 32 32 44 43 43 44 32 47 47 44 47 47 51 47 28 58 58 60 60 60 64 64 64 60 66 64 71 71 71 71 66 60 60 82 77 77 74 81 81 81 77 60 84 82 89 89 89 89 60 93 93 93 89 93 96 93 60 105 101 101 105 105 105 105 121 109 109 109 105 121 114 114 114 121 119 119 119 119 114 121 121 123 121 128 128 128 128 123 130 121 133 133 130 135 133 135 140 140 140 136 145 145 145 145 136 121 148 158 148 152 152 158 156 156 156 152 158 158 160 158 160 163 168 163 168 168 168 158 168 171 174 171 174 168 177 177 174 177 177 177 174 168 184 188 188 188 188 168 190 188 190 190 190 190 190 190 190 190 158 205 203 203 200 205 205 207 205 209 207 212 212 209 205 216 216 217 217 225 225 223 223 223 219 225 217 229 229 229 225 229 232 240 234 240 238 238 238 234 240 229 242 240 245 245 242 248 248 245 217 253 253 253 254 254 271 271 261 261 261 261 271 271 264 271 266 264 268 266 271 271 254 273 271 271 276 271 278 276 254 300 283 283 280 287 287 287 283 287 291 291 287 300 295 295 300 299 299 299 295 300 303 303 300 300 306 307 307 314 312 312 312 314 314 307 317 317 314 320 320 317 325 325 325 325 320 327 325|326 325 325|326 314 331 314 333 336 336 336 331 307	Association
18372405	Disease	Gene	D001943	3294	True	0	What is [EMU_BC] between @DiseaseSrc$ breast cancer @/DiseaseSrc$ and @GeneTgt$ 17beta-hydroxysteroid dehydrogenase type 2 @/GeneTgt$ ? [SEP] Mutation analysis and characterization of @GeneTgt$ HSD17B2 @/GeneTgt$ sequence variants in @DiseaseSrc$ breast cancer @/DiseaseSrc$ cases from French Canadian families with high risk of breast and ovarian cancer . Estrogen exposure is a risk factor for @DiseaseSrc$ breast cancer @/DiseaseSrc$ . Given that @GeneTgt$ HSD17B2 @/GeneTgt$ gene encodes an enzyme that catalyses estradiol inactivation , it appears as a good candidate @DiseaseSrc$ breast cancer @/DiseaseSrc$ susceptibility gene . This study was designed to screen for @GeneTgt$ HSD17B2 @/GeneTgt$ germline mutations potentially involved in @DiseaseSrc$ breast cancer @/DiseaseSrc$ predisposition . Our re-sequencing analysis did not identify any deleterious germline mutations , and therefore mutations in @GeneTgt$ HSD17B2 @/GeneTgt$ do not explain the clustering of @DiseaseSrc$ breast cancer @/DiseaseSrc$ cases in non-BRCA1/2 high-risk French Canadian families . However , six sequence variants were identified , including two novel missense variants . Expression assays revealed that p. Ala111Asp and p. Gly160Arg did not alter the catalytic properties of @GeneTgt$ 17beta-hydroxysteroid dehydrogenase type 2 @/GeneTgt$ enzyme , although p. Ala111Asp appears to affect protein stability resulting in significant decreases in the protein levels , providing valuable information on structure-function relationship .	2 2 2 2 9 9|5 9 9|5 9 4 14 9|14 9|14 14 9|14 9 18 18 18 14 21 21 4 23 21 23 26 23 2 31 35 35 35 35 35 37 37|35|36 37|35|36 37|35 37|35|36 35 46 46 43|46 46 43|46 47 47 49 47 51 49 53 51 56 56 47 65 65 65 65 65|59 65|59 65 65|59 65 56 47 70 72 72 72 74 72 79 79|75 79 79|75 79 74 81 79 86 86|81 86|81 86 86|81 81 72 92 92 95 95 95 95 99 99 99 95 95 95 109 109 105 103|104 103 103|104 109 109 95 111 109 116 116|111 116|111 116 116|111 111 122 122 122 122 122 111 95 132 132 130 130 132 132 132 132 138 138 138 138 132 132 141 142 142 151 145 151 145 148 145 151 151 142 154 154 151 161 155|161 155|161 155|161 155|161 161 155|161 154 151 166 165 166 151 168 166 170 168 170 174 174 171 178 178 178 174 168 168 182 180 185 185 182 142	Association
